[
  {
    "question": "A 68-year-old male with a history of hypertension and type 2 diabetes presents with a 3-day history of cough, fever, and shortness of breath. He is diagnosed with community-acquired pneumonia (CAP). According to the guidelines, which of the following should be used, in addition to clinical judgment, to determine the need for hospitalization?",
    "context": "urea level, respiratory rate, blood pressure, and age &gt;=65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP.\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,\nIn addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate,\nClinical severity is not the only consideration in determining the need for hospital admission (49, 50). Some patients have medical and/or psychosocial contraindications to outpatient therapy, such as inability to maintain oral intake, history of substance abuse, cognitive impairment, severe\nThis document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia.",
    "ground_truth_context": "In addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate, blood pressure, and age >65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP. [1]",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Pneumonia Severity Index (PSI) preferentially over CURB-65",
    "correct_answer_idx": 1,
    "model_reasoning": "According to the guidelines for managing community-acquired pneumonia (CAP), clinicians are advised to use a validated clinical prediction rule for prognosis, specifically recommending the Pneumonia Severity Index (PSI) preferentially over the CURB-65 score. This recommendation is based on a strong endorsement and moderate quality of evidence. The PSI is designed to assess the severity of pneumonia and help determine the need for hospitalization, while CURB-65 is considered a conditional recommendation with lower quality evidence. \n\nThe other options, such as using the CURB-65 score alone, serum procalcitonin levels, or influenza virus testing, do not align with the guidelines for determining hospitalization needs. Serum procalcitonin levels are more relevant for guiding antibiotic therapy, and influenza testing is primarily for identifying the influenza virus rather than assessing the need for hospitalization in pneumonia cases. Therefore, the correct choice is B, as it directly follows the guideline's recommendation.",
    "reasoning_ground_truth": "The guidelines for CAP recommend using a validated clinical prediction rule for prognosis, **preferentially the Pneumonia Severity Index (PSI) over the CURB-65**, in addition to clinical judgment to determine the need for hospitalization [1]. Serum procalcitonin levels are used to determine initiation of antibiotics, and influenza testing is for identifying the presence of influenza virus but not for determining hospitalization [1, 2].",
    "is_correct": true
  },
  {
    "question": "A 55-year-old female with a history of chronic kidney disease (CKD) and hypertension presents for a routine follow-up. Her eGFRcr is 40 mL/min/1.73 m2. Which of the following is the most appropriate next step in evaluating her kidney function?",
    "context": "In this section, we describe the overall approach for the evaluation of GFR. As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, the first method to evaluate GFR should be eGFRcr. If necessary for greater accuracy, the approach then\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Guideline for the Evaluation and Management of Chronic Kidney Disease1 for GFR estimation in adults, there have been 3 main sources of validated equations: those developed by the CKD-EPI, those developed by EKFC, and modifications of each for use in specific regions (Table 14\nPractice Point 2.1.3: For people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.\nFor people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.\nSome authors have suggested that the GFR threshold for CKD of 60 ml/min per 1.73 m2 should be raised to 75 ml/min per 1.73 m2 for younger adults and lowered to 45 ml/min per 1.73 m2 for older adults. In younger adults, the purpose of a higher GFR threshold reflects the longer risk horizon for\nPractice Point 2.2.1: A 5-year kidney failure risk of 3%\u20135% can be used to determine need for nephrology referral in addition to criteria based on eGFR or urine ACR, and other clinical considerations.\n|---|---|---|---|---|---|\n|eGFR 45 to <60 m/min per 1.73 m\u00b2|2377 (3.6%)|3013 (4.6%)|0.76 (0.70\u20130.81)| | |\n|eGFR 30 to <45 m/min per 1.73 m\u00b2|863 (4.5%)|1014 (5.2%)|0.85 (0.75\u20130.96)| | |\n|eGFR <30 m/min per 1.73 m\u00b2 not on dialysis|320 (3.0%)|364 (3.5%)|0.85 (0.71\u20131.02)| | |\n|---|---|---|---|---|---|\n|eGFR 45 to <60 m/min per 1.73 m\u00b2|575 (0.8%)|708 (1.0%)|0.81 (0.70\u20130.93)| | |\n|eGFR 30 to <45 m/min per 1.73 m\u00b2|263 (1.3%)|284 (1.4%)|0.91 (0.73\u20131.13)| | |\n|eGFR <30 m/min per 1.73 m\u00b2 not on dialysis|116 (1.1%)|137 (1.3%)|0.83 (0.63\u20131.10)| | |\n- Report eGFR in addition to the serum concentrations of filtration markers using validated equations.\n- Report eGFR rounded to the nearest whole number and relative to a body surface area (BSA) of 1.73 m2 in adults using the units ml/min per 1.73 m2.\ndata were anto mGFR most consistently (i) review of past measurements/estimations of GFR; (ii) review of past measurements of albuminuria or proteinuria and urine microscopic examinations; (iii) imaging findings such as reduced kidney size and reduction in cortical thickness; (iv) kidney",
    "ground_truth_context": "The initial test for the evaluation of GFR is creatinine-based estimated GFR (eGFRcr), which will be available for most people because creatinine is measured routinely as part of the basic metabolic panel. If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated. [3] eGFRcr-cys provides the most accurate estimate and is recommended as the primary supportive test for people in whom there are concerns about eGFRcr accuracy [4] ",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Measure cystatin C to calculate eGFRcr-cys",
    "correct_answer_idx": 0,
    "model_reasoning": "According to the guidelines for evaluating glomerular filtration rate (GFR), the initial test is the creatinine-based estimated GFR (eGFRcr). In cases where the eGFRcr is thought to be inaccurate or when a more precise assessment of GFR is required, measuring cystatin C is recommended. This is particularly relevant for the patient in question, a 55-year-old female with chronic kidney disease (CKD) and an eGFRcr of 40 mL/min/1.73 m\u00b2, which indicates a significant reduction in kidney function. \n\nThe guidelines suggest that if there are concerns about the accuracy of eGFRcr, cystatin C should be measured to calculate eGFRcr-cys, as it provides a more accurate estimate of kidney function. Therefore, the most appropriate next step in evaluating her kidney function is to measure cystatin C to calculate eGFRcr-cys, making option A the correct choice. \n\nOptions B, C, and D are not appropriate next steps based on the guidelines. Option B suggests proceeding directly to measuring GFR using an exogenous filtration marker, which is not the first step recommended. Option C, repeating eGFRcr in 3 months, does not address the need for a more accurate assessment at this time. Option D, stating no additional testing is needed, is incorrect given the patient's CKD status and the need for accurate GFR evaluation.",
    "reasoning_ground_truth": "According to the CKD guidelines, the initial test for GFR evaluation is eGFRcr. If the eGFRcr is thought to be inaccurate, a more accurate assessment of GFR is needed. In such cases, cystatin C should be measured to estimate eGFRcr-cys.  If eGFRcr-cys is inaccurate, then mGFR can be considered [3, 4].",
    "is_correct": true
  },
  {
    "question": "A 70-year-old male with a history of a recent acute coronary syndrome (ACS) is currently on dual antiplatelet therapy (DAPT). He is now 18 months post-ACS and has had no recurrent events. What is the recommended approach for his DAPT?",
    "context": "Guidelines from the cardiology community provide recommendations for the use of dual antiplatelet therapy for a period after acute coronary syndrome or percutaneous coronary intervention. These guidelines recommend to apply the same diagnostic and therapeutic strategies in people with CKD.663 CKD\n|COR|LOE|RECOMMENDATIONS|\n|---|---|---|\n|I|B-R|In patients with ACS who are managed with medical therapy alone (without revascularization or fibrinolytic therapy) and treated with DAPT, P2Y12 inhibitor therapy (clopidogrel or ticagrelor) should be continued for at least 12 months (52,71,140,141).|\n|IIa|B-R|In patients with NSTE\u2013ACS who are managed with medical therapy alone (without revascularization or fibrinolytic therapy) and treated with DAPT, it is reasonable to use ticagrelor in preference to clopidogrel for maintenance P2Y12 inhibitor therapy (53,71).|\n- Assess ischemic and bleeding risks using validated risk predictors (e.g., CHA2DS2-VASc, HAS-BLED)\n- Keep triple therapy duration as short as possible; dual therapy only (oral anticoagulant and clopidogrel) may be considered in select patients\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\nindividual basis and should integrate clinical judgment, assessment of the benefit/risk ratio, and patient preference. Aspirin therapy is almost always continued indefinitely in patients with CAD, and recommendations on duration of DAPT should be taken to mean the recommended duration of P2Y12",
    "ground_truth_context": "patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD.  This focused update is designed to function both as a standalone document and to serve as an update to the relevant sections on duration of DAPT in the 6 clinical practice guidelines, replacing relevant text, figures, and recommendations. [5]",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Transition to single antiplatelet therapy.",
    "correct_answer_idx": 1,
    "model_reasoning": "According to the guidelines referenced in the context, patients who have a history of acute coronary syndrome (ACS) and are more than one year post-ACS without any recurrent events are considered to have transitioned to stable ischemic heart disease (SIHD). In such cases, the recommended approach is to transition from dual antiplatelet therapy (DAPT) to single antiplatelet therapy. This is based on the understanding that the risk of recurrent ischemic events decreases significantly after the first year, and continuing DAPT may expose patients to unnecessary bleeding risks without substantial benefits. Therefore, for the 70-year-old male in the scenario, the appropriate recommendation is to transition to single antiplatelet therapy, making option B the correct choice.",
    "reasoning_ground_truth": "According to the guidelines, patients with a history of ACS >1 year prior who have remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD). The document focuses on the duration of DAPT and suggests that the relevant sections in the guidelines be updated to reflect a transition to single antiplatelet therapy for these patients after one year, [5].",
    "is_correct": true
  },
  {
    "question": "A 35-year-old female presents with a 5-day history of nasal congestion, facial pain, and purulent nasal discharge. She reports no improvement with over-the-counter decongestants. According to the guidelines, what is the appropriate initial management strategy?",
    "context": "Oral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the\nagents, nasal saline, decongestants, antihistamines, mucolytics, cough suppressants, and topical or oral corticosteroids\u2014may be used alone or in varying combinations for symptom relief.\nAdjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and\nDecongestants may help you breathe easier and can be taken as a nasal spray (for no more than 3 days in a row to avoid worsening congestion) or by mouth.|\n5 days, as recommended by the manufacturers, to avoid rebound congestion and rhinitis medicamentosa. Clinical experience suggests oral antihistamines may provide symptomatic relief of excessive secretions and sneezing, although there are no clinical studies supporting the use of antihistamines in\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without",
    "ground_truth_context": "Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhi-nosinusitis (ABRS) regardless of severity, not just patients with \u201cmild\u201d illness (prior guideline) [6]. The purpose of this statement is to encourage consideration of supportive therapies that may improve quality of life for indi-viduals with viral rhinosinusitis (VRS) and to avoid unneces-sary prescribing of antibiotics for viral disease. [7]",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Watchful waiting without antibiotics",
    "correct_answer_idx": 1,
    "model_reasoning": "According to the guidelines for managing uncomplicated acute bacterial rhinosinusitis (ABRS), the appropriate initial management strategy is to adopt a \"watchful waiting\" approach without the immediate use of antibiotics. This recommendation applies regardless of the severity of the symptoms. The rationale behind this strategy is to avoid unnecessary antibiotic prescriptions, especially since many cases of rhinosinusitis are viral in nature and do not require antibiotic treatment. Supportive therapies may be considered to alleviate symptoms, but the primary recommendation is to monitor the patient's condition before deciding on further interventions. Therefore, in this case, the correct choice is \"Watchful waiting without antibiotics.\"",
    "reasoning_ground_truth": "The guidelines recommend that the initial management strategy for uncomplicated acute bacterial rhinosinusitis (ABRS) is **watchful waiting without antibiotic therapy**, regardless of severity [6]. Supportive therapies for symptom relief can also be considered [7].",
    "is_correct": true
  },
  {
    "question": "A 40-year-old male presents to the emergency department with a witnessed seizure lasting 7 minutes. He has no known history of epilepsy. According to the guidelines, what is the recommended initial therapy?",
    "context": "The second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy\nBased on the evidence-based answers to the above questions, a treatment algorithm is proposed for convulsive status epilepticus (Figure 1). As stated earlier, clinical trials have arbitrarily focused on either adults or children, and only three trials (24, 27, 30) included both. The guideline\u2019s\nmore than 5 minutes it is likely to be prolonged (3), status treatment protocols have used a 5-minute definition to minimize both the risk of seizures reaching 30 minutes and the adverse outcomes associated with needlessly intervening on brief, self-limited seizures (2, 4). This guideline follows\nThe third therapy phase should begin when the seizure duration reaches 40 minutes. There is no clear evidence to guide therapy in this phase (level U). Compared with initial therapy, second therapy is often less effective (adults\u2014level A, one class I RCT; children\u2014level C, two class III RCTs), and\nThis guideline will address the evidence regarding the treatment of convulsive status epilepticus. For the purposes of this guideline, only studies that enrolled subjects having a seizure duration of at least 5 minutes were considered. The guideline\u2019s analysis is presented by subject age (adult",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). A benzodiazepine (specifically IM mid-azolam, IV lorazepam, or IV diazepam) is recommended as the initial therapy of choice [8, 9]",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 1,
    "model_reasoning": "According to the guidelines for treating convulsive status epilepticus, the initial therapy of choice is a benzodiazepine. The options include intramuscular midazolam, intravenous lorazepam, intravenous diazepam, and intravenous phenobarbital. Among these, intramuscular midazolam is particularly recommended when intravenous access is not established, as it has shown superior effectiveness in adults. In this scenario, the patient has a witnessed seizure lasting 7 minutes, which qualifies for immediate intervention. Therefore, the best choice for initial therapy in this case is intramuscular midazolam (Option B). Intravenous phenytoin and intravenous phenobarbital are not first-line treatments for initial therapy in this context, and while intravenous lorazepam is also an option, midazolam is preferred when IV access is not available.",
    "reasoning_ground_truth": "For convulsive status epilepticus, the guidelines recommend that a benzodiazepine (specifically IM midazolam, IV lorazepam, or IV diazepam) is the initial therapy of choice. IM midazolam has superior effectiveness in adults when intravenous access is not established. IV Phenobarbital is an alternative, not first line [8, 9].",
    "is_correct": true
  },
  {
    "question": "A 60-year-old female presents with a 6-month history of persistent nasal congestion and facial pressure. She has tried over-the-counter remedies with no relief. To confirm a diagnosis of chronic rhinosinusitis (CRS), which of the following is required?",
    "context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over\n|Chronic rhinosinusitis|Twelve weeks or longer of two or more of the following signs and symptoms: \u2022 mucopurulent drainage (anterior, posterior, or both), \u2022 nasal obstruction (congestion), \u2022 facial pain-pressure-fullness, or \u2022 decreased sense of smell. AND inflammation is documented by one or more\n|7B. Objective confirmation of a diagnosis of CRS|The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.|\nSymptoms of CRS vary in severity and prevalence. Nasal obstruction is most common (81%-95%) followed by facial congestion-pressure-fullness (70%-85%), discolored nasal discharge (51%-83%) and hyposmia (61%-69%). The presence of 2 or more signs or symptoms persisting beyond 12 weeks is highly\nClinicians should assess the patient with chronic rhinosinusitis or recurrent acute rhinosinusitis for multiple chronic conditions that would modify management such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia. Recommendation based on one systematic review and multiple",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed  tomography. [10] The purpose of this statement is to strongly emphasize that a diagnosis of CRS cannot be based on signs and symptoms alone but also requires objective evidence of sinonasal inflammation [11]",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Objective documentation of sinonasal inflammation",
    "correct_answer_idx": 1,
    "model_reasoning": "The guidelines for diagnosing chronic rhinosinusitis (CRS) clearly state that a clinical diagnosis cannot be made based solely on self-reported symptoms. Instead, it requires objective documentation of sinonasal inflammation. This can be achieved through methods such as anterior rhinoscopy, nasal endoscopy, or computed tomography (CT). The patient's symptoms of persistent nasal congestion and facial pressure, while indicative of CRS, must be supported by objective evidence of inflammation to confirm the diagnosis. Therefore, the correct answer is B, \"Objective documentation of sinonasal inflammation.\"",
    "reasoning_ground_truth": "The guidelines state that a diagnosis of CRS cannot be based on signs and symptoms alone, but also requires **objective evidence of sinonasal inflammation**, which can be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography [10, 11].",
    "is_correct": true
  },
  {
    "question": "A 45-year-old male with a new diagnosis of primary open-angle glaucoma is being educated about his condition. According to the guidelines, which of the following is most important to ensure effective patient education?",
    "context": "When deciding to treat a patient with glaucoma, it is important to remember that the goal of treatment is to maintain the IOP within a range at which visual field loss is unlikely to substantially reduce a patient\u2019s health-related quality of life over his or her lifetime.322\nmedications and to barriers to self-management. Ophthalmologists should remain mindful that the diagnosis of glaucoma can itself lead to negative psychological effects and to fear of blindness.691-695\n- Educate and involve the patient and appropriate family members/caregivers in the management of the disease.\n- Maintain quality of vision and preserve quality of life.\nGuidelines for follow-up of patients with POAG are summarized in Table 7. These recommendations apply to ongoing glaucoma management and not to visits for other purposes. The purpose of follow-up examination is to evaluate IOP level, visual field status, and optic disc appearance as well as ONH,\nThe goals of managing patients with POAG are to control IOP in a target range and to prevent progressive visual field and optic nerve/RNFL damage in order to preserve visual function and quality of life. The initial glaucoma evaluation includes all components of the comprehensive adult medical\nOphthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s). Patients with poor health literacy skills may be especially vulnerable to worse visual outcomes.696 Limiting dense text and using \u201cteach-back\u201d techniques such as asking",
    "ground_truth_context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s). Patients with poor health literacy skills may be especially vulnerable to worse visual outcomes.696 Limiting dense text and using \u201cteach-back\u201d techniques such as asking patients to explain what they understand about glaucoma may be helpful for patients with limited literacy skills. [12]",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Ensuring the information is clear, relevant, and accessible",
    "correct_answer_idx": 2,
    "model_reasoning": "The guidelines emphasize the importance of providing education that is \"clear, relevant, and accessible\" to patients and their caregivers. This approach is particularly crucial for patients with poor health literacy skills, who may struggle to understand complex medical information. Providing lengthy written materials (Option A) may overwhelm the patient, while using complex medical terminology (Option B) can lead to confusion and misunderstanding. Relying solely on verbal explanations (Option D) may not be sufficient, especially if the patient has difficulty retaining information. Therefore, ensuring that the information is clear, relevant, and accessible (Option C) is the most effective strategy for patient education in the context of managing primary open-angle glaucoma.",
    "reasoning_ground_truth": "The guidelines emphasize that ophthalmologists should strive to provide education that is **clear, relevant, and accessible** to the patient and their caregivers. Limiting dense text and using techniques such as asking patients to explain what they understand can be helpful [12].",
    "is_correct": true
  },
  {
    "question": "A 50-year-old female with rheumatoid arthritis (RA) has moderate-to-high disease activity despite being treated with methotrexate. Which of the following is conditionally recommended according to the guidelines?",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nMethotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.  \n|Continuation of all DMARDs at their current dose|is conditionally recommended over a dose reduction of a DMARD.|\n|---|---|\nMethotrexate monotherapy is conditionally recommended over dual or triple csDMARD therapy for DMARD-naive patients with moderate-to-high disease activity. The recommendation favors methotrexate monotherapy because the higher burden of combination therapy (e.g., multiple medications, higher cost)\n|Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.**|Moderate/very low|PICO 6b.C1\u20134/C5\u00a7|p. 136\u201356|\nmonotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients\nA split dose of oral methotrexate over 24 hours or weekly subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.\nMethotrexate monotherapy is conditionally recommended over methotrexate plus a tumor necrosis factor (TNF) inhibitor for DMARD-naive patients with moderate-to-high disease activity. Methotrexate monotherapy is strongly preferred given the lack of proven benefit and additional risks and costs",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD [13]",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Continuing methotrexate monotherapy",
    "correct_answer_idx": 2,
    "model_reasoning": "According to the guidelines, for patients with moderate-to-high disease activity who are already being treated with methotrexate, the recommendation is to continue methotrexate monotherapy rather than switching to a different DMARD or adding a biologic or targeted synthetic DMARD. This is based on the evidence that methotrexate monotherapy is conditionally recommended over the combination of methotrexate with a biologic DMARD (bDMARD) or a targeted synthetic DMARD (tsDMARD). Therefore, in this scenario, the best option is to continue with methotrexate monotherapy, making option C the correct choice.",
    "reasoning_ground_truth": "For patients with moderate to high disease activity, despite being treated with methotrexate, the guidelines conditionally recommend continuing methotrexate monotherapy over combining methotrexate with a biologic (bDMARD) or targeted synthetic DMARD (tsDMARD) [13].",
    "is_correct": true
  },
  {
    "question": "A 25-year-old male is diagnosed with gonococcal urethritis.  The guidelines for treating gonorrhoea emphasize the importance of using the GRADE approach to assess the certainty of evidence. What is one way this is achieved?",
    "context": "The GRADE approach was used to assess the overall certainty of the evidence for each critical or important outcome.145 The GRADEPro Guideline Development Tool was used to create evidence profiles that categorized the overall quality of the body of evidence for each outcome into 1 of 4 categories:\nthe basis for quantifying the overall certainty of the evidence using the \u201cGrading of Recommendations Assessment, Development, and Evaluation\u201d (GRADE) approach. The penultimate version of the guideline also undergoes public review to capture additional perspectives. Thus, guidelines are the result\n|Recommendations|Strength of recommendation and quality of evidence|\n|---|---|\n|Genital and anorectal gonococcal infections| |\n|Recommendation 1|Good practice statement|\nThe quality of the evidence for the effects of treatments for gonococcal infections is low. Evidence is available from 108 studies, including 14 randomized and 94 non-randomized studies, which were conducted in a broad range of high-, middle- and low-income countries. Although high cure rates were\nThe quality of the evidence for the effects of different treatments for oropharyngeal gonococcal infections is low and very low, and therefore, overall, the evidence for this recommendation is very low. Evidence from 28 studies was identified: eight randomized and 20 non-randomized studies\n- Aggregate evidence quality: Grade B, randomized controlled trials with limitations supporting a cut-point of 7 days for lack of improvement; Grade D, expert opinion and first principles for changing therapy, including the use of rescue antibiotic in randomized controlled trials 5,132\nThese guidelines provide recommendations for treatment of gonorrhoea based on the best global evidence available at the time of compilation. However, the epidemiology and AMR of STIs vary by geographical location and are constantly changing, sometimes rapidly. It is recommended that countries",
    "ground_truth_context": "Briefly, the GRADE approach assesses the quality of evidence for treatment interventions using well-established criteria for the design, risk of bias, inconsistency, indirectness, imprecision, effect size, dose\u2013response curve and other considerations that may affect the quality of the evidence. [14]",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "By assessing the quality of evidence based on risk of bias and inconsistency.",
    "correct_answer_idx": 2,
    "model_reasoning": "The GRADE approach is a systematic method used to assess the quality of evidence for treatment interventions. It evaluates various factors that can affect the quality of evidence, including risk of bias, inconsistency, indirectness, imprecision, and effect size. This comprehensive assessment allows for a more nuanced understanding of the evidence rather than relying solely on expert opinions, conducting narrative reviews, or only including data from randomized controlled trials. Therefore, the correct answer is that the GRADE approach achieves its assessment of evidence quality by evaluating these specific criteria, particularly focusing on risk of bias and inconsistency.",
    "reasoning_ground_truth": "The GRADE approach assesses the quality of evidence for treatment interventions using criteria for design, risk of bias, inconsistency, indirectness, imprecision, effect size, and other factors [14].",
    "is_correct": true
  },
  {
    "question": "A 65-year-old male is admitted to the hospital with an acute medical illness. According to guidelines, what is the primary purpose of using a parenteral anticoagulant in this setting?",
    "context": "to prevent VTE in these adult in-hospital and outpatient medical populations who are not on chronic anticoagulants for other indications.\nany parenteral anticoagulant for VTE prevention so that the desirable consequences were greater than the undesirable consequences.\nConclusions and research needs for this recommendation. The panel determined that there is low certainty in the evidence for a net health benefit from using any parenteral anticoagulant in acutely ill medical patients. Other EtD criteria were generally in favor of using any parenteral anticoagulant\nRecommendations 1, 2, and 3. In acutely ill medical patients, the American Society of Hematology (ASH) guideline panel suggests using UFH, LMWH, or fondaparinux rather than no parenteral anticoagulant (conditional recommendation, low certainty in the evidence of effects). Among these anticoagulants,\nIn acutely ill medical patients, the ASH guideline panel suggests using UFH, LMWH, or fondaparinux rather than no parenteral anticoagulant (conditional recommendation, low certainty in the evidence of effects \u00c5\u00c5\u25ef\u25ef). Among these anticoagulants, the panel suggests using LMWH (low certainty in the\n- Acutely ill patients: pharmacological prophylaxis addressing the following comparisons\n1. Parenteral anticoagulant vs no parenteral anticoagulant\n2. LMWH vs unfractionated heparin\n3. Fondaparinux vs low molecular weight heparin or unfractionated heparin\n- More information on the optimal dosing of parenteral anticoagulation to prevent VTE in medical inpatients is needed. In particular, can lower or higher doses be used in different settings (perhaps dependent on baseline risk), and should dosing be adjusted in obese patients, underweight patients,\nIn the 2013 IUA updated guidelines, risk assessment of medically ill patients and treatment with LMWH or fondaparinux was recommended, as was consideration of postdischarge treatment of women, patients older than 75 years, or those with severe immobility. They also recommended, with moderate",
    "ground_truth_context": "The panel also considered the randomized controlled trial (RCT) by Cohen et al28 that compared fondaparinux against no parenteral anticoagulation and felt that the results were similar enough to include fondaparinux with UFH and LMWH. The EtD framework is shown online at https://dbep.gradepro.org/profile/ 54B577E9-7F80-3A78-B3EA-3850E9A1D432.[15]",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "To prevent the development of venous thromboembolism (VTE)",
    "correct_answer_idx": 1,
    "model_reasoning": "The primary purpose of using a parenteral anticoagulant in acutely ill medical patients is to prevent the development of venous thromboembolism (VTE), which encompasses conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). The guidelines specifically recommend the use of anticoagulants like unfractionated heparin (UFH), low molecular weight heparin (LMWH), or fondaparinux for this preventive measure, indicating that the focus is on reducing the risk of VTE rather than treating existing conditions, managing bleeding events, or addressing arterial thrombosis. The context provided emphasizes the importance of VTE prevention in hospitalized patients, aligning with the correct answer choice.",
    "reasoning_ground_truth": "The primary purpose of parenteral anticoagulation in acutely ill medical patients is to **prevent the development of VTE**, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE) [15].",
    "is_correct": true
  },
  {
    "question": "A 60-year-old male with a history of smoking and hypertension presents with a persistent cough, fever, and shortness of breath. A chest X-ray reveals a right lower lobe infiltrate. Initial blood cultures are negative. What is the most appropriate next step in his management?",
    "context": "and symptoms of pneumonia with radiographic confirmation) to completion of antimicrobial therapy and follow-up chest imaging.\nIn Adults with CAP Who Are Improving, Should Follow-up Chest Imaging Be Obtained?\n|Routine use of follow-up chest imaging|Not addressed|Recommended not to obtain. Patients may be eligible for lung cancer screening, which should be performed as clinically indicated|\nIn adults with CAP whose symptoms have resolved within 5 to 7 days, we suggest not routinely obtaining follow-up chest imaging (conditional recommendation, low quality of evidence).\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,",
    "ground_truth_context": "our recommendations are to initially treat empirically for possible bacterial infection or coinfection. Routinely obtaining blood cultures may generate false-positive results that lead to unnecessary antibiotic use and increased length of stay.",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
    "correct_answer_idx": 0,
    "model_reasoning": "The patient presents with symptoms and radiographic findings consistent with community-acquired pneumonia (CAP), specifically a right lower lobe infiltrate on chest X-ray. Given the clinical context, the most appropriate next step in management is to start empiric antibiotic therapy for CAP. This is in line with clinical guidelines that recommend initiating treatment for suspected bacterial infections without delay, even if blood cultures are negative. \n\nThe other options are less appropriate in this scenario:\n- Option B (Prescribe cough suppressants and monitor symptoms) does not address the underlying infection and could lead to worsening of the patient's condition.\n- Option C (Perform a bronchoscopy to obtain lower respiratory secretions for culture) is not typically the first step in managing CAP unless there are specific indications for it, such as suspicion of an atypical pathogen or failure to respond to initial therapy.\n- Option D (Order a CT scan of the chest with contrast to rule out pulmonary embolism) is unnecessary at this stage, as the primary concern is the pneumonia, and the clinical presentation does not strongly suggest a pulmonary embolism.\n\nTherefore, starting empiric antibiotic therapy is the most appropriate and evidence-based choice for this patient.",
    "reasoning_ground_truth": "The patient's symptoms and chest X-ray findings are consistent with CAP. The guidelines recommend initiating **empiric antibiotic therapy** for possible bacterial infection or coinfection. Although blood cultures are recommended, they should not delay the start of antibiotic treatment. The other options are not the first-line steps for a typical CAP case.",
    "is_correct": true
  },
  {
    "question": "A 72-year-old female with known chronic kidney disease (CKD) and type 2 diabetes is admitted for a urinary tract infection. Her estimated glomerular filtration rate (eGFR) based on serum creatinine (SCr) is 35 mL/min/1.73 m\u00b2. What is the most appropriate approach for medication dosing?",
    "context": "Practice Point 4.1.2: Monitor eGFR, electrolytes, and therapeutic medication levels, when indicated, in people with CKD receiving medications with narrow therapeutic windows, potential adverse effects, or nephrotoxicity, both in outpatient practice and in hospital settings.\nMonitor eGFR, electrolytes, and therapeutic medication levels, when indicated, in people with CKD receiving medications with narrow therapeutic windows, potential adverse effects, or nephrotoxicity, both in outpatient practice and in hospital settings. Ensuring a safe use of medication requires\nMany medications and/or their active metabolites are excreted by the kidneys. Failure to properly account for the effect of GFR when designing appropriate drug-dosing regimens can predispose a person to treatment failure or adverse events. 725, 728 Although guidelines for adjustment of the dosing\nPractice Point 3.6.5: Consider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate [eGFR] &lt;15\n36. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839\u20132844.\n37. Erler A, Beyer M, Petersen JJ, et al. How to improve drug dosing for patients with renal impairment in primary care\u2014a cluster-randomized controlled trial. BMC Fam Pract. 2012;13:91.\n1. Khanal A, Castelino RL, Peterson GM, et al. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources? Intern Med J. 2014;44:77\u201385.\nRecommendation 3.7.3: We suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).\nWe suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).\nPractice Point 3.7.1: Once an SGLT2i is initiated, it is reasonable to continue an SGLT2i even if the eGFR falls below 20 ml/min per 1.73 m\u00b2, unless it is not tolerated or KRT is initiated.  \nRecommendation 3.7.2: We recommend treating adults with CKD with an SGLT2i for the following (1A):\nPractice Point 4.2.1: Consider GFR when dosing medications cleared by the kidneys.  \nPractice Point 4.2.2: For most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing.",
    "ground_truth_context": "Where more accuracy is required for drug-related decision-making (e.g., dosing due to narrow therapeutic or toxic range), drug toxicity, or clinical situations where eGFRcr estimates may be unreliable, use of equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Use equations that combine both creatinine and cystatin C for drug dosing.",
    "correct_answer_idx": 1,
    "model_reasoning": "In the context of the 72-year-old female patient with chronic kidney disease (CKD) and an estimated glomerular filtration rate (eGFR) of 35 mL/min/1.73 m\u00b2, it is crucial to ensure accurate medication dosing to avoid potential adverse effects or treatment failure. The guidelines suggest that for most patients, validated eGFR equations using serum creatinine (SCr) are appropriate for drug dosing. However, when more accuracy is required\u2014such as in cases involving medications with narrow therapeutic windows, potential toxicity, or when eGFR estimates may be unreliable\u2014using equations that combine both creatinine and cystatin C is recommended. This approach provides a more precise assessment of kidney function, which is essential for safe and effective medication management in patients with CKD. Therefore, option B is the most appropriate approach for medication dosing in this scenario.",
    "reasoning_ground_truth": "For most people, validated eGFR equations using SCr are appropriate for drug dosing. However, when **more accuracy** is needed, such as with a narrow therapeutic range, drug toxicity, or when eGFR estimates may be unreliable, equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old male presents with a first-time seizure lasting 7 minutes. He has no history of epilepsy. Intravenous (IV) access is difficult to obtain. What is the preferred initial pharmacologic treatment?",
    "context": "The following conclusions were drawn. In adults, IM midazolam, IV lorazepam, IV diazepam (with or without phenytoin), and IV phenobarbital are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Intramuscular midazolam has superior effectiveness compared with IV\nThe second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nreceive a second dose of medication if the seizures continued after 10 minutes. For all patients, phenytoin was given after 30 minutes. A total of 70 patients were randomized to either lorazepam (n = 37) or diazepam (n = 33) (25). Lorazepam was successful for 78% of subjects after one dose and 89%\nIntravenous lorazepam (0.1 mg/kg over 2\u20134 minutes) was compared with IV levetiracetam (20 mg/kg over 15 minutes) in a class III RCT involving children with either convulsive or subtle convulsive status epilepticus. As first therapy, lorazepam success rate (29/38, 76.3%) was similar to that for\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy\nNine RCTs (three class I [22\u201324], one class II [25], and five class III [26\u201330]) addressed the efficacy of initial therapy. The 1998 Veteran\u2019s Affairs status epilepticus study was a multi-center randomized comparison of four different IV treatments: lorazepam (0.1 mg/kg), diazepam (0.15 mg/kg)",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 0,
    "model_reasoning": "In the scenario presented, the patient is experiencing a first-time seizure lasting 7 minutes, and intravenous (IV) access is difficult to obtain. According to the guidelines for treating convulsive status epilepticus, intramuscular midazolam is the preferred initial pharmacologic treatment when IV access is not readily available. \n\nIntramuscular midazolam has been shown to have superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus when IV access cannot be established. While IV lorazepam is a first-line treatment for status epilepticus, it requires IV access, which is not feasible in this case. \n\nRectal diazepam is another alternative, but midazolam is favored due to its better effectiveness in this context. Therefore, the best choice for this patient is intramuscular midazolam (Option A).",
    "reasoning_ground_truth": "For patients with convulsive status epilepticus where **IV access is difficult**, intramuscular midazolam is superior to intravenous lorazepam. IV lorazepam is a first line treatment for status epilepticus, but if an IV line cannot be established, IM midazolam is prefered. Rectal diazepam is a reasonable alternative, but midazolam has better effectiveness when IV access is not established.",
    "is_correct": true
  },
  {
    "question": "A 48-year-old woman with a history of heavy alcohol use presents with jaundice, ascites, and confusion. She has been diagnosed with alcoholic hepatitis. What is the initial nutritional recommendation?",
    "context": "In patients with severe alcoholic hepatitis, oral intake is consistently reduced [110,111,142,181]. When the treatments are consistent in the groups, supplemental nutrition does improve infection and acute mortality, specifically in hospital deaths over ad lib oral dietary intake [186e188]. Enteral\n1.2.16 Explain to people with NAFLD who drink alcohol the importance of staying within the national recommended limits for alcohol consumption.\nin patients with NAFLD [288]. These findings were not included in the AASLD/AG [120] and EASL/EASD/EASO [119] guidelines recommending only to abstain from heavy amounts of alcohol. Until evidence from intervention studies is available it seems unjustified to suggest a potential health benefit from\nTake an alcohol history to rule out alcohol-related liver disease. See also NICE's guideline on cirrhosis.\n44. Nasrallah SM, Galambos JT. Aminoacid therapy of alcoholic hepatitis. Lancet 1980;2(8207):1276e7.\n45. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev 2012;(5), Cd008344.\nA total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury distinct\n47. Fialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. Liver Int Off J Int Assoc Stud Liver 2015;35(9):2072e8.\nintake [186e188]. Enteral or supplemental feeding has been evaluated in severe alcoholic hepatitis, but no mortality benefit has been consistently reported. In the VA studies, a survival advantage to supplemental nutrition was reported in patients with malnutrition. In a meta-analysis of 13\n40. Mendenhall C, Bongiovanni G, Goldberg S, Miller B, Moore J, Rouster S, et al. VA cooperative study on alcoholic hepatitis. III: changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. J Parenter Enteral Nutr\n19. Bunout D, Aicardi V, Hirsch S, Petermann M, Kelly M, Silva G, et al. Nutritional support in hospitalized patients with alcoholic liver disease. Eur J Clin Nutr 1989;43(9):615e21.",
    "ground_truth_context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Start enteral nutrition with a standard formula",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient in this scenario has been diagnosed with alcoholic hepatitis, which is a serious condition that requires careful nutritional management. According to guidelines for managing patients with liver disease, particularly those with severe conditions like alcoholic hepatitis, enteral nutrition is recommended as it provides a safe and effective means of delivering necessary nutrients. \n\nStarting enteral nutrition with a standard formula is crucial because it helps to address the nutritional deficiencies that often accompany liver disease, especially in patients who may have reduced oral intake due to their condition. This approach can improve outcomes, including reducing the risk of infections and mortality associated with malnutrition.\n\nOn the other hand, options A (restricting fluid intake) and D (delaying nutritional support) could potentially worsen the patient's condition by exacerbating malnutrition and leading to further complications. Option B (initiating a high-protein, low-carbohydrate diet) is not appropriate as it does not align with the standard nutritional recommendations for patients with liver disease, where enteral nutrition is preferred.\n\nTherefore, the best initial nutritional recommendation for this patient is to start enteral nutrition with a standard formula.",
    "reasoning_ground_truth": "The patient has signs of liver disease, which requires nutritional management. Based on the liver disease guideline, enteral nutrition should be started and is a safe route for delivery of nutritional support for patients with liver disease. Restricting fluids and or delaying nutrition may cause significant harm.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old patient with a history of coronary artery disease underwent percutaneous coronary intervention (PCI) with drug-eluting stent placement. How long should dual antiplatelet therapy (DAPT) be continued?",
    "context": "|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable\nboth in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone (51,52). Available evidence from this trial, as well as from PLATO (53,71,72) and TRITON-TIMI 38 (54,55), supports DAPT duration of at least 12 months for patients with NSTE-ACS.\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\nrecommended duration of P2Y12 inhibitor therapy (in addition to aspirin therapy). Figure 1 summarizes recommendations for duration of DAPT according to clinical status.\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\nof patients 1 to 3 years after myocardial infarction (MI) assessing the efficacy of DAPT compared with aspirin monotherapy (28). These studies were published after the formulation of recommendations for duration of DAPT in prior guidelines. The specific mandate of the present writing group is to",
    "ground_truth_context": "Most contemporary studies of DAPT have compared either shorter (3 to 6 months) (17\u201321) or longer (18 to 48 months) (16,22\u201326) duration of therapy with 12 months of DAPT, which is the recom-mended or minimal duration of therapy for most patients in ACC/AHA (9,13,14) and European Society of Cardiology (31\u201333) guidelines published between 2011 and 2014.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "12 months",
    "correct_answer_idx": 2,
    "model_reasoning": "The recommended or minimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) with drug-eluting stent placement is 12 months. This recommendation is supported by various guidelines, including those from the American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology. While some studies have explored shorter (3 to 6 months) or longer (18 to 48 months) durations of therapy, 12 months remains the standard recommendation for most patients. Therefore, for a 50-year-old patient with a history of coronary artery disease who underwent PCI with drug-eluting stent placement, continuing DAPT for 12 months is the appropriate course of action.",
    "reasoning_ground_truth": "For most patients, 12 months of DAPT is the recommended or minimal duration of therapy following PCI with drug-eluting stent placement. The duration can vary based on the patient profile, but 12 months is the standard recommendation.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male with a history of benign prostatic hyperplasia (BPH) and hypertension presents with new-onset fatigue, constipation, and dry skin. His TSH level is elevated, and free T4 level is low. What is the appropriate initial treatment?",
    "context": "Treatment based on individual factors for patients with TSH levels between the upper limit of a given laboratory\u2019s reference range and 10 mIU/L should be considered particularly if patients have symptoms suggestive of hypothyroidism, positive TPOAb or evidence of atherosclerotic cardiovascular\nPatients whose serum TSH levels exceed 10 mIU/L are at increased risk for heart failure and cardiovascular mortality, and should be considered for treatment with L-thyroxine. Grade B, BEL 1\ntherapy (54,55) (see L-thyroxine treatment of hypothyroidism).\nPatients with hypothyroidism should be treated with L-thyroxine monotherapy. Grade A, BEL 1  \nSee: L-thyroxine treatment of hypothyroidism\nwith L-thyroxine. This has been reported in 20% of those treated with thyroid hormone (12). The principal adverse consequences of subtle or frank overtreatment are cardiovascular (187-190), skeletal (191-194), and possibly affective disturbances (195-197). The elderly are particularly susceptible to\nWhen initiating therapy in patients older than 50-60 years with overt hypothyroidism, without evidence of coronary heart disease, an L-thyroxine dose of 50 \u00b5g daily should be considered. Grade D, BEL 4  \nSee: L-thyroxine treatment of hypothyroidism\nWhen initiating therapy in young healthy adults with overt hypothyroidism, beginning treatment with full replacement doses should be considered. Grade B, BEL 2  \nSee: L-thyroxine treatment of hypothyroidism",
    "ground_truth_context": "The standard treatment is replacement with L-thyroxine which must be tailored to the individual patient.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Levothyroxine (T4) monotherapy",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient in the scenario is a 68-year-old male presenting with symptoms and laboratory findings consistent with primary hypothyroidism, indicated by elevated TSH levels and low free T4 levels. According to the guidelines for treating hypothyroidism, the standard initial treatment is L-thyroxine (T4) monotherapy. This is supported by the context provided, which states that patients with hypothyroidism should be treated with L-thyroxine monotherapy, and combination therapy with T3 is not recommended in the majority of cases. Given the patient's age and the absence of coronary heart disease, starting with a dose of 50 \u00b5g daily is appropriate. Therefore, the correct treatment option is Levothyroxine (T4) monotherapy (Option C).",
    "reasoning_ground_truth": "The patient's symptoms and lab results are consistent with primary hypothyroidism. The standard treatment is replacement with L-thyroxine (T4). Combination therapy with T3 is not recommended in the majority of cases.",
    "is_correct": true
  },
  {
    "question": "A 35-year-old pregnant woman, at 20 weeks gestation, presents with a new diagnosis of gonococcal infection. What is the recommended treatment?",
    "context": "Conditional  \nIn neonates with gonococcal conjunctivitis, the WHO STI guideline suggests one of the following treatment options:  \n- ceftriaxone 50 mg/kg (maximum 150 mg) IM as a single dose\n- kanamycin 25 mg/kg (maximum 75 mg) IM as a single dose\nRemarks: Treatment failures have been observed after single therapy for gonococcal oropharyngeal infections and therefore dual therapy is suggested over single therapy. This recommendation applies to pregnant women, who should be closely monitored for complications.\nRemarks: Treatment failures have been observed after single therapy for gonococcal oropharyngeal infections and therefore dual therapy is suggested over single therapy. This recommendation applies to pregnant women, who should be closely monitored for complications.\nIn neonates with gonococcal conjunctivitis, the WHO STI guideline suggests one of the following treatment options:  \n- ceftriaxone 50 mg/kg (maximum 150 mg) IM as a single dose\n- kanamycin 25 mg/kg (maximum 75 mg) IM as a single dose\n- spectinomycin 25 mg/kg (maximum 75 mg) IM as a single dose.\nIn people with gonococcal infections who have failed treatment, the WHO STI guideline suggests the following options.  \n- If reinfection is suspected, re-treat with a WHO-recommended regimen, reinforce sexual abstinence or condom use, and provide partner treatment.",
    "ground_truth_context": "Six PICO questions were identified for the update on the treatment of genital, anorectal and oropharyngeal gonococcal infections, management of treatment failure, and prevention and treatment of neonatal ophthalmia (see Annex B). These questions pertained to adults and other special populations,  namely adolescents, pregnant women, people living  with HIV, and populations at high risk of acquiring  and transmitting STIs, such as men who have sex with men (MSM) and sex workers.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Intramuscular ceftriaxone 500 mg single dose",
    "correct_answer_idx": 1,
    "model_reasoning": "The recommended treatment for gonococcal infection in pregnant women is intramuscular ceftriaxone 500 mg as a single dose. This is because ceftriaxone is effective against Neisseria gonorrhoeae, the bacteria responsible for gonococcal infections, and it is safe to use during pregnancy. \n\nOral azithromycin, while sometimes used in other contexts, may not provide adequate coverage for gonococcal infections on its own, especially given the potential for treatment failures. Oral doxycycline is contraindicated in pregnancy due to its association with adverse effects on fetal development. Topical erythromycin ointment is not an adequate treatment for systemic gonococcal infections, as it does not effectively treat the infection in the body. \n\nTherefore, the best and most appropriate choice for treating a pregnant woman with a gonococcal infection is option B: Intramuscular ceftriaxone 500 mg single dose.",
    "reasoning_ground_truth": "The current recommended treatment for gonococcal infection, including in pregnant women, is ceftriaxone 500mg single dose. Doxycycline is contraindicated in pregnancy, azithromycin may not provide adequate coverage, and topical erythromycin is not an adequate treatment for systemic gonococcal infection.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old patient with rheumatoid arthritis (RA) is currently on methotrexate. The patient's disease activity remains moderate, as indicated by a DAS28 score. What is the next appropriate step in managing RA?",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nMethotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.  \n|Continuation of all DMARDs at their current dose|is conditionally recommended over a dose reduction of a DMARD.|\n|---|---|\nmonotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients\nThe recommendation is conditional because the voting panel thought that some patients who have already had persistent disease activity despite use of \u22651 csDMARD will prefer combination treatment for a more rapid response.  \nRecommendations for administration of methotrexate (Table 3)\nMethotrexate monotherapy is conditionally recommended over methotrexate plus a tumor necrosis factor (TNF) inhibitor for DMARD-naive patients with moderate-to-high disease activity. Methotrexate monotherapy is strongly preferred given the lack of proven benefit and additional risks and costs\nMethotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD physician and patient preferences regarding the tradeoff between the increased efficacy and risks of toxicity associated with higher starting doses. This recommendation refers only to\nin csDMARD-treated, but methotrexate-naive, patients with moderate-to-high disease activity#|Initiation of treatment in csDMARD-treated, but methotrexate-naive, patients with moderate-to-high disease activity#|\nMethotrexate monotherapy is conditionally recommended over dual or triple csDMARD therapy for DMARD-naive patients with moderate-to-high disease activity. The recommendation favors methotrexate monotherapy because the higher burden of combination therapy (e.g., multiple medications, higher cost)",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Add a biologic or targeted synthetic DMARD to methotrexate",
    "correct_answer_idx": 1,
    "model_reasoning": "In the context of managing rheumatoid arthritis (RA) for a patient whose disease activity remains moderate despite being on methotrexate, the most appropriate next step is to add a biologic or targeted synthetic DMARD to the current treatment regimen. This approach is supported by the guidelines, which suggest that if a patient's RA remains moderately active while on methotrexate, it is beneficial to introduce an additional DMARD to better control disease activity. \n\nWhile increasing the dose of methotrexate (Option A) could be considered in some cases, the guidelines emphasize that adding a second DMARD is generally more effective for managing moderate disease activity. Switching to sulfasalazine monotherapy (Option C) is not advisable since the patient is already on methotrexate, and it would not adequately address the moderate disease activity. Prescribing a short course of oral prednisone (Option D) may provide temporary relief but does not address the underlying disease management strategy and is not a long-term solution.\n\nTherefore, the best choice is to add a biologic or targeted synthetic DMARD to methotrexate (Option B) to enhance disease control and improve the patient's overall management of RA.",
    "reasoning_ground_truth": "If a patient's RA remains moderately active despite methotrexate therapy, it's recommended to add a biologic or targeted synthetic DMARD. Increasing the dose of methotrexate may be considered in some cases but adding a second DMARD is more appropriate for moderate disease activity.",
    "is_correct": true
  },
  {
    "question": "A 62-year-old male with a history of primary open-angle glaucoma (POAG) is being treated with prostaglandin eye drops. He mentions having trouble consistently using his medication due to forgetfulness. What is the most appropriate next step?",
    "context": "Instilling eye drops correctly is difficult for many patients, and their ability to do so may worsen with aging, comorbidities, and as glaucoma progresses.355, 356 Repeated instruction and counseling about proper techniques for using medication, including waiting at least 5 minutes between multiple\nEven patients with experience using glaucoma drops may struggle to administer drops successfully.355 Many patients depend on companions to assist with their drops.697 Ophthalmologists should consider instructing patients, and companions if applicable, on drop administration techniques. For some\nof patient education combined with personalized behavioral change interventions, including tailoring daily routines to promote adherence to eye drops, may improve adherence to glaucoma medications, overall there is insufficient evidence to recommend a particular intervention. Simplified drug\nAt each examination, medication dosage and frequency of use should be reviewed and recorded. Reviewing the time medication was taken may help patients link eye-drop administration to common activities of daily living and help to ensure patients are actually using their eye drops. Adherence to the\nimpotence that might occur with topical beta-blockers) may impact adherence to therapy.348, 354 Even with instruction, free medication, once-daily administration, use of a dosing aid, and electronic monitoring of adherence, nearly 45% of patients in one study took fewer than 75% of their prescribed\nPatient education through oral, written, and online information and informed participation in treatment decisions may improve adherence357 and overall effectiveness of glaucoma management. Adherence to medical therapy may be handicapped when patients run out of medication, due to inadvertent drop\nthan 75% of their prescribed doses.353 Fixed combinations of two medications may improve patient adherence by reducing the number of drops required for therapy.\n5 minutes between multiple drop regimens as well as a clearly written medication regimen and follow-up telephone calls or smartphone reminders, may improve adherence to therapy.353, 357 A Cochrane Systematic Review in 2013 found that although complex interventions consisting of patient education",
    "ground_truth_context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s).",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Encourage the use of a medication reminder system",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient in this scenario is experiencing difficulty with adherence to his glaucoma medication due to forgetfulness. The most appropriate next step is to encourage the use of a medication reminder system. This approach directly addresses the issue of forgetfulness and aims to improve adherence to the prescribed treatment regimen. \n\nSwitching to a beta-blocker eye drop (Option A) or recommending laser trabeculoplasty (Option B) may not effectively resolve the underlying issue of forgetfulness and could lead to further complications if the patient continues to struggle with adherence. Discontinuing treatment (Option D) is not advisable, as it would leave the patient's glaucoma untreated, potentially leading to disease progression.\n\nImplementing a medication reminder system is a practical and supportive strategy that can help the patient remember to take his eye drops consistently, thereby improving adherence and overall management of his glaucoma. This aligns with the context provided, which emphasizes the importance of patient education and strategies to enhance adherence to therapy.",
    "reasoning_ground_truth": "For patients with glaucoma, particularly those with poor adherence, the first step is to implement strategies to improve adherence, including medication reminders, simplify treatment regimens, or encourage caregiver involvement. Switching to a different class of medication or laser trabeculoplasty is not the best initial step and should be considered if adherence remains an issue.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male is admitted to the hospital with an acute illness. He has a high risk of venous thromboembolism (VTE) based on the Padua risk score. What is the recommended approach for VTE prophylaxis?",
    "context": "*A total of 60.3% of patients in this study were low risk (Padua score 0-3). VTE prophylaxis was administered by provider choice from among several medications and with or without concomitant compression stockings.  \nVTE incidence without VTE prophylaxis:  \n- Padua score 0 to 3: 0.3%\n- Padua score 0 to 3: 0.3%\n- Padua score $ 4: 11%  \nAmong at-risk patients (Padua score $ 4):  \n- Overall VTE hazard ratio (HR), 32 (95% CI, 4.1-251)\n- Incidence of VTE\n- - No prophylaxis: 11%\n- With prophylaxis: 2.2%\n- VTE HR with prophylaxis, 0.13 (95% CI, 0.04-0.4)\nShould VTE prophylaxis be used in medical outpatients with minor provoking factors for VTE (eg, immobility, minor injury, illness/infection)?\nIncidence of major or clinically relevant nonmajor bleeding with prophylaxis 5 1.6% (95% CI, 0.5-4.6)  \nInterpretation: among at-risk patients (Padua score $ 4), the reduction in VTE appears to outweigh the increased risk of bleeding with pharmacologic prophylaxis.\nAll guidelines advocated assessing the risk of VTE and bleeding in admitted medical patients. The American College of Physicians issued 2 additional recommendations: for the use of heparin or a related drug, unless patients were at high bleeding risk, and against use of graduated compression\nhospitalization, and against extending pharmacological prophylaxis after hospital discharge. Conditional recommendations included not to use VTE prophylaxis routinely in long-term care patients or outpatients with minor VTE risk factors. The panel conditionally recommended use of graduated\nThe 2017 Asian Venous Thrombosis Forum updated guidelines for medically ill patients concluded that, if prophylaxis was used, pharmacological prophylaxis was preferred in the absence of bleeding risk; otherwise, intermittent pneumatic compression, but not graduated compression stockings, were",
    "ground_truth_context": "We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89 (H. Vissinger and S. Husted, unpublished data, 1995) in these reviews evaluating outcomes relevant to this question.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Pharmacological prophylaxis with parenteral anticoagulation",
    "correct_answer_idx": 2,
    "model_reasoning": "The context indicates that patients with a high risk of venous thromboembolism (VTE), as determined by the Padua risk score, should receive pharmacological prophylaxis with parenteral anticoagulation. The guidelines specifically recommend this approach for acutely ill patients at high risk, emphasizing that pharmacological prophylaxis is preferred in the absence of bleeding risk. While mechanical prophylaxis, such as intermittent pneumatic compression, may be considered in cases where anticoagulation is contraindicated or as an adjunct therapy, it is not the first-line strategy. Therefore, for a 68-year-old male admitted with an acute illness and identified as high risk for VTE, the recommended approach is pharmacological prophylaxis with parenteral anticoagulation.",
    "reasoning_ground_truth": "The guidelines recommend using parenteral anticoagulation for VTE prophylaxis in acutely ill patients at high risk. Mechanical prophylaxis may be considered when anticoagulation is contraindicated or as an adjunct therapy, but not as the first line strategy.",
    "is_correct": true
  },
  {
    "question": "A 58-year-old male with a history of chronic kidney disease (CKD) is being evaluated for kidney function. His eGFR based on creatinine is 40 mL/min/1.73m^2. What additional test should be considered?",
    "context": "Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nIdentify adults at risk for CKD  \nTest for GFR* and ACR \u00b1 other markers of kidney damage \u2020  \nGFR &lt;60 ml/min per 1.73 m2 or ACR \u226530 mg/g [3 mg/mmol]2 and/or other markers of kidney damage present  \nTest for GFR or ACR if not performed and exclude AKI/AKD\nPractice Point 1.1.1.2: Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nand urine to detect CKD is important, with confirmatory testing if initial findings indicate the presence of abnormalities of creatinine/eGFR or albuminuria.\ndecisions as an assessment of excretory kidney function (Table 4) to detect and stage AKD and CKD, determine CKD progression, dose medications, determine appropriate use of diagnostic tests, and guide treatment decisions around KRT therapies. Equations are available that estimate GFR using SCr and\nImplications for aging adults with CKD are important in both diagnosis and treatment. The interpretation of laboratory results (specifically SCr) used in the staging system should factor in an older adult\u2019s habitus given the frequency of sarcopenia. A creatinine-based eGFR (eGFRcr) will\ndata were anto mGFR most consistently (i) review of past measurements/estimations of GFR; (ii) review of past measurements of albuminuria or proteinuria and urine microscopic examinations; (iii) imaging findings such as reduced kidney size and reduction in cortical thickness; (iv) kidney",
    "ground_truth_context": "If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Measure cystatin C to estimate eGFR",
    "correct_answer_idx": 1,
    "model_reasoning": "In the context of evaluating kidney function for a patient with chronic kidney disease (CKD) and an eGFR of 40 mL/min/1.73m\u00b2, it is important to ensure that the assessment of kidney function is accurate. The initial test for estimating GFR is based on creatinine (eGFRcr). However, if there are concerns that this measurement may be inaccurate\u2014such as in cases where muscle mass may affect creatinine levels, which is common in older adults\u2014then measuring cystatin C is recommended. Cystatin C is a protein that can provide a more accurate estimate of GFR, especially when creatinine-based estimates may not reflect true kidney function.\n\nThe other options are less appropriate in this scenario:\n- A. Repeating the creatinine-based eGFR in 3 months does not address the potential inaccuracies in the current measurement.\n- C. Performing a kidney biopsy is typically reserved for cases where the underlying cause of CKD is uncertain, rather than for evaluating GFR.\n- D. Starting renal replacement therapy is not indicated unless the eGFR is significantly lower or the patient is experiencing severe symptoms related to kidney failure.\n\nThus, measuring cystatin C to estimate eGFR is the most appropriate next step for this patient.",
    "reasoning_ground_truth": "The initial test for evaluating GFR is eGFRcr. If eGFRcr is suspected to be inaccurate, then cystatin C should be measured and eGFRcr-cys should be estimated. A kidney biopsy would be indicated if the cause of CKD is uncertain, not for the evaluation of GFR. Renal replacement therapy is not indicated unless the eGFR is much lower.",
    "is_correct": true
  },
  {
    "question": "A 42-year-old female with a history of migraine presents with frequent, severe headaches. She has tried several abortive therapies with limited success. What is the next step in her management?",
    "context": "Objective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention?\nmigraine prevention, similar evidence is unavailable to help the practitioner choose one therapy over another. Treatment regimens, therefore, need to be designed case by case, which may include complex or even nontraditional approaches. Moreover, decision-making must remain with the physician and\nThe following medications are established as effective and should be offered for migraine prevention:  \n- Antiepileptic drugs (AEDs): divalproex sodium, sodium valproate, topiramate\n- \u03b2-Blockers: metoprolol, propranolol, timolol\n- Triptans: frovatriptan for short-term MAMs prevention\nEvidence to support pharmacologic treatment strategies for migraine prevention indicates which treatments might be effective but is insufficient to establish how to choose an optimal therapy. Consequently, although Level A recommendations can be made for pharmacologic migraine prevention, similar\n- Assessed the efficacy of therapeutic agents for headache other than episodic migraine in adults\n- Assessed acute migraine treatment, migraine aura treatment/prevention, or nonpharmacologic treatments (e.g., behavioral approaches)\nStudies are needed that specifically evaluate when preventive therapy is warranted and how medications should be titrated. Table e-1 lists some specific consensus-based clinical circumstances wherein considering preventive therapy would be reasonable. A shortcoming of migraine prevention clinical",
    "ground_truth_context": "Evidence to support pharmacologic treatment strategies for migraine prevention indicates which treatments might be effective but is insufficient to establish how to choose an optimal therapy.",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Initiate a preventative migraine therapy",
    "correct_answer_idx": 0,
    "model_reasoning": "The context indicates that for patients with frequent and severe migraines, especially when abortive therapies have proven ineffective, it is appropriate to consider initiating a preventative migraine therapy. This aligns with the evidence-based recommendations for migraine management, which suggest that preventive treatments should be offered when patients experience significant headache frequency or severity. The other options are not suitable at this stage: referring for neurosurgery is typically reserved for more severe cases or specific conditions, prescribing a higher dose of abortive medication may not address the underlying issue of frequent migraines, and recommending lifestyle modifications alone may not be sufficient given the patient's history of limited success with abortive therapies. Therefore, the best next step in management is to initiate a preventative migraine therapy.",
    "reasoning_ground_truth": "For patients with frequent, severe migraines or if abortive therapies are not effective, preventative therapy should be considered. Other options are not appropriate at this stage.",
    "is_correct": true
  },
  {
    "question": "A 30-year-old male presents with a 3-day history of nasal congestion, facial pain, and purulent nasal discharge. He reports no improvement after using over-the-counter decongestants. What is the most appropriate initial management strategy?",
    "context": "Oral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nAdjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and\nagents, nasal saline, decongestants, antihistamines, mucolytics, cough suppressants, and topical or oral corticosteroids\u2014may be used alone or in varying combinations for symptom relief.\nand nasal mucosa on imaging studies65,108 and is superior to a single orally administered dose of pseudoephedrine.108 Another small, nonrandomized study showed improved outcomes when xylometazoline spray was added to antibiotics for ABRS.97 Topical decongestants should not be used more than 3 to 5\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without",
    "ground_truth_context": "Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhi-nosinusitis (ABRS) regardless of severity, not just patients with \u201cmild\u201d illness (prior guideline).",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Recommend watchful waiting for 7 days",
    "correct_answer_idx": 2,
    "model_reasoning": "The context indicates that for uncomplicated acute bacterial rhinosinusitis (ABRS), the initial management strategy should involve watchful waiting without immediate antibiotic therapy. This approach is recommended regardless of the severity of the symptoms. In the case presented, the patient has a 3-day history of symptoms consistent with ABRS, but since he has not shown improvement with over-the-counter decongestants, it is still appropriate to recommend watchful waiting for 7 days before considering antibiotics. Starting antibiotics immediately is not warranted unless symptoms fail to improve, and ordering a sinus CT scan is unnecessary at this stage. Therefore, the most appropriate initial management strategy is to recommend watchful waiting for 7 days.",
    "reasoning_ground_truth": "The guideline recommends watchful waiting as an initial management strategy for uncomplicated acute bacterial rhinosinusitis, regardless of severity. Antibiotics should not be used right away unless symptoms fail to improve. A CT scan is not required at this stage.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old male with a long history of sun exposure presents with several rough, scaly lesions on his scalp and face. He is diagnosed with actinic keratoses (AKs). What is the recommended initial treatment?",
    "context": "Actinic keratoses are keratinocyte neoplasms occurring on skin that has had long-term exposure to ultraviolet radiation.\ncombined with vehicle applied twice daily for 4 consecutive days for the field treatment of AKs on the face, scalp, and upper extremities. Although outside the scope of the present guidelines, which are focused on currently available treatment options, the Work Group considered the evidence to be\n|Jorizzo 2006|Face or scalp|Field|Cream|0.5|1/d|7 d|\n|Pomerantz 2015|Face|Field|Cream|5|2/d|28 d|\n|Weiss 2002|Face or scalp|Field|Cream|0.5|1/d|7, 14, or 28 d|\n|Imiquimod|Face or scalp|Field|Cream|5|3/wk|4 or 8 wks (1 or 2 courses)|\nActinic keratosis (AK) is one of the most common conditions diagnosed and treated by dermatologists in the United States (US). These guidelines address the management of AK from the perspective of US dermatologists, other practitioners who treat AK, and patients. Premalignant neoplasia on\nrecognized to be at increased risk for the development of cutaneous malignancies, particularly SCC.138,139 A lack of evidence prevented development of recommendations for treatment in this patient population. The high level of evidence required from larger RCTs can be difficult to achieve for\nFormulation of questions and rating the importance of outcomes. The expert Work Group identified 5 clinical questions on the management of actinic keratoses using the Population, Intervention, Comparator, Outcome (PICO) format (Table V). After selecting the questions that would be addressed in the\nThe literature on AK treatment supports a strong recommendation for field treatment with either 5-fluorouracil (5-FU) or imiquimod.\nAnalysis of the evidence from this systematic review based on 5 research questions resulted in 18 evidence-based recommendations and suggests there are several effective treatments available for AK. Strong recommendations were made for the use of UV protection, cryosurgery, topical imiquimod, and",
    "ground_truth_context": "Clinical question (CQ) 1 asks: Should topically applied agents be used for the treatment of AKs?.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Topical application of a medication approved for AKs",
    "correct_answer_idx": 2,
    "model_reasoning": "The context provided indicates that actinic keratoses (AKs) are commonly treated with topical medications, which are considered a standard first-line treatment option. The guidelines emphasize the use of topical agents such as 5-fluorouracil (5-FU) and imiquimod for the management of AKs. While cryotherapy is also a recognized treatment option, the question specifically asks for the recommended initial treatment, which aligns with the use of topical medications approved for AKs. Surgical excision and observation are not standard initial treatments for AKs, making option C the most appropriate choice.",
    "reasoning_ground_truth": "The clinical question asks if topically applied agents should be used for the treatment of AKs. Topical therapy is a standard first line treatment option for AK's.",
    "is_correct": true
  },
  {
    "question": "A 45-year-old patient with chronic kidney disease (CKD) and type 2 diabetes is starting on a new antihypertensive medication. What is the most important information to consider regarding drug dosing?",
    "context": "In particular, can lower or higher doses be used in different settings (perhaps dependent on baseline risk), and should dosing be adjusted in obese patients, underweight patients, and patients with renal disease?\nPractice Point 3.6.5: Consider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate [eGFR] &lt;15\nAppropriate dosing of medications according to different biological parameters in people with CKD is critical to evaluating benefits and risks; thus, studies targeted at answering these questions will be valuable.\nrecommended for younger people with CKD, as they may not necessarily be transferable to older adults. Strict BP-lowering, for example, may come with the risk of dizziness, falls, and fractures in older adults, many of whom are on anticoagulants risking severe hemorrhage.\nConsider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate [eGFR] <15 ml/min per 1.73 m2).",
    "ground_truth_context": "An assessment of GFR is important for guiding decisions related to the choice and dosing of medications. Section 1.2 addresses the accuracy of validated eGFR equations, as well as indications for the use of eGFRcr-cys or mGFR.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "The patient's estimated glomerular filtration rate (eGFR)",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient's estimated glomerular filtration rate (eGFR) is crucial for guiding decisions related to the choice and dosing of medications in patients with chronic kidney disease (CKD). Medications that are renally cleared require careful dosing adjustments based on kidney function to avoid toxicity and ensure efficacy. In the context of CKD, understanding the eGFR helps healthcare providers determine the appropriate dosage and monitor for potential adverse effects, particularly in patients with conditions like type 2 diabetes, which can further complicate kidney function. The other options, while relevant in certain contexts, do not directly address the critical need for dose adjustment based on renal function in this specific patient population.",
    "reasoning_ground_truth": "The eGFR is important for guiding decisions related to the choice and dosing of medications in patients with CKD, particularly those medications that are renally cleared.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old woman with a recent diagnosis of community acquired pneumonia (CAP) is being discharged from the hospital. She has multiple comorbidities. Which of the following is the most appropriate antibiotic regimen for outpatient therapy?",
    "context": "In the Inpatient Setting, Which Antibiotic Regimens Are Recommended for Empiric Treatment of CAP in Adults without Risk Factors for MRSA and P. aeruginosa?\nLonger courses of antibiotic therapy are recommended for 1) pneumonia e59\nIn the Outpatient Setting, Which Antibiotics Are Recommended for Empiric Treatment of CAP in Adults?\nFor adults with community-acquired pneumonia (CAP) at risk for MRSA or P. aeruginosa (see Recommendation 11), we recommend the following empiric treatment regimens (in no order of preference) (Table 4):\nRegimens recommended for patients with comorbidities include a b-lactam or cephalosporin in combination with either a macrolide or doxycycline. These combinations should effectively target macrolide- and doxycycline-resistant S. pneumoniae (as b-lactam resistance in S. pneumoniae remains less\nAmerican Thoracic Society Documents  \n|Nonsevere inpatient pneumonia*|Severe inpatient pneumonia*|\n|---|---|\n|Levofloxacin 750 mg daily or moxifloxacin 400 mg daily.|Ampicillin 500 mg twice daily.|\n|Standard Regimen|\u2020macrolide|\n|\u2021uroquinolone|-lactam|",
    "ground_truth_context": "the panel believed that fluoroquinolone therapy was justified for adults with comorbidities and CAP managed in the outpatient setting.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "A fluoroquinolone",
    "correct_answer_idx": 2,
    "model_reasoning": "For adults with community-acquired pneumonia (CAP) who have multiple comorbidities, the recommended empiric treatment in the outpatient setting includes either a respiratory fluoroquinolone or a combination of a beta-lactam and a macrolide. In this case, the 68-year-old woman has multiple comorbidities, which necessitates a more robust antibiotic regimen to ensure adequate coverage against potential pathogens associated with CAP. \n\nMonotherapy options such as amoxicillin, azithromycin, or doxycycline are generally reserved for patients without comorbidities, as they may not provide sufficient coverage for all possible pathogens in patients with more complex health issues. Therefore, a fluoroquinolone, which is effective against a broader range of bacteria, is the most appropriate choice for her outpatient therapy.",
    "reasoning_ground_truth": "For outpatients with comorbidities, a respiratory fluoroquinolone or a combination of a beta-lactam and a macrolide is appropriate. Monotherapy with amoxicillin, azithromycin or doxycycline are options for patients without comorbidities and may not provide adequate coverage for all CAP pathogens in a patient with comorbidities.",
    "is_correct": true
  },
  {
    "question": "A 70-year-old man with a history of heart failure is hospitalized for an acute exacerbation. He develops acute kidney injury. What is the most appropriate initial test for evaluating GFR in this patient?",
    "context": "|Most used method to assess GFR. In most cases, initial test for the evaluation of GFR. Standardized assay required to decrease between-center analytical variation|Most used method to assess GFR. In most cases, initial test for the evaluation of GFR. Standardized assay required to decrease\nGFR (eGFRcr-cys) should be estimated. If eGFRcr-cys is expected to be inaccurate, or if an even more accurate assessment of GFR is needed for clinical decision-making, then, if available, GFR should be measured using plasma or urinary clearance of exogenous filtration markers. *Initial test may be\nEvaluate changes in kidney functional reserve after AKI episodes irrespective of baseline GFR and recovery.\ndecision-making. The initial test for the evaluation of GFR is creatinine-based estimated GFR (eGFRcr), which will be available for most people because creatinine is measured routinely as part of the basic metabolic panel. If eGFRcr is expected to be inaccurate, or if a more accurate assessment of\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nBetter-preserved GFRs, earlier blood sampling is most accurate, and in people with extensive edema or ascites, plasma clearance protocols are very inaccurate and not recommended; instead, urinary clearance protocols are recommended. Finally, it is well recognized that assessing GFR using the\nIdentify adults at risk for CKD  \nTest for GFR* and ACR \u00b1 other markers of kidney damage \u2020  \nGFR &lt;60 ml/min per 1.73 m2 or ACR \u226530 mg/g [3 mg/mmol]2 and/or other markers of kidney damage present  \nTest for GFR or ACR if not performed and exclude AKI/AKD\nFollowing incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.",
    "ground_truth_context": "As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,1 the first method to evaluate GFR should be eGFRcr. If necessary for greater accuracy, the approach then recommends subsequent supportive tests from either the more accurate eGFRcr-cys or measurement of GFR using urinary or plasma clearance of exogenous filtration markers.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "eGFR based on serum creatinine (eGFRcr)",
    "correct_answer_idx": 2,
    "model_reasoning": "The most appropriate initial test for evaluating glomerular filtration rate (GFR) in this patient is the estimated GFR based on serum creatinine (eGFRcr). According to the guidelines, eGFRcr is the standard initial method for assessing kidney function. It is widely used due to its availability and reliability in most clinical settings. \n\nWhile measured GFR using exogenous filtration markers (Option A) can provide more accurate results, it is typically reserved for situations where eGFRcr is suspected to be inaccurate or when precise GFR measurements are critical for clinical decision-making. \n\neGFR based on serum cystatin C (eGFRcys) (Option B) is considered a supportive test and is used when there are concerns about the accuracy of eGFRcr, but it is not the first-line test. \n\nA renal ultrasound (Option D) may be indicated if there is uncertainty about the cause of acute kidney injury (AKI), but it does not evaluate GFR directly.\n\nTherefore, the correct and most appropriate initial test for evaluating GFR in this patient is eGFR based on serum creatinine (eGFRcr).",
    "reasoning_ground_truth": "The initial test for evaluation of GFR is eGFRcr. Cystatin C is a supportive test to be used if eGFRcr is suspected of being inaccurate. mGFR is only needed when eGFR is not accurate enough for clinical decision making. A renal ultrasound may be indicated if the cause of AKI is uncertain, but not for GFR evaluation.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old female with a recent diagnosis of CKD is being educated about her condition. What is the most important aspect to address in her education?",
    "context": "CKD G1\u2013G2\nCKD G3\u2013G4\nCKD G5\nFigure 53 | Strategy for effective patient education programs for people with chronic kidney disease (CKD). *Should be tailored to individual needs and wishes. KRT, kidney replacement therapy.\nUse renal dietitians or accredited nutrition providers to educate people with CKD about dietary adaptations regarding sodium, phosphorus, potassium, and protein intake, tailored to their individual needs, and severity of CKD and other comorbid conditions.\nUse renal dietitians or accredited nutrition providers to educate people with CKD about dietary adaptations regarding sodium, phosphorus, potassium, and protein intake, tailored to their individual needs, and severity of CKD and other comorbid conditions.\nPractice Point 3.11.5.1: Implement an individualized approach in people with CKD G3\u2013G5 and emergent hyperkalemia that includes dietary and pharmacologic interventions and takes into consideration associated comorbidities and quality of life (QoL). Assessment and education through a renal dietitian\n- Improving CKD awareness\n- Empower self-management\n- Management of CKD complications\n- Target high-risk people with CKD\n- Triage patient to specific educational topics they need\n- Engage family members and/or caregivers\nPractice Point 3.1.1: Treat people with CKD with a comprehensive treatment strategy to reduce risks of progression of CKD and its associated complications (Figure 17).\nSpecial considerations for chronic kidney disease (CKD) care across the lifespan. BSA, body surface area.  \nKidney International (2024) 105 (Suppl 4S), S117\u2013S314\nKidney failure risk:  \n- CKD G5: Kidney failure risk \u226540% in 2 years\n- CKD G4: Preparing for KRT, Kidney failure risk \u226510% in 2 years, Discuss KRT options\n- CKD G3: Education, Promote self-management\n- CKD G2: Prevention and management of complications\nEducation programs that also involve care partners where indicated are important to promote informed, activated people with CKD.  \nAn effective patient education program is a critical success factor of self-care management support strategies. Education should address 3 main issues:",
    "ground_truth_context": "Standardized educational topics should cover 3 main subject areas: knowledge about CKD, knowledge about treatment to slow progression and complications of CKD, and knowledge about the kidney failure management options.",
    "model_answer": "D",
    "model_answer_idx": 3,
    "correct_answer_text": "The etiology of CKD, its management, and the available kidney failure management options",
    "correct_answer_idx": 3,
    "model_reasoning": "The most important aspect to address in the education of a patient with a recent diagnosis of chronic kidney disease (CKD) is the etiology of CKD, its management, and the available kidney failure management options. This is crucial for empowering the patient with knowledge about their condition, which is essential for effective self-management. \n\nEducational programs for CKD patients should cover comprehensive topics that include understanding the causes of CKD, recognizing signs and symptoms, and knowing the treatment strategies to slow disease progression and manage complications. By focusing on the etiology and management options, the patient can better understand their condition and make informed decisions regarding their health. \n\nWhile detailed kidney anatomy, specific dietary restrictions, and the type of kidney failure and its treatment options are important, they are secondary to understanding the overall management and implications of CKD. Therefore, option D encompasses the most critical information needed for the patient to effectively manage their condition.",
    "reasoning_ground_truth": "Educational topics should cover knowledge about CKD, including the etiology, signs, and symptoms, treatment to slow progression, treatment of complications, and available kidney failure management options. Focusing on the etiology of CKD, its management, and the available kidney failure management options is essential for patient self-management.",
    "is_correct": true
  },
  {
    "question": "A 35-year-old male presents with a 2-day history of fever, cough, and shortness of breath. He is diagnosed with community-acquired pneumonia (CAP). He is admitted to the hospital.  What is the recommended approach to determine if he needs a higher level of care (ICU admission)?",
    "context": "The 2007 IDSA/ATS CAP guidelines recommended a set of two major and nine minor criteria to define severe pneumonia requiring ICU admission (Table 1). These criteria were based on empirical evidence from published studies and expert consensus. All elements are routinely available in emergency\nsensitivity of 84% and a specificity of 78% for predicting ICU admission (62). Without the major criteria, a threshold of three or more minor criteria (recommended in the 2007 IDSA/ATS guideline) had a pooled sensitivity of 56% and specificity of 91% for predicting ICU admission (63).\nurea level, respiratory rate, blood pressure, and age &gt;=65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP.\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,\nIn addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate,\nThe PSI and CURB-65 were not designed to help select the level of care needed by a patient who is hospitalized for CAP. Several prognostic models have been designed to predict the need for higher levels of inpatient treatment intensity using severity-of-illness parameters based on patient outcomes\nBoth the PSI and CURB-65 were developed as prognostic models in immunocompetent patients with pneumonia, using patient demographic and clinical variables from the time of diagnosis to predict 30-day mortality (39, 40). When compared with CURB-65, PSI identifies larger proportions of patients as low",
    "ground_truth_context": "We recommend the 2007 IDSA/ATS severe CAP criteria over other published scores, because they are composed of readily available severity parameters and are more accurate than the other scores described above.",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Use a clinical prediction tool plus clinical judgment.",
    "correct_answer_idx": 0,
    "model_reasoning": "The guidelines recommend using a validated clinical prediction tool, such as the Pneumonia Severity Index (PSI), in conjunction with clinical judgment to determine the need for a higher level of care, such as ICU admission, for patients diagnosed with community-acquired pneumonia (CAP). This approach is supported by evidence indicating that combining these methods can lead to more accurate assessments of patient severity and reduce unnecessary variability in admission rates. The other options do not align with the recommended evidence-based approach, as relying solely on clinical judgment (Option B) may overlook critical severity indicators, using a serum procalcitonin test (Option C) does not encompass the comprehensive assessment needed, and waiting for blood culture results (Option D) could delay necessary treatment decisions. Therefore, the best practice is to use a clinical prediction tool alongside clinical judgment, making Option A the correct choice.",
    "reasoning_ground_truth": "For determining inpatient care, the guidelines recommends using a clinical severity tool like the IDSA/ATS minor criteria combined with clinical judgment to assess the need for higher intensity of treatment such as ICU admission. Other options do not use the best evidence based approach.",
    "is_correct": true
  },
  {
    "question": "A 58-year-old patient with CKD is being evaluated for the cause of his condition. After initial evaluation, a kidney biopsy is being considered. When is it most appropriate to perform a kidney biopsy?",
    "context": "This recommendation places a high value on an acceptable safety profile of kidney biopsies when used to evaluate the cause of CKD and to plan appropriate treatment.\nValues and preferences. The Work Group judged that many people with CKD would choose to undergo a kidney biopsy to establish the cause of their CKD more accurately and potentially offer prognostic information. Thus, this recommendation puts a high value on the specificity of a kidney biopsy for the\nthickness; (iv) kidney pathological findings such as fibrosis and atrophy; (v) medical history, especially conditions known to cause or contribute to CKD; (vi) repeat measurements within and beyond the 3-month point.\nWhat is the diagnostic and prognostic bene\ufb01t and safety of kidney biopsy among people with CKD?\nWe suggest performing a kidney biopsy as an acceptable, safe, diagnostic test to evaluate cause and guide treatment decisions when clinically appropriate.\nbenefit of kidney biopsy or influence of biopsy results on management decisions. The diagnostic findings were heterogeneous and variable, which did not lend themselves to further synthesis. The rate of mortality after native kidney biopsy in people with suspected or diagnosed CKD was low. Across\nDetermine the prevalence of kidney biopsy\u2013related complications in different clinical circumstances (age, size of kidneys, acute vs. chronic, and comorbidities) to inform risk estimates appropriate to those in the current era dependent on methods (e.g., blind, ultrasound-guided, CT-guided, open, and\nPractice Point 2.2.1: A 5-year kidney failure risk of 3%\u20135% can be used to determine need for nephrology referral in addition to criteria based on eGFR or urine ACR, and other clinical considerations.",
    "ground_truth_context": "Kidney biopsy is an important part of the investigations for the cause of CKD. It is often deferred because of the potential for harm or lack of recognition of potential utility. The evi-dence to support safety of biopsy is heterogeneous and therefore uncertain, but in the studies evaluated, appears to confer low risk of harm, supporting our suggestion that kidney biopsies should be considered when it is thought that they can provide information to identify cause, facilitate prognostication, and inform treatment strategies.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "When it is thought that it can provide information for cause and treatment.",
    "correct_answer_idx": 1,
    "model_reasoning": "The context emphasizes that kidney biopsy should be performed when it is believed to provide valuable information regarding the cause of chronic kidney disease (CKD) and to guide treatment decisions. The other options do not align with this principle. \n\n- Option A suggests that a specific eGFR threshold should dictate the need for a biopsy, which is not supported by the context. The decision to perform a biopsy should be based on the potential for diagnostic and prognostic benefit rather than solely on eGFR levels.\n- Option C implies that a biopsy is warranted only if diabetes is suspected as the cause of CKD, which is too narrow and does not consider other potential causes that a biopsy could help identify.\n- Option D states that a biopsy should only be performed after exhausting all other tests, which contradicts the recommendation that a biopsy can be a valuable diagnostic tool when it is thought to provide relevant information.\n\nThus, the most appropriate time to perform a kidney biopsy is when it is believed to provide information for cause and treatment, making option B the correct choice.",
    "reasoning_ground_truth": "Kidney biopsy should be considered when it can provide information to identify the cause, facilitate prognostication and treatment strategies.. The eGFR value does not dictate the need for a biopsy. Other options are not the correct reason for performing a biopsy.",
    "is_correct": true
  },
  {
    "question": "A 65-year-old male with a history of atrial fibrillation and CKD is being started on anticoagulation. What is the most appropriate approach for selecting the medication?",
    "context": "limited pharmacokinetic and pharmacodynamic data (i.e., there are no randomized efficacy or safety trial data assessing clinical outcomes for stroke thromboprophylaxis in atrial fibrillation at chronic kidney disease [CKD] G4\u2013G5). a Cockcroft-Gault estimated creatinine clearance (eCrCl). b Apixaban\npatients with moderate renal impairment. Circ J. 2013;77:632\u2013638 720; Stanifer J, Pokorney S, Chertow G, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141:1384\u20131392 721; Hijazi Z, Alexander JH, Li Z, et al. Apixaban or\nConsiderations for implementation. A decision not to anticoagulate for thromboembolic prophylaxis due to low risk would ideally be re-evaluated at each consultation and at least every 6 months. When using antithrombotic therapy in people with CKD, it is prudent to treat modifiable risk factors for\n43. Su X, Yan B, Wang L, et al. Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis. Am J Kidney Dis. 2021;78:678\u2013689.e1.\nWe recommend use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial \ufb01brillation in people with CKD G1\u2013G4 (1C).\nWe recommend use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial fibrillation in people with CKD G1\u2013G4 (1C).\nRecent cardiology guidelines recommend a risk factor\u2013based approach to stroke thromboprophylaxis decisions in atrial fibrillation using the Congestive heart failure, Hypertension, Age $75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65 to 74, and Sex category (female) (CHA 2DS -2\nFigure 40 | Strategies for the diagnosis and management of atrial fibrillation. *Consider dose adjustments necessary in people with chronic kidney disease (CKD). \u2020The following has been recommended as a standard package for diagnostic evaluation of new atrial fibrillation: (i) a 12-lead",
    "ground_truth_context": "Figure S12. PRISMA diagram for the clinical question \u201cWhat are the effects of NOACs with or without warfarin compared to placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?\u201d",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Use a NOAC, but monitor for bleeding risks.",
    "correct_answer_idx": 2,
    "model_reasoning": "The guidelines recommend the use of non-vitamin K antagonist oral anticoagulants (NOACs) for thromboprophylaxis in patients with atrial fibrillation and chronic kidney disease (CKD) G1\u2013G4. In this case, the 65-year-old male has a history of atrial fibrillation and CKD, making NOACs a suitable choice for anticoagulation. However, it is crucial to monitor for bleeding risks, especially in patients with CKD, as their renal function can affect the pharmacokinetics of these medications. \n\nStarting warfarin (Option A) is not recommended due to the challenges associated with monitoring INR and its efficacy in patients with CKD. Option B suggests using a NOAC without regard to kidney function, which is inappropriate since renal function must be considered when dosing NOACs. Option D, avoiding anticoagulation altogether, is not justified as anticoagulation is indicated for stroke prevention in atrial fibrillation, provided that the risks are carefully assessed. Therefore, the most appropriate approach is to use a NOAC while monitoring for bleeding risks, making Option C the correct choice.",
    "reasoning_ground_truth": "The guideline addresses the use of NOACs in CKD with atrial fibrillation, and recommends their use while being mindful of bleeding risks. Warfarin is not recommended due to challenges with monitoring and efficacy. Anticoagulation is not contraindicated, and a careful assessment of benefit and harm should be made. NOAC use in CKD requires assessment of dose and kidney function.",
    "is_correct": true
  },
  {
    "question": "A 75 year old male is admitted to the hospital with decompensated heart failure. He is treated with IV furosemide but remains volume overloaded. What type of fluid should be used for volume resuscitation in this case?",
    "context": "or renal failure), then it is highly likely that they are volume depleted and will respond to an appropriate fluid challenge. There is little evidence supporting the use of any specific fluid for volume loading in ALF. However, general critical care literature [130\u2013133]. The choice should be guided\n- Most patients are volume depleted at presentation and require crystalloid volume resuscitation (evidence level II-1, grade of recommendation 1).\nresuscitation needs to be assessed individually. In patients with elevated right sided cardiac pressures and ascites, further fluid therapy is likely to have limited or minimal improve venous return and improve cardiac index [148].\nFollowing adequate volume loading, persistent hypotension requires treatment with vasopressors. Given the usual clinical picture in ALF of an elevated cardiac output and decreased vascular tone, norepinephrine, at a starting dose of 0.05 lg/kg/min. Additional low dose vasopressin (1\u20132 units/hour),\nway to the setting of a hyperdynamic circulation [139]. ScvO2 will be elevated even if the patient is volume depleted and fluid responsive [140]. The purpose of bolus fluid therapy is to increase stroke volume and subsequently, cardiac output. Assessment of an appropriate increase in cardiac output",
    "ground_truth_context": "If used in this context, albumin should be viewed more as a drug, than as a resuscitative solution.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Albumin",
    "correct_answer_idx": 2,
    "model_reasoning": "In the context of a 75-year-old male with decompensated heart failure who is volume overloaded despite treatment with IV furosemide, the choice of fluid for volume resuscitation is critical. While normal saline (0.9% Normal Saline) and other crystalloids can be used for volume resuscitation, they may not be the best option for patients with conditions like heart failure where there is a risk of fluid overload.\n\nAlbumin, on the other hand, is often used in patients with hypoalbuminemia or those who require volume expansion without the risk of further fluid overload. In this case, although the patient does not have liver failure, the principles of managing volume status in heart failure patients can be similar. Albumin can help to increase oncotic pressure and improve venous return, making it a suitable choice for this patient.\n\nTherefore, given the patient's condition and the context provided, albumin is the most appropriate fluid for volume resuscitation in this scenario.",
    "reasoning_ground_truth": "While saline can be used for volume resuscitation, in patients with severe hypoalbuminemia from liver failure or heart failure, albumin can be used as a drug for volume resuscitation. Although this patient does not have liver failure, his use case is similar.",
    "is_correct": true
  },
  {
    "question": "A 50 year old male is admitted for a planned coronary artery bypass graft (CABG) surgery. He is currently on dual antiplatelet therapy (DAPT).  What is the recommendation for continuation of DAPT?",
    "context": "Issues related to the timing of discontinuation of DAPT before CABG are beyond the scope of this update but are addressed in the 2011 CABG guideline (10). Figure 3 summarizes recommendations for the management and duration of P2Y12 inhibitor therapy in patients undergoing CABG.\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\n|I|C-LD|In patients with ACS (NSTE-ACS or STEMI) being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).| |\nIntensification of antiplatelet therapy, with the addition of a P2Y12 inhibitor to aspirin monotherapy, as well as prolongation of DAPT, necessitates a fundamental tradeoff between decreasing ischemic risk and increasing bleeding risk. Decisions about treatment with and duration of DAPT require a\n|I|C-EO|In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y12 platelet receptor inhibitor be restarted as soon as",
    "ground_truth_context": "Issues and recommendations with regard to P2Y12 inhibitor \u201cpre-treatment,\u201d \u201cpreloading,\u201d and loading are beyond the scope of this document but are addressed in other guidelines.",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "DAPT should be stopped at least 5 days prior to surgery.",
    "correct_answer_idx": 0,
    "model_reasoning": "The recommendation for patients undergoing elective surgeries, including coronary artery bypass graft (CABG) surgery, is to stop dual antiplatelet therapy (DAPT) at least 5 days prior to the procedure. This is primarily to reduce the risk of bleeding during surgery, as the antiplatelet effects of medications can increase bleeding complications. While the specific guidelines referenced in the context focus on the management and duration of DAPT postoperatively, the general consensus in clinical practice is to discontinue DAPT at least 5 days before surgery. This aligns with the correct answer option A, which states that DAPT should be stopped at least 5 days prior to surgery. The other options either suggest continuing DAPT or stopping it too close to the surgery date, which does not align with the standard recommendations for managing patients on DAPT prior to surgical procedures.",
    "reasoning_ground_truth": "While the guidelines focus on duration of DAPT, the general consensus for elective surgeries including CABG is to stop DAPT at least 5 days prior to surgery, with some exceptions made for very high risk patients.",
    "is_correct": true
  },
  {
    "question": "A 60-year-old male with a history of hypertension presents with a persistent cough, fever, and shortness of breath. A chest X-ray reveals a right lower lobe infiltrate. Initial blood cultures are negative. What is the most appropriate next step in his management?",
    "context": "and symptoms of pneumonia with radiographic confirmation) to completion of antimicrobial therapy and follow-up chest imaging.\nIn Adults with CAP Who Are Improving, Should Follow-up Chest Imaging Be Obtained?\nIn adults with CAP whose symptoms have resolved within 5 to 7 days, we suggest not routinely obtaining follow-up chest imaging (conditional recommendation, low quality of evidence).\ndeterioration, aspiration and poor compliance. Regular chest physiotherapy should be carried out and ventilator associated pneumonia avoided (evidence level III, grade of recommendation 1).\nswab is positive, coverage for MRSA pneumonia should generally be initiated, but blood and sputum cultures should be sent and therapy deescalated if cultures are negative.\nLonger courses of antibiotic therapy are recommended for 1) pneumonia e59\n|Recommendation|2007 ATS/IDSA Guideline|2019 ATS/IDSA Guideline|\n|---|---|---|\n|Sputum culture|Primarily recommended in patients with severe disease|Now recommended in patients with severe disease as well as in all inpatients empirically treated for MRSA or Pseudomonas aeruginosa|\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,\nradiographically confirmed CAP, b-lactam plus macrolide combination therapy, or fluoroquinolone monotherapy were generally associated with lower mortality than b-lactam monotherapy (105). Therefore, the panel recommends a b-lactam (ampicillin plus sulbactam, cefotaxime, ceftaroline, or ceftriaxone)",
    "ground_truth_context": "our recommendations are to initially treat empirically for possible bacterial infection or coinfection. Routinely obtaining blood cultures may generate false-positive results that lead to unnecessary antibiotic use and increased length of stay.",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
    "correct_answer_idx": 0,
    "model_reasoning": "The patient's presentation of a persistent cough, fever, and shortness of breath, along with the chest X-ray findings of a right lower lobe infiltrate, is indicative of community-acquired pneumonia (CAP). According to the guidelines, the most appropriate next step in management for suspected CAP is to start empiric antibiotic therapy. This is crucial to address the potential bacterial infection or coinfection promptly. \n\nWhile blood cultures are important for identifying the causative organism, they should not delay the initiation of antibiotic treatment, especially since the initial blood cultures in this case are negative. The other options provided are not appropriate first-line interventions for this scenario: \n\n- Option B (prescribing cough suppressants) does not address the underlying infection and is not suitable for a patient with pneumonia.\n- Option C (performing a bronchoscopy) is typically reserved for cases where there is a need for further investigation of the lungs, such as in cases of suspected complicated pneumonia or when initial treatments fail.\n- Option D (ordering a CT scan to rule out pulmonary embolism) is unnecessary at this stage, as the clinical picture aligns more closely with pneumonia rather than a pulmonary embolism.\n\nTherefore, starting empiric antibiotic therapy for CAP is the most appropriate and immediate management step.",
    "reasoning_ground_truth": "The patient's symptoms and chest X-ray findings are consistent with CAP. The guidelines recommend initiating **empiric antibiotic therapy** for possible bacterial infection or coinfection. Although blood cultures are recommended, they should not delay the start of antibiotic treatment. The other options are not the first-line steps for a typical CAP case.",
    "is_correct": true
  },
  {
    "question": "A 72-year-old female with known chronic kidney disease (CKD) and type 2 diabetes is admitted for a urinary tract infection. Her estimated glomerular filtration rate (eGFR) based on serum creatinine (SCr) is 35 mL/min/1.73 m\u00b2. What is the most appropriate approach for medication dosing?",
    "context": "Practice Point 4.1.2: Monitor eGFR, electrolytes, and therapeutic medication levels, when indicated, in people with CKD receiving medications with narrow therapeutic windows, potential adverse effects, or nephrotoxicity, both in outpatient practice and in hospital settings.\nMonitor eGFR, electrolytes, and therapeutic medication levels, when indicated, in people with CKD receiving medications with narrow therapeutic windows, potential adverse effects, or nephrotoxicity, both in outpatient practice and in hospital settings. Ensuring a safe use of medication requires\nMany medications and/or their active metabolites are excreted by the kidneys. Failure to properly account for the effect of GFR when designing appropriate drug-dosing regimens can predispose a person to treatment failure or adverse events. 725, 728 Although guidelines for adjustment of the dosing\nPractice Point 3.6.5: Consider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate [eGFR] &lt;15\n36. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839\u20132844.\n37. Erler A, Beyer M, Petersen JJ, et al. How to improve drug dosing for patients with renal impairment in primary care\u2014a cluster-randomized controlled trial. BMC Fam Pract. 2012;13:91.\n1. Khanal A, Castelino RL, Peterson GM, et al. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources? Intern Med J. 2014;44:77\u201385.\nRecommendation 3.7.3: We suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).\nWe suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).\nPractice Point 3.7.1: Once an SGLT2i is initiated, it is reasonable to continue an SGLT2i even if the eGFR falls below 20 ml/min per 1.73 m\u00b2, unless it is not tolerated or KRT is initiated.  \nRecommendation 3.7.2: We recommend treating adults with CKD with an SGLT2i for the following (1A):\nPractice Point 4.2.1: Consider GFR when dosing medications cleared by the kidneys.  \nPractice Point 4.2.2: For most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing.",
    "ground_truth_context": "Where more accuracy is required for drug-related decision-making (e.g., dosing due to narrow therapeutic or toxic range), drug toxicity, or clinical situations where eGFRcr estimates may be unreliable, use of equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Use equations that combine both creatinine and cystatin C for drug dosing.",
    "correct_answer_idx": 1,
    "model_reasoning": "In the context of the 72-year-old female patient with chronic kidney disease (CKD) and an estimated glomerular filtration rate (eGFR) of 35 mL/min/1.73 m\u00b2, it is crucial to ensure accurate medication dosing to avoid potential adverse effects or treatment failure. While validated eGFR equations using serum creatinine (SCr) are generally appropriate for drug dosing, there are situations where more accuracy is required, particularly when dealing with medications that have a narrow therapeutic window or when eGFR estimates may be unreliable.\n\nIn this case, using equations that combine both creatinine and cystatin C can provide a more accurate assessment of kidney function, which is essential for safe and effective medication dosing. This approach is particularly relevant for patients with CKD, where renal function can fluctuate and affect drug clearance. Therefore, option B is the most appropriate approach for medication dosing in this scenario. \n\nOptions A, C, and D are not suitable: \n- Option A (using eGFR based solely on SCr) may not provide the necessary accuracy for dosing.\n- Option C (immediately initiating dialysis) is not warranted based on the provided information.\n- Option D (discontinuing all medications) is overly cautious and could lead to inadequate treatment of her urinary tract infection.",
    "reasoning_ground_truth": "For most people, validated eGFR equations using SCr are appropriate for drug dosing. However, when **more accuracy** is needed, such as with a narrow therapeutic range, drug toxicity, or when eGFR estimates may be unreliable, equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old male presents with a first-time seizure lasting 7 minutes. He has no history of epilepsy. Intravenous (IV) access is difficult to obtain. What is the preferred initial pharmacologic treatment?",
    "context": "The second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy\nfrom ICH and reduce the risk of seizures. A short acting opiate should be added to provide adequate analgesia. In case of concern of seizure activity, EEG monitoring should be undertaken and antiepileptic drugs administered; however, the prophylactic use of antiepileptic drugs is not warranted.\nreceive a second dose of medication if the seizures continued after 10 minutes. For all patients, phenytoin was given after 30 minutes. A total of 70 patients were randomized to either lorazepam (n = 37) or diazepam (n = 33) (25). Lorazepam was successful for 78% of subjects after one dose and 89%\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nIntravenous lorazepam (0.1 mg/kg over 2\u20134 minutes) was compared with IV levetiracetam (20 mg/kg over 15 minutes) in a class III RCT involving children with either convulsive or subtle convulsive status epilepticus. As first therapy, lorazepam success rate (29/38, 76.3%) was similar to that for\nConvulsive status epilepticus treated with placebo indicating that respiratory problems are an important consequence of untreated convulsive status epilepticus (Level A). When both are available, fosphenytoin is preferred over phenytoin based on tolerability but phenytoin is an acceptable",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 0,
    "model_reasoning": "In the scenario presented, the patient is experiencing a first-time seizure lasting 7 minutes, and obtaining intravenous (IV) access is difficult. According to the context provided, intramuscular (IM) midazolam is established as a preferred treatment for patients with convulsive status epilepticus when IV access is not available. While IV lorazepam is a first-line treatment for status epilepticus, it requires IV access, which is not feasible in this case. \n\nThe context specifically states that IM midazolam has superior effectiveness compared to IV lorazepam in adults with convulsive status epilepticus when IV access is difficult. Although rectal diazepam is mentioned as a reasonable alternative, midazolam is noted to have better effectiveness in this situation. Therefore, the best choice for initial pharmacologic treatment in this case is intramuscular midazolam.",
    "reasoning_ground_truth": "For patients with convulsive status epilepticus where **IV access is difficult**, intramuscular midazolam is superior to intravenous lorazepam. IV lorazepam is a first line treatment for status epilepticus, but if an IV line cannot be established, IM midazolam is prefered. Rectal diazepam is a reasonable alternative, but midazolam has better effectiveness when IV access is not established.",
    "is_correct": true
  },
  {
    "question": "A 48-year-old woman with a history of heavy alcohol use presents with jaundice, ascites, and confusion. She has been diagnosed with alcoholic hepatitis. What is the initial nutritional recommendation?",
    "context": "In patients with severe alcoholic hepatitis, oral intake is consistently reduced [110,111,142,181]. When the treatments are consistent in the groups, supplemental nutrition does improve infection and acute mortality, specifically in hospital deaths over ad lib oral dietary intake [186e188]. Enteral\nin patients with NAFLD [288]. These findings were not included in the AASLD/AG [120] and EASL/EASD/EASO [119] guidelines recommending only to abstain from heavy amounts of alcohol. Until evidence from intervention studies is available it seems unjustified to suggest a potential health benefit from\n47. Fialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. Liver Int Off J Int Assoc Stud Liver 2015;35(9):2072e8.\n1.2.16 Explain to people with NAFLD who drink alcohol the importance of staying within the national recommended limits for alcohol consumption.\nintake [186e188]. Enteral or supplemental feeding has been evaluated in severe alcoholic hepatitis, but no mortality benefit has been consistently reported. In the VA studies, a survival advantage to supplemental nutrition was reported in patients with malnutrition. In a meta-analysis of 13\nIn cirrhotic patients, nutritional intervention (either oral, EN or PN) shall be implemented according to current guidelines for non-cirrhotic patients. (BM)  \nGrade of recommendation A e Consensus (89% agreement)\n40. Mendenhall C, Bongiovanni G, Goldberg S, Miller B, Moore J, Rouster S, et al. VA cooperative study on alcoholic hepatitis. III: changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. J Parenter Enteral Nutr\nTake an alcohol history to rule out alcohol-related liver disease. See also NICE's guideline on cirrhosis.",
    "ground_truth_context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Start enteral nutrition with a standard formula",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient in this scenario has been diagnosed with alcoholic hepatitis, which is a serious condition that requires careful nutritional management. According to the guidelines referenced in the context, enteral nutrition is recommended as a safe and effective method for delivering nutritional support to patients with liver disease. Starting enteral nutrition with a standard formula is crucial because it helps to provide adequate calorie and protein intake, which is essential for recovery and to prevent further complications associated with malnutrition.\n\nRestricting fluid intake (Option A) may be necessary in some cases to manage ascites, but it should not be the initial focus without addressing nutritional needs. Initiating a high-protein, low-carbohydrate diet (Option B) is not specifically indicated in the context provided, and such a diet may not be appropriate for all patients with liver disease. Delaying nutritional support until liver function stabilizes (Option D) could lead to significant harm, as malnutrition can worsen liver function and overall health.\n\nTherefore, the best initial nutritional recommendation for this patient is to start enteral nutrition with a standard formula (Option C).",
    "reasoning_ground_truth": "The patient has signs of liver disease, which requires nutritional management. Based on the liver disease guideline, enteral nutrition should be started and is a safe route for delivery of nutritional support for patients with liver disease. Restricting fluids and or delaying nutrition may cause significant harm.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old patient with a history of coronary artery disease underwent percutaneous coronary intervention (PCI) with drug-eluting stent placement. How long should dual antiplatelet therapy (DAPT) be continued?",
    "context": "|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable\nboth in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone (51,52). Available evidence from this trial, as well as from PLATO (53,71,72) and TRITON-TIMI 38 (54,55), supports DAPT duration of at least 12 months for patients with NSTE-ACS.\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\nrecommended duration of P2Y12 inhibitor therapy (in addition to aspirin therapy). Figure 1 summarizes recommendations for duration of DAPT according to clinical status.\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\nThe recommended minimum duration of DAPT in patients treated with first-generation DES, based primarily on observational data and one subgroup analysis, has been 12 months (9,51,97,104,105). Compared with first-generation DES, currently used newer-generation DES have a lower risk of stent",
    "ground_truth_context": "Most contemporary studies of DAPT have compared either shorter (3 to 6 months) (17\u201321) or longer (18 to 48 months) (16,22\u201326) duration of therapy with 12 months of DAPT, which is the recom-mended or minimal duration of therapy for most patients in ACC/AHA (9,13,14) and European Society of Cardiology (31\u201333) guidelines published between 2011 and 2014.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "12 months",
    "correct_answer_idx": 2,
    "model_reasoning": "The context provided indicates that for most patients who undergo percutaneous coronary intervention (PCI) with drug-eluting stent placement, the recommended or minimal duration of dual antiplatelet therapy (DAPT) is 12 months. This recommendation is supported by various guidelines, including those from the ACC/AHA and the European Society of Cardiology. While the duration of DAPT can vary based on individual patient profiles and specific circumstances, 12 months is the standard recommendation for the majority of patients. Therefore, the correct answer is C (12 months).",
    "reasoning_ground_truth": "For most patients, 12 months of DAPT is the recommended or minimal duration of therapy following PCI with drug-eluting stent placement. The duration can vary based on the patient profile, but 12 months is the standard recommendation.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male with a history of benign prostatic hyperplasia (BPH) and hypertension presents with new-onset fatigue, constipation, and dry skin. His TSH level is elevated, and free T4 level is low. What is the appropriate initial treatment?",
    "context": "Treatment based on individual factors for patients with TSH levels between the upper limit of a given laboratory\u2019s reference range and 10 mIU/L should be considered particularly if patients have symptoms suggestive of hypothyroidism, positive TPOAb or evidence of atherosclerotic cardiovascular\nPatients whose serum TSH levels exceed 10 mIU/L are at increased risk for heart failure and cardiovascular mortality, and should be considered for treatment with L-thyroxine. Grade B, BEL 1\ntherapy (54,55) (see L-thyroxine treatment of hypothyroidism).\nPatients with hypothyroidism should be treated with L-thyroxine monotherapy. Grade A, BEL 1  \nSee: L-thyroxine treatment of hypothyroidism\nwith L-thyroxine. This has been reported in 20% of those treated with thyroid hormone (12). The principal adverse consequences of subtle or frank overtreatment are cardiovascular (187-190), skeletal (191-194), and possibly affective disturbances (195-197). The elderly are particularly susceptible to\nWhen initiating therapy in young healthy adults with overt hypothyroidism, beginning treatment with full replacement doses should be considered. Grade B, BEL 2  \nSee: L-thyroxine treatment of hypothyroidism\nWhen initiating therapy in patients older than 50-60 years with overt hypothyroidism, without evidence of coronary heart disease, an L-thyroxine dose of 50 \u00b5g daily should be considered. Grade D, BEL 4  \nSee: L-thyroxine treatment of hypothyroidism",
    "ground_truth_context": "The standard treatment is replacement with L-thyroxine which must be tailored to the individual patient.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Levothyroxine (T4) monotherapy",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient's symptoms of fatigue, constipation, and dry skin, along with elevated TSH and low free T4 levels, indicate primary hypothyroidism. According to the context provided, the standard treatment for hypothyroidism is L-thyroxine (T4) monotherapy. This is supported by the recommendation that patients with hypothyroidism should be treated with L-thyroxine monotherapy (Grade A, BEL 1). \n\nLiothyronine (T3) monotherapy (Option A) is not recommended as a standard treatment for hypothyroidism, and combination therapy with T4 and T3 (Option B) is also not typically advised in most cases. Thyroid-stimulating hormone (TSH) injection therapy (Option D) is not a standard treatment for hypothyroidism either. Therefore, the most appropriate initial treatment for this patient is Levothyroxine (T4) monotherapy (Option C).",
    "reasoning_ground_truth": "The patient's symptoms and lab results are consistent with primary hypothyroidism. The standard treatment is replacement with L-thyroxine (T4). Combination therapy with T3 is not recommended in the majority of cases.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male with a history of hypertension and type 2 diabetes presents with a 7-day history of cough, fever, and purulent nasal discharge. He reports no improvement with over-the-counter cold medications. What is the most appropriate next step in management?",
    "context": "documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\ncorroborate the diagnosis. 163 Examination of the middle meatus for purulence in the decongested state may strongly suggest ABRS and allows endoscopically guided culture.164\nin the patient initially managed with observation, the clinician should begin antibiotic therapy. If the patient was initially managed with an antibiotic, the clinician should change the antibiotic. Recommendation based on randomized controlled trials with limitations supporting a cut-point of 7\nOral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the\nIn Adults with CAP Who Test Positive for In\ufb02uenza, Should the Treatment Regimen Include Antibacterial Therapy?\nRecommendation. We recommend that standard antibacterial treatment be initially prescribed for adults with clinical and radiographic evidence of CAP who test positive for influenza in the inpatient and outpatient settings (strong recommendation, low quality of evidence).\n- Monotherapy with a respiratory fluoroquinolone (levofloxacin 750 mg daily, moxifloxacin 400 mg daily) (strong recommendation, high quality of evidence).  \nA third option for adults with CAP who have contraindications to both macrolides and fluoroquinolones is:\nIn inpatient adults with severe CAP (see Table 1) without risk factors for MRSA or P. aeruginosa, we recommend (Table 4) (note, specific agents and doses are the same as 9.1):  \n- A b-lactam plus a macrolide (strong recommendation, moderate quality of evidence); or\nhigh fever and purulent nasal discharge as a \u201csevere\u201d presentation of ABRS that warrants antibiotic therapy. Similarly, the Infectious Disease Society of America guideline on ABRS recommended that the clinician consider a diagnosis of ABRS if the patient presented with severe symptoms at the onset\nimprove diagnostic accuracy for adult rhinosinusitis, promote judicious use of systemic and topical therapy, and promote appropriate use of ancillary tests to confirm diagnosis and guide management, which include radiography, nasal endoscopy, computed tomography, and testing for allergy and immune",
    "ground_truth_context": "For acute bacterial rhinosinusitis (ABRS), amoxicillin with or without clavulanate is a recommended antibiotic. If a patient is allergic to penicillin, doxycycline or a respiratory quinolone can be used. Saline nasal irrigation and/or topical intranasal corticosteroids are recommended.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Begin a course of amoxicillin with or without clavulanate for possible acute bacterial rhinosinusitis (ABRS)",
    "correct_answer_idx": 3,
    "model_reasoning": "The patient's symptoms of cough, fever, and purulent nasal discharge, combined with the lack of improvement from over-the-counter cold medications, strongly suggest acute bacterial rhinosinusitis (ABRS). According to the guidelines, the appropriate initial treatment for ABRS is to begin a course of amoxicillin with or without clavulanate. \n\nWhile pneumonia is a potential differential diagnosis, the primary presentation aligns more closely with ABRS, especially given the purulent nasal discharge. Initiating azithromycin for presumed community-acquired pneumonia (CAP) is not appropriate as it is not the first-line treatment for ABRS. Prescribing oral prednisone for symptomatic relief does not address the underlying infection and is not indicated in this scenario. Ordering a chest x-ray to evaluate for pneumonia may be considered if pneumonia were strongly suspected, but the clinical presentation is more indicative of ABRS. Therefore, the most appropriate next step in management is to begin a course of amoxicillin with or without clavulanate for possible ABRS.",
    "reasoning_ground_truth": "The patient's symptoms of fever, purulent nasal discharge, and lack of improvement with over-the-counter medications suggest **acute bacterial rhinosinusitis (ABRS)**. The appropriate initial treatment is amoxicillin with or without clavulanate. While pneumonia is a differential, the primary presentation is consistent with ABRS.  Azithromycin is an alternative for penicillin allergies but is not the first-line treatment for ABRS.",
    "is_correct": false
  },
  {
    "question": "A 55-year-old female with a history of chronic kidney disease (CKD) and hypertension is started on a new medication for her blood pressure. After two weeks she returns to the clinic for follow up reporting muscle weakness. Her labs show an increase in serum potassium. What is the most appropriate next step?",
    "context": "- Hold finerenone\n- Consider adjustments to diet or concomitant medications to mitigate hyperkalemia\n- Recheck K+\n- Consider reinitiation if/when K+ \u22645.0 mmol/l\nPractice Point 3.6.5: Consider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate [eGFR] &lt;15\nMonitor serum creatinine and potassium (within 2\u20134 weeks after starting or changing dose)  \n|Normokalemia|Hyperkalemia|\u226530% decrease in eGFR|<30% decrease in eGFR|\n|---|---|---|---|\nTo mitigate risk of hyperkalemia, select people with consistently normal serum potassium concentration and monitor serum potassium regularly after initiation of a nonsteroidal MRA.\nhyperkalemia and K+ now \u22645.0 mmol/l|\u2022 Continue finerenone 10 mg or 20 mg \u2022 Monitor K+ every 4 months|\nPractice Point 3.11.5.2: Provide advice to limit the intake of foods rich in bioavailable potassium (e.g., processed foods) for people with CKD G3\u2013G5 who have a history of hyperkalemia or as a prevention strategy during disease periods in which hyperkalemia risk may be a concern. Diet may increase\n| |\u2022 Moderate dietary potassium intake|\u2022 Reassess concomitant medications (e.g., diuretics, NSAIDs)|\u2022 Consider renal artery stenosis|\n| |\u2022 Consider:| | |\n| |- diuretics| | |\n| |- sodium bicarbonate| | |\n| |- potassium binders| | |\nTo mitigate risk of hyperkalemia, select people with consistently normal serum potassium concentration and monitor serum potassium regularly after initiation of a nonsteroidal MRA (Figure 26).  \n|K \u22644.8 mmol/l+|K 4.9\u20135.5 mmol/l+|\n|---|---|",
    "ground_truth_context": "Hyperkalemia associated with RASi use can often be managed without stopping RASi. Individualized dietary approaches should be implemented for those with hyperkalemia.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Add a potassium-binding agent and continue the medication, with dietary modification",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient is experiencing hyperkalemia, which is likely a result of the new blood pressure medication she has started. According to the context provided, hyperkalemia associated with the use of medications such as ACE inhibitors or ARBs can often be managed without discontinuing the medication. The most appropriate next step in this scenario is to add a potassium-binding agent to help lower the serum potassium levels while continuing the blood pressure medication. Additionally, dietary modifications should be implemented to limit potassium intake, which is crucial for managing hyperkalemia, especially in patients with chronic kidney disease (CKD). \n\nDiscontinuing the medication (Option A) should be considered a last resort, as it may be necessary for managing her hypertension. Referring to nephrology for hemodialysis evaluation (Option C) is not warranted at this stage, as hyperkalemia can often be managed with pharmacologic and dietary interventions. Prescribing an oral diuretic (Option D) may not effectively address the hyperkalemia in this context and could potentially worsen the patient's condition. Therefore, Option B is the most appropriate and effective next step.",
    "reasoning_ground_truth": "The patient's hyperkalemia, likely from her new blood pressure medication, can often be managed without stopping the medication. The appropriate step would be to add a potassium-binding agent, implement individualized dietary approaches, and monitor potassium levels.  Discontinuing the medication should be considered as a last resort,.",
    "is_correct": false
  },
  {
    "question": "A 72-year-old male with a history of stable ischemic heart disease (SIHD) is being discharged after a recent hospitalization for pneumonia, He has been on dual antiplatelet therapy (DAPT) for 12 months following a percutaneous coronary intervention (PCI). What is the most appropriate duration of DAPT at this point?",
    "context": "recommended duration of P2Y12 inhibitor therapy (in addition to aspirin therapy). Figure 1 summarizes recommendations for duration of DAPT according to clinical status.\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\n|COR|LOE|RECOMMENDATIONS|\n|---|---|---|\n|I|B-R|In patients with ACS who are managed with medical therapy alone (without revascularization or fibrinolytic therapy) and treated with DAPT, P2Y12 inhibitor therapy (clopidogrel or ticagrelor) should be continued for at least 12 months (52,71,140,141).|\nboth in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone (51,52). Available evidence from this trial, as well as from PLATO (53,71,72) and TRITON-TIMI 38 (54,55), supports DAPT duration of at least 12 months for patients with NSTE-ACS.\n|I|C-LD|In patients with ACS (NSTE-ACS or STEMI) being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).| |\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable",
    "ground_truth_context": "For purposes of this focused update, patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD.",
    "model_answer": "D",
    "model_answer_idx": 3,
    "correct_answer_text": "Reduce DAPT to single antiplatelet therapy with aspirin",
    "correct_answer_idx": 4,
    "model_reasoning": "The patient in the scenario has a history of stable ischemic heart disease (SIHD) and has been on dual antiplatelet therapy (DAPT) for 12 months following a percutaneous coronary intervention (PCI). According to the guidelines, patients with a history of acute coronary syndrome (ACS) greater than one year prior who have remained stable are considered to have transitioned to SIHD. In this context, the current recommendation is to reduce DAPT to single antiplatelet therapy, specifically with aspirin. This is because after 12 months of DAPT, the risk of bleeding may outweigh the benefits of continuing dual therapy, especially in patients who are stable. Therefore, the most appropriate course of action for this patient is to reduce DAPT to single antiplatelet therapy with aspirin.",
    "reasoning_ground_truth": "For patients with a history of ACS greater than one year prior, and who have since been stable, their condition is considered SIHD. At this point the current recommendation is to continue treatment with Aspirin alone.",
    "is_correct": false
  },
  {
    "question": "A 30-year-old female presents to the emergency department with a generalized tonic-clonic seizure lasting 7 minutes. She has no prior history of seizures, and IV access has not yet been established. What is the most appropriate initial therapy?",
    "context": "mg/kg), diazepam (0.15 mg/kg) followed by phenytoin (18 mg/kg), phenobarbital (18 mg/kg), and phenytoin alone (18 mg/kg) in adults with either overt or subtle status epilepticus (22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC\nBased on the evidence-based answers to the above questions, a treatment algorithm is proposed for convulsive status epilepticus (Figure 1). As stated earlier, clinical trials have arbitrarily focused on either adults or children, and only three trials (24, 27, 30) included both. The guideline\u2019s\nlorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). In children, intravenous lorazepam and intravenous diazepam are established as efficacious at stopping seizures lasting at least 5 minutes (Level A) while rectal diazepam, intramuscular\nIntravenous lorazepam (0.1 mg/kg over 2\u20134 minutes) was compared with IV levetiracetam (20 mg/kg over 15 minutes) in a class III RCT involving children with either convulsive or subtle convulsive status epilepticus. As first therapy, lorazepam success rate (29/38, 76.3%) was similar to that for\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy\nmore than 5 minutes it is likely to be prolonged (3), status treatment protocols have used a 5-minute definition to minimize both the risk of seizures reaching 30 minutes and the adverse outcomes associated with needlessly intervening on brief, self-limited seizures (2, 4). This guideline follows\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nand timely therapy of status epilepticus reduces the associated mortality and morbidity (9). Ultimately, the prognosis is most strongly related to the etiology, duration of status epilepticus, and the age of the patient (10\u201312). Basic critical care and emergency principles of therapy such as\nadults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intramuscular midazolam has superior effectiveness compared to intravenous lorazepam in adults",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 2,
    "model_reasoning": "In the scenario presented, the patient is a 30-year-old female experiencing a generalized tonic-clonic seizure lasting 7 minutes, and she does not have established intravenous (IV) access. According to the evidence-based guidelines for treating convulsive status epilepticus in adults, when IV access is not available, **intramuscular midazolam** is the recommended first-line therapy. This is because it is both efficacious and can be administered rapidly. \n\nWhile intravenous lorazepam is typically preferred if IV access is established, in this case, it is not an option. Fosphenytoin is considered a second-line therapy and is not appropriate as an initial treatment in this situation. Rectal diazepam is an alternative but is not the first choice when intramuscular midazolam is available. Therefore, the most appropriate initial therapy for this patient is **intramuscular midazolam**.",
    "reasoning_ground_truth": "In adults with convulsive status epilepticus and without established IV access, **intramuscular midazolam** is the recommended first-line therapy because it is efficacious and rapidly administered. Intravenous lorazepam is preferred if IV access is established. Fosphenytoin is second-line therapy. Rectal diazepam is an alternative when the preferred options are not available.",
    "is_correct": false
  },
  {
    "question": "A 45-year-old male with a history of alcohol abuse presents with jaundice, ascites, and altered mental status. His labs indicate acute liver failure. He is hypotensive and requires volume resuscitation. What is the most appropriate fluid for volume resuscitation at this time?",
    "context": "In the cohort of patients with ascites due to subacute liver failure or acute Budd-Chiari syndrome, elevated intra-abdominal pressure may be present. This may alter response to volume loading, in addition to increasing risk of gut dysfunction and AKI, response to fluid resuscitation needs to be\nthe initial cardiac index. Drainage of some ascites may be recommended. Furthermore, hypoxic hepatitis is a secondary form of ALF and as such, the primary presenting organ failure needs to be addressed and managed to facilitate liver recovery. LTx is not indicated. The use of hydrocortisone to\nor renal failure), then it is highly likely that they are volume depleted and will respond to an appropriate fluid challenge. There is little evidence supporting the use of any specific fluid for volume loading in ALF. However, general critical care literature [130\u2013133]. The choice should be guided\nStudies of microcirculatory resuscitation as opposed to pressures. Appropriate utilisation of VA status in patients with ALF and hypoxic hepatitis. In a few cases, there may also be evidence of a toxic liver syndrome with increased lung water and ARDS. Assessment of intra-abdominal lung water may\n- Most patients are volume depleted at presentation and require crystalloid volume resuscitation (evidence level II-1, grade of recommendation 1).\nresuscitation needs to be assessed individually. In patients with elevated right sided cardiac pressures and ascites, further fluid therapy is likely to have limited or minimal improve venous return and improve cardiac index [148].",
    "ground_truth_context": "If used in this context, albumin should be viewed more as a drug, than as a resuscitative solution.",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Normal saline",
    "correct_answer_idx": 1,
    "model_reasoning": "In the context of acute liver failure (ALF), the patient is hypotensive and requires volume resuscitation. The first-line treatment for hypotension in this scenario is normal saline, which is a crystalloid solution. Normal saline is effective for volume resuscitation and helps to restore intravascular volume. \n\nWhile albumin can also be used in certain situations, it is recommended to be viewed more as a therapeutic agent rather than a primary resuscitative fluid. The context indicates that albumin should not be the first choice for volume resuscitation in acute liver failure, but rather considered later in the management plan. \n\nHypertonic saline and dextrose 5% in water are not appropriate choices for initial volume resuscitation in this case. Hypertonic saline is typically used in specific situations such as severe hyponatremia or traumatic brain injury, and dextrose 5% in water does not provide the necessary volume expansion needed for resuscitation.\n\nTherefore, normal saline is the most appropriate fluid for volume resuscitation in this patient with acute liver failure and hypotension.",
    "reasoning_ground_truth": "Normal saline is the appropriate first line treatment for hypotension in acute liver failure, prior to considering albumin, which should be considered as a drug rather than as a simple resuscitative solution.",
    "is_correct": false
  },
  {
    "question": "A 60-year-old male with a history of primary open-angle glaucoma (POAG) has been using prescribed eye drops for the past year. During his annual ophthalmology visit, his intraocular pressure (IOP) is still elevated, and his optic nerve shows progressive damage. He reports variable adherence to his medication regimen. What is the most appropriate next step in management?",
    "context": "- Estimate an IOP below which further optic nerve damage is unlikely to occur (see Target Intraocular Pressure subsection in the Care Process section).\n- Perform and document gonioscopy.\n- Monitor the structure and function of the optic nerve for further damage and adjust the target IOP to a lower level if deterioration occurs.\n- Minimize the side effects of treatment and their impact on the patient\u2019s vision, general health, and quality of life.\n- Stable optic nerve status and low IOP occur for a prolonged period in a patient taking topical ocular hypotensive agents. Under these circumstances, a carefully monitored attempt to reduce the medical regimen may be appropriate.\nIf a drug fails to reduce IOP sufficiently, then either switching to an alternative medication as monotherapy or adding medication is appropriate until the desired IOP level is attained.259 Since some studies have shown that adding a second medication decreased adherence to glaucoma treatment,347,\nThe indications for adjusting therapy are as follows:  \n- Target IOP is not achieved and the benefits of a change in therapy outweigh the risks for the patient\n- A patient has progressive optic nerve damage despite achieving the target IOP\nWhen deciding to treat a patient with glaucoma, it is important to remember that the goal of treatment is to maintain the IOP within a range at which visual field loss is unlikely to substantially reduce a patient\u2019s health-related quality of life over his or her lifetime.322\nFor patients initially treated with ALT, the amount of medical treatment required for glaucoma control is often reduced.319, 385 Results from long-term studies of patients receiving maximum medical therapy who subsequently had laser and incisional surgery indicate that 30% to more than 50% of eyes",
    "ground_truth_context": "Patient education and informed participation in treatment decisions may improve adherence.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Review patient education materials and discuss adherence.",
    "correct_answer_idx": 3,
    "model_reasoning": "In the management of primary open-angle glaucoma (POAG), ensuring patient adherence to the prescribed medication regimen is crucial for effective treatment. The patient in this scenario has a history of variable adherence to his medication, which is likely contributing to the elevated intraocular pressure (IOP) and progressive optic nerve damage. Before considering changes to the medication regimen, such as increasing the dose or adding a second medication, it is essential to address the patient's understanding of the treatment plan and the importance of consistent medication use. Reviewing patient education materials and discussing adherence can help improve the patient's compliance, potentially leading to better control of IOP and prevention of further optic nerve damage. Therefore, option C is the most appropriate next step in management.",
    "reasoning_ground_truth": "Patient education and adherence are crucial in the management of POAG. Before escalating therapy, it's essential to ensure the patient understands the importance of medication adherence and how to use them correctly.",
    "is_correct": false
  },
  {
    "question": "A 50-year-old female with rheumatoid arthritis (RA) has been on methotrexate for three months. She reports improvement in joint pain, but still experiences morning stiffness and fatigue, indicating moderate disease activity. What is the most appropriate next step?",
    "context": "A split dose of oral methotrexate over 24 hours or weekly subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.\nMethotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.  \n|Continuation of all DMARDs at their current dose|is conditionally recommended over a dose reduction of a DMARD.|\n|---|---|\nMethotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\n- Does switching to non-methotrexate DMARDs improve tolerability over increasing the dose of folic acid, or using folinic acid or using split dose or subcutaneous dosing, for RA patients with side effects when taking methotrexate?\nMethotrexate monotherapy is conditionally recommended over dual or triple csDMARD therapy for DMARD-naive patients with moderate-to-high disease activity. The recommendation favors methotrexate monotherapy because the higher burden of combination therapy (e.g., multiple medications, higher cost)\nmonotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.",
    "model_answer": "D",
    "model_answer_idx": 3,
    "correct_answer_text": "Continue methotrexate monotherapy for another 3 months",
    "correct_answer_idx": 4,
    "model_reasoning": "According to the guidelines, methotrexate monotherapy is conditionally recommended for patients with moderate-to-high disease activity, especially for those who are DMARD-naive or have not had an adequate trial of methotrexate. In this case, the patient has been on methotrexate for only three months and is still experiencing moderate disease activity, which indicates that she has not yet had a sufficient trial of the medication. The guidelines suggest continuing methotrexate monotherapy for another three months before considering additional treatments or modifications. This approach allows for the possibility of further improvement in her symptoms without prematurely escalating therapy or introducing additional medications. Therefore, the most appropriate next step is to continue methotrexate monotherapy for another three months.",
    "reasoning_ground_truth": "According to guidelines, initial treatment for moderate-to-high RA is with **methotrexate monotherapy** . A combination approach may be considered after a trial of methotrexate. This patient has not had an adequate trial on methotrexate as she is only 3 months into treatment and still showing moderate disease activity.",
    "is_correct": false
  },
  {
    "question": "A 22-year-old male presents with urethral discharge and dysuria for 3 days. A gram stain of the discharge shows gram-negative diplococci. Which of the following is the recommended treatment approach?",
    "context": "C. trachomatis, increasing the dosage of ceftriaxone to 250 mg for treatment of N. gonorrhoeae with continued monitoring of antimicrobial susceptibility, and consideration of whether azithromycin (2 g, single dose) should be recommended in early syphilis (16).\nIn people with gonococcal infections who have failed treatment, the WHO STI guideline suggests the following options.  \n- If reinfection is suspected, re-treat with a WHO-recommended regimen, reinforce sexual abstinence or condom use, and provide partner treatment.\nmg orally x 1; cefixime 800 mg orally x 1; cefixime 400 mg orally x 2; or gentamicin 240 mg IM x 1|Critical: Microbiological cure, clinical cure, N. gonorrhoeae antimicrobial in vitro resistance, compliance Important: STI complications, side-effects (including allergy, toxicity), quality of life,\nSince laboratory diagnostic tests are not available in the majority of countries, diagnosis is often made clinically, based on the presence of symptoms such as vaginal and urethral discharge. Presumptive treatment is sometimes provided to those at high risk of gonococcal infection, if indicated\n|Adults and adolescents with treatment failure of N. gonorrhoeae (genital or oropharyngeal) to cephalosporins|Gentamicin 240 mg IM + azithromycin 2 g orally x 1 Gentamicin 240 mg IM + azithromycin 1 g orally x 1 Spectinomycin 2 g IM + azithromycin 2 g orally x 1 Gemifloxacin 320 mg orally +\nGemifloxacin 320 mg orally + azithromycin 2 g orally x 1 Ceftriaxone 1 g IM + azithromycin 2 g orally x 1 Gentamicin 240 mg IM + spectinomycin 2 g IM x 1 Azithromycin 2 g orally x 1|Critical: Microbiological cure, compliance, STI complications, clinical cure, N. gonorrhoeae antimicrobial in vitro",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Intramuscular ceftriaxone and oral azithromycin",
    "correct_answer_idx": 2,
    "model_reasoning": "The clinical presentation of the 22-year-old male, which includes urethral discharge and dysuria, along with the gram stain showing gram-negative diplococci, is indicative of a gonococcal infection caused by Neisseria gonorrhoeae. According to the recommended treatment guidelines for gonococcal infections, the preferred regimen is a combination of intramuscular ceftriaxone and oral azithromycin. This dual therapy is important not only to effectively treat the gonococcal infection but also to cover potential co-infection with Chlamydia trachomatis and to mitigate the risk of developing antimicrobial resistance. The other options, such as oral azithromycin monotherapy, oral doxycycline, and oral ciprofloxacin, are not recommended as first-line treatments for gonorrhea, particularly in light of increasing resistance to fluoroquinolones and the need for effective coverage against both gonorrhea and potential chlamydia co-infection. Therefore, the correct treatment approach for this patient is option B: Intramuscular ceftriaxone and oral azithromycin.",
    "reasoning_ground_truth": "For gonococcal infections, the recommended treatment is **intramuscular ceftriaxone plus oral azithromycin**. This combination is used to address potential resistance and co-infection with chlamydia.",
    "is_correct": false
  },
  {
    "question": "A 65-year-old male, recently hospitalized for an acute exacerbation of COPD, is being considered for discharge. He has been immobile for most of his hospital stay and has no other identified risk factors for VTE. Which VTE prophylaxis is recommended?",
    "context": "Should VTE prophylaxis be used in medical outpatients with minor provoking factors for VTE (eg, immobility, minor injury, illness/infection)?\nhospitalization, and against extending pharmacological prophylaxis after hospital discharge. Conditional recommendations included not to use VTE prophylaxis routinely in long-term care patients or outpatients with minor VTE risk factors. The panel conditionally recommended use of graduated\nShould pharmacological VTE prophylaxis be used in chronically ill medical patients or nursing home patients?\nQuestion: Should mechanical VTE prophylaxis vs no VTE prophylaxis be used in acutely or critically ill medical patients?\nwith stroke who receive VTE prophylaxis.\nShould extended-duration pharmacological VTE prophylaxis after discharge (ie, up to 30 or 40 days) vs in-hospital\u2013only pharmacological VTE prophylaxis be used in acutely ill hospitalized medical patients?\nStudies on identification of high-risk subgroups of chronically ill medical patients who could benefit from VTE prophylaxis, with consideration given to those who are immobilized.\nAll guidelines advocated assessing the risk of VTE and bleeding in admitted medical patients. The American College of Physicians issued 2 additional recommendations: for the use of heparin or a related drug, unless patients were at high bleeding risk, and against use of graduated compression",
    "ground_truth_context": "Parenteral anticoagulant vs no parenteral anticoagulant in acutely ill medical patients. Summary of the evidence. We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Pharmacologic prophylaxis with subcutaneous heparin",
    "correct_answer_idx": 1,
    "model_reasoning": "The context indicates that in acutely ill medical patients, such as the 65-year-old male recently hospitalized for an acute exacerbation of COPD, pharmacologic prophylaxis is recommended to prevent VTE. Although the patient has been immobile and has no other identified risk factors for VTE, the guidelines suggest that acutely ill patients should receive pharmacologic prophylaxis, such as subcutaneous heparin, to mitigate the risk of developing VTE. Therefore, the correct choice is A, pharmacologic prophylaxis with subcutaneous heparin.",
    "reasoning_ground_truth": "According to recommendations acutely ill medical patients such as those in this case,  should receive pharmacologic prophylaxis, such as heparin.",
    "is_correct": false
  },
  {
    "question": "A 70-year-old female presents with cough, fever and shortness of breath. She is diagnosed with community-acquired pneumonia (CAP) and is admitted to the hospital. Her blood cultures taken on admission come back negative. What is the most appropriate step?",
    "context": "Longer courses of antibiotic therapy are recommended for 1) pneumonia e59\nswab is positive, coverage for MRSA pneumonia should generally be initiated, but blood and sputum cultures should be sent and therapy deescalated if cultures are negative.\nFor adults with community-acquired pneumonia (CAP) at risk for MRSA or P. aeruginosa (see Recommendation 11), we recommend the following empiric treatment regimens (in no order of preference) (Table 4):\nIn Adults with CAP Who Test Positive for In\ufb02uenza, Should the Treatment Regimen Include Antibacterial Therapy?\nwith deescalation at 48 hours if cultures are negative and the patient is improving.\nand symptoms of pneumonia with radiographic confirmation) to completion of antimicrobial therapy and follow-up chest imaging.\n|Recommendation|2007 ATS/IDSA Guideline|2019 ATS/IDSA Guideline|\n|---|---|---|\n|Sputum culture|Primarily recommended in patients with severe disease|Now recommended in patients with severe disease as well as in all inpatients empirically treated for MRSA or Pseudomonas aeruginosa|\n[173]. Care of the airway, appropriate use of physiotherapy and patient positioning should decrease the risk of ventilator associated pneumonia. Secretions should be sampled regularly using non-directed broncho-alveolar lavage, and sent for culture.\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Continue antibiotics until a validated measure of clinical stability is achieved and for no less than 5 days.",
    "correct_answer_idx": 2,
    "model_reasoning": "The context indicates that the duration of antibiotic therapy for community-acquired pneumonia (CAP) should be guided by a validated measure of clinical stability and continued for no less than 5 days. The negative blood culture results do not warrant the immediate discontinuation of antibiotics, as the patient's clinical condition must be assessed to determine the appropriate duration of therapy. Therefore, the most appropriate step is to continue antibiotics until clinical stability is achieved and for at least 5 days, making option B the correct choice.",
    "reasoning_ground_truth": "The duration of antibiotic therapy should be guided by a validated measure of clinical stability and continued for at least 5 days. Negative blood cultures do not indicate discontinuing treatment.",
    "is_correct": false
  },
  {
    "question": "A 62-year-old man with a history of heavy alcohol use presents with new onset jaundice, ascites, and confusion. His labs are suggestive of acute liver failure (ALF). He is hemodynamically stable and is being admitted for ongoing care. Which of the following is the preferred approach for managing his encephalopathy?",
    "context": "Development of encephalopathy is of key prognostic importance, with onset indicating critically impaired liver function. In subacute presentations, even low grade transaminases, increasing bilirubin and INR and encephalopathy may indicate extremely poor prognosis (evidence level II-2, grade of\nAccording to ESICM guidelines [179] low dose EN should be started when acute, immediately life-threatening metabolic derangements are controlled with or without liver support strategies, independent on grade of encephalopathy. Arterial ammonia levels should be monitored.\n43. Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: international society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology 2013;58(1):325e36.\n- In patients with severe ALI, screen intensively for any signs of hepatic encephalopathy.\n- Exclude the presence of cirrhosis, alcohol induced liver injury or malignant infiltration of the liver.\n6. Michel H, Bories P, Aubin JP, Pomier-Layrargues G, Bauret P, Bellet-Herman H. Treatment of acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver 1985;5(5):282e9.\ncourse. In \u2018hyper-acute\u2019 liver failure the onset of hepatic encephalopathy (HE) occurs within seven days of the onset of jaundice and patients most often recover promptly with medical therapy alone or after transplantation or die soon after illness onset. Due to the short duration of illness in",
    "ground_truth_context": "Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF. Serum osmolarity should be maintained below 320 mOsmol with RRT as required.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Initiate lactulose and rifaximin.",
    "correct_answer_idx": 2,
    "model_reasoning": "The preferred approach for managing hepatic encephalopathy in a patient with acute liver failure (ALF) involves the use of lactulose and rifaximin. These medications work by reducing the production and absorption of neurotoxins, which are responsible for the symptoms of encephalopathy. \n\nStarting intravenous steroids (Option A) is not recommended for treating elevated intracranial pressure (ICP) in the context of ALF. Maintaining serum osmolarity above 320 mOsmol using hypertonic saline (Option C) is not appropriate; instead, serum osmolarity should be maintained below this threshold. Monitoring ICP without intervention (Option D) does not provide an active treatment approach for the patient's condition.\n\nTherefore, the correct and most effective management strategy for this patient is to initiate lactulose and rifaximin (Option B).",
    "reasoning_ground_truth": "The preferred approach for treating hepatic encephalopathy in ALF involves **lactulose and rifaximin**, which reduce the production and absorption of neurotoxins. Steroids are not recommended for treating elevated ICP in ALF. Serum osmolarity should be maintained below 320 mOsmol. ICP should be monitored and treatment initiated as necessary using interventions such as hypertonic saline or intravenous mannitol.",
    "is_correct": false
  },
  {
    "question": "A 48-year-old female with a 10-year history of type 1 diabetes is being screened for chronic kidney disease (CKD). Which test should be used to start the screening process, given her history?",
    "context": "Practice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nFollowing incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nIdentify adults at risk for CKD  \nTest for GFR* and ACR \u00b1 other markers of kidney damage \u2020  \nGFR &lt;60 ml/min per 1.73 m2 or ACR \u226530 mg/g [3 mg/mmol]2 and/or other markers of kidney damage present  \nTest for GFR or ACR if not performed and exclude AKI/AKD\nFigure 3 | Screening algorithm for diagnosis and staging of chronic kidney disease (CKD) in adults. Risk factor conditions are listed in Table 5. *For recommended methods to estimate glomerular filtration rate (eGFR), see Section 1.2. \u2020Markers of kidney damage other than albuminuria may also be",
    "ground_truth_context": "As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, the first method to evaluate GFR should be eGFRcr.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Serum creatinine and calculate eGFR",
    "correct_answer_idx": 2,
    "model_reasoning": "The context specifies that the initial screening test for chronic kidney disease (CKD) should involve assessing the glomerular filtration rate (GFR) using serum creatinine to calculate the estimated GFR (eGFR). In the case of the 48-year-old female with a history of type 1 diabetes, she is at risk for CKD, and the appropriate first step in screening is to measure serum creatinine and calculate eGFR. While urine albumin measurement is also important in the evaluation of CKD, the eGFR is the primary test used to start the screening process. Therefore, option B, \"Serum creatinine and calculate eGFR,\" is the correct choice.",
    "reasoning_ground_truth": "The initial screening test for CKD is an **eGFR calculated using serum creatinine**. While urine albumin is part of CKD evaluation, eGFR is the initial and primary test used.",
    "is_correct": false
  },
  {
    "question": "A 78-year-old male is diagnosed with acute bacterial rhinosinusitis (ABRS). He has a known penicillin allergy. Which antibiotic is most appropriate?",
    "context": "National ambulatory care data from 2006 to 2010 revealed that rhinosinusitis accounted for more outpatient antibiotic prescriptions than any other diagnosis. Despite guidelines that encourage judicious antibiotic use for ARS, they are prescribed in about 82% of visits. From 2006 to 2010,\nFor penicillin-allergic patients, either doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is recommended as an alternative agent for empiric antimicrobial therapy. Fluoroquinolones, however, are not recommended for first-line therapy of ABRS in patients without penicillin\n- Change in recommendation from first-line antibiotic therapy for acute bacterial rhinosinusitis amoxicillin, with or without clavulanate, from amoxicillin alone (prior guideline)\n- Addition of asthma as a chronic condition that modifies management of chronic rhinosinusitis (CRS)\n|Offer a safety-net or wait-and-see antibiotic prescription|Prescribe amoxicillin, with or without clavulanate|KAS 9|\n|If penicillin allergy prescribe doxycycline or a respiratory quinolone|Treatment failure?**|Yes|\npatients without penicillin allergy because outcomes are comparable to amoxicillin-clavulanate, and adverse events are higher in some trials. Combination therapy with clindamycin plus a third-generation oral cephalosporin (cefixime or cefpodoxime) is recommended in adults with a history of non\u2013type\nfor watchful waiting (without antibiotic therapy) as initial therapy of acute bacterial rhinosinusitis (ABRS), and 3 new recommendations for managing chronic rhinosinusitis (CRS).",
    "ground_truth_context": "For acute bacterial rhinosinusitis (ABRS), amoxicillin with or without clavulanate is a recommended antibiotic. If a patient is allergic to penicillin, doxycycline or a respiratory quinolone can be used.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Oral doxycycline",
    "correct_answer_idx": 3,
    "model_reasoning": "For patients diagnosed with acute bacterial rhinosinusitis (ABRS) who have a known penicillin allergy, the recommended alternative antibiotic is doxycycline. According to the guidelines, doxycycline is specifically suggested for penicillin-allergic patients as an effective treatment option for ABRS. While azithromycin could be considered as an alternative, doxycycline is the preferred choice in this scenario. Oral amoxicillin/clavulanate is not appropriate due to the patient's penicillin allergy, and topical intranasal corticosteroids, while helpful for symptom relief, do not serve as an antibiotic treatment for ABRS. Therefore, the most appropriate antibiotic for this patient is oral doxycycline.",
    "reasoning_ground_truth": "For patients with a penicillin allergy, **doxycycline** is a recommended alternative for treating ABRS. Azithromycin may be considered as an alternative to doxycycline. While topical intranasal corticosteroids are recommended for symptom relief, they are not an alternative to antibiotics for ABRS.",
    "is_correct": false
  },
  {
    "question": "A 28-year-old pregnant female at 32 weeks gestation is admitted to the hospital with a first-time seizure lasting 8 minutes.  IV access has been obtained. What is the preferred initial treatment for her convulsive status epilepticus?",
    "context": "The second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nfrom ICH and reduce the risk of seizures. A short acting opiate should be added to provide adequate analgesia. In case of concern of seizure activity, EEG monitoring should be undertaken and antiepileptic drugs administered; however, the prophylactic use of antiepileptic drugs is not warranted.\nA, one class I RCT; children\u2014level U) than initial therapy. Thus, if second therapy fails to stop the seizures, treat-phase (66). Evidence for use of levetiracetam and lacosamide is limited to retrospective studies (67\u201372). Given the favorable pharmacokinetic characteristics and adverse-effect\nreceive a second dose of medication if the seizures continued after 10 minutes. For all patients, phenytoin was given after 30 minutes. A total of 70 patients were randomized to either lorazepam (n = 37) or diazepam (n = 33) (25). Lorazepam was successful for 78% of subjects after one dose and 89%\nmg/kg), diazepam (0.15 mg/kg) followed by phenytoin (18 mg/kg), phenobarbital (18 mg/kg), and phenytoin alone (18 mg/kg) in adults with either overt or subtle status epilepticus (22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC\nlorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). In children, intravenous lorazepam and intravenous diazepam are established as efficacious at stopping seizures lasting at least 5 minutes (Level A) while rectal diazepam, intramuscular\nA 1983 class II study compared IV lorazepam 4 mg and IV diazepam 10 mg in adults with convulsive status epilepticus (defined as \u22653 GTC seizures in 1 hour or \u22652 in rapid succession), absence status epilepticus, or complex partial status epilepticus (25). The patients could receive a second dose of\nallowed a repeat dose if the seizure continued after 4 minutes (for a maximum lorazepam dose of 4 mg and diazepam dose of 10 mg). For this study, status epilepticus was defined as continuous or repeated seizure for >5 minutes without recovery of consciousness. Overall, 205 patients were randomized\nFIGURE 1. Proposed treatment algorithm for status epilepticus.\nand timely therapy of status epilepticus reduces the associated mortality and morbidity (9). Ultimately, the prognosis is most strongly related to the etiology, duration of status epilepticus, and the age of the patient (10\u201312). Basic critical care and emergency principles of therapy such as\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Intravenous lorazepam",
    "correct_answer_idx": 3,
    "model_reasoning": "For a patient experiencing convulsive status epilepticus with established intravenous (IV) access, the preferred initial treatment is **intravenous lorazepam**. This is supported by the context provided, which states that intravenous lorazepam is established as an efficacious initial therapy for adults with convulsive status epilepticus when IV access is available. \n\nWhile intravenous phenytoin is mentioned as an acceptable second-line medication, it is not the first choice for initial treatment. Intramuscular midazolam is preferred when IV access has not been established, and rectal diazepam is considered an alternative when preferred options are unavailable. Since the patient in this scenario has IV access, lorazepam is the most appropriate and effective choice for immediate seizure control.",
    "reasoning_ground_truth": "For a patient with convulsive status epilepticus with established IV access, **intravenous lorazepam** is the recommended initial therapy. Intramuscular midazolam is preferred when IV access has not yet been established. Phenytoin is an acceptable alternative second line medication. Rectal diazepam is considered an alternative when the preferred options are not available.",
    "is_correct": false
  },
  {
    "question": "A 52-year-old male with a history of chronic liver disease presents with worsening ascites and is being evaluated for possible liver transplant. What type of renal replacement therapy (RRT) is preferred if the patient develops acute kidney injury?",
    "context": "Practice Point 5.4.3: Consider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is <15\u201320 ml/min per 1.73 m2 or risk of KRT is >40% over 2 years.\nConsider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is <15\u201320 ml/min per 1.73 m2 or risk of KRT is >40% over 2 years.\nA 2-year kidney failure risk threshold of >40% can be used to determine the modality education, timing of preparation for kidney replacement therapy (KRT) including vascular access planning or referral for transplantation, in addition to eGFR-based criteria and other clinical considerations.\nA 2-year kidney failure risk threshold of >40% can be used to determine the modality education, timing of preparation for kidney replacement therapy (KRT) including vascular access planning or referral for transplantation, in addition to eGFR-based criteria and other clinical considerations.",
    "ground_truth_context": "Continuous renal replacement therapy (RRT) is preferred over intermittent dialysis to avoid metabolic and hemodynamic fluctuations.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Continuous renal replacement therapy (CRRT)",
    "correct_answer_idx": 2,
    "model_reasoning": "In patients with acute liver failure who also develop acute kidney injury, continuous renal replacement therapy (CRRT) is the preferred modality of renal replacement therapy (RRT). This preference is due to CRRT's ability to provide more stable hemodynamic support and avoid the metabolic and hemodynamic fluctuations that can occur with intermittent hemodialysis. CRRT allows for a slower and more controlled removal of waste products and excess fluid, which is particularly beneficial in patients with compromised liver function. Therefore, in this scenario, CRRT is the most appropriate choice for managing the patient's acute kidney injury.",
    "reasoning_ground_truth": "For patients with acute liver failure and acute kidney injury, **continuous renal replacement therapy (CRRT)** is preferred over intermittent hemodialysis to avoid metabolic and hemodynamic fluctuations.",
    "is_correct": false
  },
  {
    "question": "A 68-year-old male with established primary open-angle glaucoma (POAG) is using a single eye drop medication. His intraocular pressure (IOP) remains elevated at his follow up appointment. What is the next step in the treatment of this patient?",
    "context": "If a drug fails to reduce IOP sufficiently, then either switching to an alternative medication as monotherapy or adding medication is appropriate until the desired IOP level is attained.259 Since some studies have shown that adding a second medication decreased adherence to glaucoma treatment,347,\nMedical therapy is presently the most common initial intervention to lower IOP (see Table 4 for an overview of options available). Prostaglandin analogs are the most frequently prescribed eye drops for lowering IOP in patients with glaucoma because they are most efficacious and well tolerated, and\nto glaucoma treatment,347, 348 fixed combination therapy may improve patient adherence, and reduce exposure to preservatives, although it is not recommended for initial treatment in most circumstances. However, when the necessary reduction of IOP exceeds the expected efficacy of a single drug,\n|Advanced Glaucoma Intervention Study, 2000|POAG after medical therapy failure with no previous surgery: laser trabeculoplasty first vs. trabeculectomy first|591|10\u201313|\n|United Kingdom Glaucoma Treatment Study, 2014|Newly diagnosed OAG: latanoprost 0.005% vs. placebo|516|2|\nGuidelines for follow-up of patients with POAG are summarized in Table 7. These recommendations apply to ongoing glaucoma management and not to visits for other purposes. The purpose of follow-up examination is to evaluate IOP level, visual field status, and optic disc appearance as well as ONH,\nWhen deciding to treat a patient with glaucoma, it is important to remember that the goal of treatment is to maintain the IOP within a range at which visual field loss is unlikely to substantially reduce a patient\u2019s health-related quality of life over his or her lifetime.322\non several medications or there is evidence of glaucomatous progression in a patient with a moderate cataract, glaucoma surgery may be indicated initially, with the plan to perform cataract surgery once IOP is adequately controlled. In between these two extremes, the decision of which procedure(s)\nOther glaucoma medications include alpha 2 adrenergic agonists, parasympathomimetics, rho-kinase inhibitors, and topical and oral carbonic anhydrase inhibitors.335-337",
    "ground_truth_context": "Patient education and informed participation in treatment decisions may improve adherence.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Add a second medication to his current eye drop",
    "correct_answer_idx": 2,
    "model_reasoning": "In the context of managing primary open-angle glaucoma (POAG), if a patient is using a single eye drop medication and their intraocular pressure (IOP) remains elevated, the recommended next step is to add a second medication to the current eye drop. This approach is preferred because it allows for better control of IOP without immediately resorting to more invasive procedures like laser trabeculoplasty or surgery. Increasing the dose of the current medication may not be effective if the initial dose is already optimal, and it does not address the need for additional therapeutic options. Therefore, adding a second medication is the most appropriate and effective strategy in this scenario.",
    "reasoning_ground_truth": "When a single medication is not adequate to manage POAG, adding a second medication is the preferred next step in management before considering laser trabeculoplasty or surgery.",
    "is_correct": false
  },
  {
    "question": "A 58-year-old female with rheumatoid arthritis (RA) is currently treated with methotrexate, but is still having persistent moderate disease activity. Which of the following is the next recommended step?",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nMethotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.  \n|Continuation of all DMARDs at their current dose|is conditionally recommended over a dose reduction of a DMARD.|\n|---|---|\nMethotrexate monotherapy is conditionally recommended over methotrexate plus a tumor necrosis factor (TNF) inhibitor for DMARD-naive patients with moderate-to-high disease activity. Methotrexate monotherapy is strongly preferred given the lack of proven benefit and additional risks and costs\nMethotrexate monotherapy is conditionally recommended over dual or triple csDMARD therapy for DMARD-naive patients with moderate-to-high disease activity. The recommendation favors methotrexate monotherapy because the higher burden of combination therapy (e.g., multiple medications, higher cost)\nA split dose of oral methotrexate over 24 hours or weekly subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.\n|A split dose of oral methotrexate over 24 hours or subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.|Very low|PICO 16 and PICO 15|p. 206\u201310|\nmonotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Add a biologic DMARD (bDMARD)",
    "correct_answer_idx": 3,
    "model_reasoning": "According to the guidelines provided in the context, if a patient with rheumatoid arthritis (RA) is on methotrexate monotherapy and continues to experience moderate disease activity, the next recommended step is to add a biologic DMARD (bDMARD) or a targeted synthetic DMARD (tsDMARD). The guidelines emphasize that methotrexate monotherapy is preferred over the combination of methotrexate with a bDMARD or tsDMARD, indicating that if the current treatment is insufficient, the addition of a biologic DMARD is the appropriate course of action. Therefore, option C, \"Add a biologic DMARD (bDMARD),\" is the correct choice.",
    "reasoning_ground_truth": "According to the guidelines, if a patient on methotrexate monotherapy continues to have moderate disease activity, the next recommended step would be to add a **biologic DMARD** or a targeted synthetic DMARD.",
    "is_correct": false
  },
  {
    "question": "A 26-year-old male is diagnosed with uncomplicated gonorrhea. He has no known drug allergies. What is the recommended treatment regimen?",
    "context": "C. trachomatis, increasing the dosage of ceftriaxone to 250 mg for treatment of N. gonorrhoeae with continued monitoring of antimicrobial susceptibility, and consideration of whether azithromycin (2 g, single dose) should be recommended in early syphilis (16).\nIn people with gonococcal infections who have failed treatment, the WHO STI guideline suggests the following options.  \n- If reinfection is suspected, re-treat with a WHO-recommended regimen, reinforce sexual abstinence or condom use, and provide partner treatment.\n|Adults and adolescents with treatment failure of N. gonorrhoeae (genital or oropharyngeal) to cephalosporins|Gentamicin 240 mg IM + azithromycin 2 g orally x 1 Gentamicin 240 mg IM + azithromycin 1 g orally x 1 Spectinomycin 2 g IM + azithromycin 2 g orally x 1 Gemifloxacin 320 mg orally +\nthe eventual development of untreatable gonococcal infections with serious sexual and reproductive health consequences (6). The previous WHO Guidelines for the management of sexually transmitted infections, published in 2003 (7), include ciprofloxacin as a first-line treatment for gonorrhoea, even\n- 4. Recommendations for treatment of gonococcal infections ............ 17\n- 4.1 Genital and anorectal gonococcal infections ............................ 17\n- Recommendation 1 ................................................................. 17\nGonococcal treatment guidelines need to be updated in response to the changing antimicrobial susceptibility patterns of N. gonorrhoeae. Increased resistance to most antibiotics used to treat gonococcal infections has been reported worldwide, raising concerns about the eventual development of",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Intramuscular ceftriaxone 500mg and oral azithromycin 1 gram single dose",
    "correct_answer_idx": 3,
    "model_reasoning": "The recommended treatment regimen for uncomplicated gonorrhea, as indicated in the context, is a combination of intramuscular ceftriaxone and oral azithromycin. Specifically, the guideline suggests administering 500 mg of ceftriaxone intramuscularly along with 1 gram of azithromycin orally as a single dose. This combination is effective against N. gonorrhoeae and addresses the increasing resistance patterns observed in gonococcal infections. The other options listed (A, B, and D) do not align with the current treatment recommendations for uncomplicated gonorrhea, making option C the correct choice.",
    "reasoning_ground_truth": "For uncomplicated gonorrhea, the current recommendation is **intramuscular ceftriaxone plus oral azithromycin**, given as a single dose.",
    "is_correct": false
  },
  {
    "question": "A 55-year-old female is hospitalized for an acute illness. She has no prior history of venous thromboembolism (VTE). She is being considered for discharge. What should the VTE risk stratification for her take into account?",
    "context": "Should VTE prophylaxis be used in medical outpatients with minor provoking factors for VTE (eg, immobility, minor injury, illness/infection)?\nrisk factor for VTE, and \u223c40% have $3 risk factors. In a United States population-based study, hospital-acquired DVT and PE occurred in 1.3% and 0.4% of hospital admissions, respectively. The increased risk of VTE persists for 45 to 60 days after hospital discharge. Other medical populations that\n- Chronically ill medical inpatients or nursing home residents\n- Outpatients with minor provoking VTE risk factors\n- Acutely or critically ill medical inpatients\n- Travelers\n|Previous VTE|3|\n|Known thrombophilia\u2021|2|\n|Lower limb paralysis\u00a7|2|\n|Active cancer|2|\n|Immobilization $7 d|1|\n|ICU/CCU stay|1|\n|Age .60 y|1|\n|IMPROVE bleeding RAM: score \u20217 indicates high bleeding risk{| |\n|Renal failure (GFR 30-59 vs $60 mL/min per m 2)|1|\n|Male vs female|1|\n- Studies of risk assessment tools for guidance on defining high-risk status for VTE and bleeding at discharge;\n- Trials of pharmacological or nonpharmacological interventions in selected high-risk medical patients for VTE at discharge 143;\nStudies on identification of high-risk subgroups of chronically ill medical patients who could benefit from VTE prophylaxis, with consideration given to those who are immobilized.\n- Studies on identification of high-risk subgroups of chronically ill medical patients who could benefit from VTE prophylaxis, with consideration given to those who are immobilized;\nhospitalization, and against extending pharmacological prophylaxis after hospital discharge. Conditional recommendations included not to use VTE prophylaxis routinely in long-term care patients or outpatients with minor VTE risk factors. The panel conditionally recommended use of graduated\n\u2020Risk level: score of 0 or 1 5 low risk, score of 2 or 3 5 moderate risk; score $ 4 5 high risk. For scores $ 2, VTE prophylaxis is indicated.  \nA total of 69% of patients in this study were low risk for VTE (score 0 or 1).  \nThree-month rate of symptomatic VTE:  \n- IMPROVE VTE score 0 or 1: 0.5%",
    "ground_truth_context": "Parenteral anticoagulant vs no parenteral anticoagulant in acutely ill medical patients. Summary of the evidence. We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Her risk factors for VTE and length of stay.",
    "correct_answer_idx": 3,
    "model_reasoning": "The VTE risk assessment for a hospitalized patient should take into account both the patient's risk factors for venous thromboembolism (VTE) and the length of stay in the hospital. In this case, the 55-year-old female has no prior history of VTE, but her risk factors (which may include her acute illness, immobility, or other medical conditions) and the duration of her hospitalization are critical in determining her overall risk for developing VTE. While age and comorbidities are important considerations, they are part of the broader assessment that includes the length of stay and specific risk factors. Therefore, the most comprehensive and accurate approach is to consider both her risk factors for VTE and her length of stay, making option C the correct choice.",
    "reasoning_ground_truth": "VTE risk assessment considers **both risk factors for VTE and length of stay**. Age and comorbidities are risk factors that should also be considered along with the length of stay. ",
    "is_correct": false
  },
  {
    "question": "A 67-year-old male with a history of COPD and recent hospitalization for pneumonia is now clinically stable and ready for discharge. What is the recommended duration for his antibiotic treatment?",
    "context": "In Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of Antibiotic Treatment?\nLonger courses of antibiotic therapy are recommended for 1) pneumonia e59\nAs recent data supporting antibiotic administration for ,5 days are scant, on a risk\u2013benefit basis we recommend treating for a minimum of 5 days, even if the patient has reached clinical stability before 5 days. As most patients will achieve clinical stability within the first 48 to 72 hours, a\nControlled studies are needed to establish the duration of antibiotic therapy for adults with complications of CAP, including empyema, and adults with prolonged time to achieving clinical stability.",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Continue antibiotics until clinical stability is achieved and for at least 5 days",
    "correct_answer_idx": 3,
    "model_reasoning": "The context specifies that antibiotic therapy for pneumonia should be continued until a validated measure of clinical stability has been achieved and for no less than 5 days. In the case of the 67-year-old male with a history of COPD who is now clinically stable, the recommendation is to continue antibiotics until clinical stability is confirmed and for at least 5 days. This aligns with the guidelines that emphasize the importance of both clinical stability and a minimum duration of treatment. Options A and B suggest fixed durations of 7 or 10 days without considering the patient's clinical status, which is not recommended. Option D suggests discontinuing antibiotics at discharge, which is inappropriate unless the patient has already completed at least 5 days of treatment and is clinically stable. Therefore, the correct choice is C, as it adheres to the guidelines for antibiotic treatment duration in pneumonia cases.",
    "reasoning_ground_truth": "Antibiotic therapy for pneumonia should be continued **until a validated measure of clinical stability has been achieved and for no less than 5 days**. Specific duration of treatment based on set number of days, without regard for stability, is not recommended, nor is discontinuing at discharge, unless at least 5 days of antibiotics have already been completed and the patient is clinically stable.",
    "is_correct": false
  },
  {
    "question": "A 57-year-old male with a long history of heavy alcohol use presents with worsening jaundice, ascites, and new onset confusion. He is diagnosed with acute liver failure (ALF). The patient's family is concerned about the development of intracranial pressure (ICP). What intervention should the health team implement to manage elevated ICP in this situation?",
    "context": "[278] Wendon JA, Larsen FS. Intracranial pressure monitoring in acute liver failure. A procedure with clear indications. Hepatology 2006;44:504\u2013506.\n[220] Vaquero J, Fontana RJ, Larson AM, Bass NM, Davern TJ, Shakil AO, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005;11:1581\u20131589.\n[279] Bernuau J, Durand F. Intracranial pressure monitoring in patients with acute liver failure: a questionable invasive surveillance. Hepatology 2006;44:502\u2013504.\n[277] Blei AT, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 1993;341:157\u2013158.\nMannitol or hypertonic saline should be administered for surges of ICP with consideration for short-term hyperventilation (monitor reverse jugular venous saturation to prevent excessive hyperventilation and risk of cerebral hypoxia). Mild hypothermia and indomethacin may be considered in\n4. Use of ICP monitoring is not routinely indicated but may be considered in children older than 2 years who have clinical signs of increased ICP and are awaiting LTx.\nIn patients with grade 3 or 4 encephalopathy, intubation should be undertaken to provide a safe environment and prevention of aspiration. Regular evaluation for signs of intracranial hypertension should be performed (evidence level III, grade of recommendation 1).\nGeneral measures include elevation of the head at a 30-degree upright angle, avoidance of fever, hypoglycaemia or hyperglycemia and clamping of serum sodium at 140\u2013145 mmol/L. In patients who are monitored for ICP, pressure should be maintained below 20\u201325 mmHg and the difference between MAP and\n[280] Fortea JI, Banares R, Vaquero J. Intracranial pressure in acute liver failure: to bolt or not to bolt\u2014that is the question. Crit Care Med 2014;42:1304\u20131305.\n[219] Munoz SJ, Rajender Reddy K, Lee WAcute Liver Failure Study Group. The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. Neurocrit Care 2008;9:103\u2013107.",
    "ground_truth_context": "Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Administer intravenous mannitol or hypertonic saline.",
    "correct_answer_idx": 2,
    "model_reasoning": "In the context of managing elevated intracranial pressure (ICP) in a patient with acute liver failure (ALF), the most appropriate intervention is to administer intravenous mannitol or hypertonic saline. These agents are specifically indicated for treating sustained surges in ICP, as they help to draw fluid out of the brain tissue and reduce swelling. \n\nThe other options are less suitable for this scenario:\n- A. Initiating intravenous dexamethasone is not recommended for treating elevated ICP in ALF, as steroids do not effectively address the underlying issues related to ICP in this context.\n- C. Reducing the amount of IV fluids may not effectively manage ICP and could potentially worsen the patient's condition by leading to inadequate volume status.\n- D. Administering intravenous albumin is primarily aimed at increasing intravascular volume rather than directly addressing ICP.\n\nTherefore, the best choice for managing elevated ICP in this patient is option B: Administer intravenous mannitol or hypertonic saline.",
    "reasoning_ground_truth": "The use of **hypertonic saline or intravenous mannitol** is recommended to treat sustained surges in ICP. Steroids are not recommended for treatment of elevated ICP in ALF. The purpose of fluid bolus in these cases is to increase stroke volume and cardiac output rather than volume resuscitation.",
    "is_correct": false
  },
  {
    "question": "A 60-year-old female with type 2 diabetes is being evaluated for chronic kidney disease (CKD). Her initial eGFR based on serum creatinine is 50 mL/min/1.73 m\u00b2. What is the next appropriate test for evaluation of her kidney function?",
    "context": "filtration rate (eGFR) should be monitored concurrently with serum potassium. Reproduced from Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102:S1\u2013S127.\nfiltration rate (eGFR) should be monitored concurrently with serum potassium. Reproduced from Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102:S1\u2013S127.\nFollowing incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nPrevious guidelines have suggested the routine monitoring of albuminuria and GFR. Prior guidelines have suggested annual monitoring for those with CKD G1\u2013G2, every 6 months for those with CKD G3, every 3 months for CKD G4, and every 6 weeks for CKD G5 disease. Given the greater risk of disease\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nIdentify adults at risk for CKD  \nTest for GFR* and ACR \u00b1 other markers of kidney damage \u2020  \nGFR &lt;60 ml/min per 1.73 m2 or ACR \u226530 mg/g [3 mg/mmol]2 and/or other markers of kidney damage present  \nTest for GFR or ACR if not performed and exclude AKI/AKD\nFor people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.\ndecisions as an assessment of excretory kidney function (Table 4) to detect and stage AKD and CKD, determine CKD progression, dose medications, determine appropriate use of diagnostic tests, and guide treatment decisions around KRT therapies. Equations are available that estimate GFR using SCr and",
    "ground_truth_context": "If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Measure cystatin C and calculate eGFR using both creatinine and cystatin C",
    "correct_answer_idx": 2,
    "model_reasoning": "In the context of evaluating chronic kidney disease (CKD) in a 60-year-old female with type 2 diabetes and an initial estimated glomerular filtration rate (eGFR) of 50 mL/min/1.73 m\u00b2, it is important to ensure that the assessment of kidney function is accurate. If the eGFR based on serum creatinine is suspected to be inaccurate or if a more precise evaluation of kidney function is required for clinical decision-making, the next appropriate step is to measure cystatin C and calculate eGFR using both creatinine and cystatin C. This approach provides a more reliable estimate of kidney function, especially in cases where creatinine levels may not fully reflect kidney health.\n\nThe other options are less appropriate in this scenario:\n- A. Repeating serum creatinine measurement in 1 month does not provide additional information about kidney function in the immediate term.\n- C. A 24-hour urine collection for albumin is not the next step for evaluating eGFR; it is typically used for assessing proteinuria but not for immediate kidney function assessment.\n- D. Performing a kidney biopsy is an invasive procedure that is not warranted at this stage of evaluation without further indication of specific kidney pathology.\n\nThus, option B is the most appropriate next step in the evaluation of her kidney function.",
    "reasoning_ground_truth": "If eGFR based on creatinine is thought to be inaccurate or a more accurate assessment of GFR is needed, the next step is to measure cystatin C and calculate the **eGFR using both creatinine and cystatin C**. 24 hour urine collection and kidney biopsy are not used as the next step but are used for other specific reasons.  ",
    "is_correct": false
  },
  {
    "question": "A 75-year-old male with acute bacterial rhinosinusitis (ABRS) symptoms for 10 days, including purulent nasal discharge, facial pain, and fever, reports no improvement with initial saline irrigation. He is also started on amoxicillin/clavulanate. When should the patient be reassessed?",
    "context": "ABRS when (a) symptoms or signs of acute rhinosinusitis persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms.\u201d\nAs recent data supporting antibiotic administration for ,5 days are scant, on a risk\u2013benefit basis we recommend treating for a minimum of 5 days, even if the patient has reached clinical stability before 5 days. As most patients will achieve clinical stability within the first 48 to 72 hours, a\nonset of upper respiratory symptoms, or b. symptoms or signs of acute rhinosinusitis worsen within 10 days after an initial improvement (double worsening)|\nby nasal obstruction, facial pain-pressure-fullness, or both) persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of ARS worsen within 10 days after an initial improvement (double worsening).|\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for",
    "ground_truth_context": "Define realistic expectations regarding clinical response to initial management and to articulate clearly when reassessment of the patient is warranted",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Reassess in 1 week if symptoms are persistent.",
    "correct_answer_idx": 1,
    "model_reasoning": "In the context of acute bacterial rhinosinusitis (ABRS), it is recommended to reassess patients if their symptoms persist after 7 days of initial treatment. Since the patient in the scenario has been experiencing symptoms for 10 days and has started on amoxicillin/clavulanate, it is appropriate to reassess him in 1 week if his symptoms do not improve. This aligns with the guideline that emphasizes the importance of monitoring the patient's response to treatment and determining the need for further intervention based on symptom persistence. While immediate reassessment is warranted if symptoms worsen, the question specifically asks about reassessment for persistent symptoms, making option A the most suitable choice.",
    "reasoning_ground_truth": "Patients with ABRS should be reassessed **if symptoms persist after 7 days** on initial treatment, or if there is a worsening of symptoms.",
    "is_correct": false
  },
  {
    "question": "A 35-year-old male in the hospital is experiencing a seizure. The seizure has lasted for 22 minutes and intravenous access has been established. He was treated with lorazepam at 5 minutes. What is the most appropriate next step in managing his status epilepticus?",
    "context": "allowed a repeat dose if the seizure continued after 4 minutes (for a maximum lorazepam dose of 4 mg and diazepam dose of 10 mg). For this study, status epilepticus was defined as continuous or repeated seizure for >5 minutes without recovery of consciousness. Overall, 205 patients were randomized\nlorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). In children, intravenous lorazepam and intravenous diazepam are established as efficacious at stopping seizures lasting at least 5 minutes (Level A) while rectal diazepam, intramuscular\nA second class I study in adults (older than 18 years) with status epilepticus was initiated outside the hospital by paramedics (23). In this 2001 study, patients were randomized to receive 2 mg IV lorazepam or 5 mg IV diazepam or IV placebo in the ambulance. The protocol allowed a repeat dose if\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nIntravenous lorazepam (0.1 mg/kg over 2\u20134 minutes) was compared with IV levetiracetam (20 mg/kg over 15 minutes) in a class III RCT involving children with either convulsive or subtle convulsive status epilepticus. As first therapy, lorazepam success rate (29/38, 76.3%) was similar to that for\nat stopping seizures lasting at least 5 minutes (level A). For all patients, phenytoin was given after 30 minutes. A total of 70 patients were randomized to either lorazepam (n = 37) or diazepam (n = 33). In this comparative trial, 12% of lorazepam patients and 13% of diazepam patients experienced",
    "ground_truth_context": "Reasonable options for second-line therapy include fosphenytoin, valproic acid, and levetiracetam.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Administer intravenous fosphenytoin.",
    "correct_answer_idx": 2,
    "model_reasoning": "In the management of status epilepticus, if a seizure persists after initial treatment with a benzodiazepine (in this case, lorazepam), the next step is to administer a second-line agent. The context specifies that when a seizure continues after initial benzodiazepine therapy, options for second-line therapy include fosphenytoin, valproic acid, or levetiracetam. Since the patient's seizure has lasted for 22 minutes and he has already received lorazepam at 5 minutes, it is appropriate to move on to a second-line treatment. \n\nRepeating the intravenous lorazepam dose (Option A) is not recommended because the seizure duration has exceeded the initial therapy window. Administering intramuscular midazolam (Option C) is not suitable as it is not the preferred route in this scenario where intravenous access is already established. Starting a phenobarbital infusion (Option D) is also not the immediate next step according to the guidelines provided in the context. Therefore, the most appropriate next step is to administer intravenous fosphenytoin (Option B).",
    "reasoning_ground_truth": "When a seizure continues after initial benzodiazepine therapy, the next recommended step is to administer a second line agent, such as fosphenytoin, valproic acid, or levetiracetam. Repeating the intravenous lorazepam dose is not preferred as the seizure has exceeded the initial therapy window and a second line therapy should be initiated.",
    "is_correct": false
  },
  {
    "question": "A 65 year old patient with known cirrhosis and newly diagnosed hepatic encephalopathy is admitted to the hospital. She is stable and has a history of medication intolerance. Which is the preferred medication for hepatic encephalopathy?",
    "context": "43. Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: international society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology 2013;58(1):325e36.\n6. Michel H, Bories P, Aubin JP, Pomier-Layrargues G, Bauret P, Bellet-Herman H. Treatment of acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver 1985;5(5):282e9.\n| | | | |\n| |Preventative measures:| | |\n| |Avoid sedatives| | |\n| |Avoid hepatotoxic and nephrotoxic drugs| | |\n| |In case of hepatic encephalopathy:| | |\n| |Transfer to an appropriate level of care (ideally critical care) at the first symptoms of mental alterations| | |\nAccording to ESICM guidelines [179] low dose EN should be started when acute, immediately life-threatening metabolic derangements are controlled with or without liver support strategies, independent on grade of encephalopathy. Arterial ammonia levels should be monitored.\nIn addition to cholinesterase inhibitors and memantine the 2007 guideline reviews other medications used to delay the progression of cognitive symptoms in dementia including statins nonsteroidal anti-inflammatory drugs (NSAIDs) estrogen supplements and other marketed and experimental agents. Since\nlevodopa, nonergot dopamine antagonists, or low-dose gabapentinoids.|Correction of contributing factors such as hyperphosphatemia and iron deficiency/anemia.|\nThe 2007 guideline notes that currently available data suggest that the combination of a cholinesterase inhibitor plus memantine is more likely to delay symptom progression than a cholinesterase inhibitor alone. The DOMINO trial conducted by Howard and colleagues (2012) provides additional\ndrugs is not warranted. Phenytoin has traditionally been the medication of choice; however, agents without risk of hepatotoxicity and more easily achieved therapeutic levels such as levetiracetam or lacosamide are now more frequently utilised.",
    "ground_truth_context": "Continuous renal replacement therapy (RRT) is preferred over intermittent dialysis to avoid metabolic and hemodynamic fluctuations. Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF.",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Lactulose",
    "correct_answer_idx": 1,
    "model_reasoning": "The preferred first-line treatment for hepatic encephalopathy (HE) is **Lactulose**. Lactulose works by reducing the absorption of ammonia in the gut, which is a key factor in the development of HE. While Rifaximin is also an effective treatment and may be used in conjunction with Lactulose or as an alternative, guidelines typically recommend starting with Lactulose due to its established efficacy and safety profile. \n\nIntravenous steroids are not indicated in the management of hepatic encephalopathy, as they do not address the underlying metabolic derangements associated with liver dysfunction. Oral neomycin is considered an alternative therapy for HE but is not the first-line treatment due to potential side effects and the availability of more effective options like Lactulose. Therefore, in the context of a patient with cirrhosis and newly diagnosed hepatic encephalopathy, Lactulose is the most appropriate choice.",
    "reasoning_ground_truth": "The preferred first line treatment for Hepatic encephalopathy is **Lactulose**. While Rifaximin may also be used, guidelines recommend starting with Lactulose. Intravenous steroids are not indicated in the management of HE. Oral neomycin is an alternative therapy but not first line. ",
    "is_correct": false
  },
  {
    "question": "A 50-year-old female with a diagnosis of primary open-angle glaucoma (POAG) has been treated with two different eye drop medications, but her intraocular pressure (IOP) is still not well controlled. What is the next step in her management?",
    "context": "Medical therapy is presently the most common initial intervention to lower IOP (see Table 4 for an overview of options available). Prostaglandin analogs are the most frequently prescribed eye drops for lowering IOP in patients with glaucoma because they are most efficacious and well tolerated, and\nWhen deciding to treat a patient with glaucoma, it is important to remember that the goal of treatment is to maintain the IOP within a range at which visual field loss is unlikely to substantially reduce a patient\u2019s health-related quality of life over his or her lifetime.322\nIf a drug fails to reduce IOP sufficiently, then either switching to an alternative medication as monotherapy or adding medication is appropriate until the desired IOP level is attained.259 Since some studies have shown that adding a second medication decreased adherence to glaucoma treatment,347,\nManaging glaucoma in the pregnant or lactating patient involves an interdisciplinary approach to prevent disease progression in the mother while minimizing risks to the fetus and nursing infant. Laser trabeculoplasty may be considered as an alternative or adjunct to medical therapy in select\non several medications or there is evidence of glaucomatous progression in a patient with a moderate cataract, glaucoma surgery may be indicated initially, with the plan to perform cataract surgery once IOP is adequately controlled. In between these two extremes, the decision of which procedure(s)\nto glaucoma treatment,347, 348 fixed combination therapy may improve patient adherence, and reduce exposure to preservatives, although it is not recommended for initial treatment in most circumstances. However, when the necessary reduction of IOP exceeds the expected efficacy of a single drug,\nof patient education combined with personalized behavioral change interventions, including tailoring daily routines to promote adherence to eye drops, may improve adherence to glaucoma medications, overall there is insufficient evidence to recommend a particular intervention. Simplified drug\nOther glaucoma medications include alpha 2 adrenergic agonists, parasympathomimetics, rho-kinase inhibitors, and topical and oral carbonic anhydrase inhibitors.335-337",
    "ground_truth_context": "Patients should receive proper professional support and referrals when their conditions fail to respond to treatment.",
    "model_answer": "A",
    "model_answer_idx": 0,
    "correct_answer_text": "Consider laser trabeculoplasty",
    "correct_answer_idx": 1,
    "model_reasoning": "In the management of primary open-angle glaucoma (POAG), when a patient has already been treated with two different eye drop medications and their intraocular pressure (IOP) remains uncontrolled, the next step is to consider laser trabeculoplasty. This is a minimally invasive procedure that can help lower IOP and is often preferred before escalating to more invasive surgical options. While adding a third eye drop medication is a possible approach, it is not the first-line recommendation after two medications have failed, as it may lead to decreased adherence to treatment. Increasing the dose of current eye drops is also not typically recommended in this scenario, as the patient has already been on two different medications without adequate control. Referring for glaucoma surgery immediately is usually reserved for more severe cases or when other treatments have failed, making laser trabeculoplasty the most appropriate next step in this situation.",
    "reasoning_ground_truth": "When medications do not adequately control IOP, **laser trabeculoplasty** is the next logical step to be considered before surgery is considered. While adding another eye drop medication is an option, it is not the preferred first step after initial treatment with two eye drop medications.",
    "is_correct": false
  },
  {
    "question": "A 45-year-old male with rheumatoid arthritis (RA) is on methotrexate monotherapy, but is still having moderate disease activity. He is now being started on a biologic DMARD (bDMARD). What is the best way to approach his current methotrexate therapy?",
    "context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD physician and patient preferences regarding the tradeoff between the increased efficacy and risks of toxicity associated with higher starting doses. This recommendation refers only to\nInitiation/titration of methotrexate to a weekly dose of at least 15 mg within 4 to 6 weeks is conditionally recommended over initiation/titration to a weekly dose of <15 mg.\nA split dose of oral methotrexate over 24 hours or weekly subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.\n|A split dose of oral methotrexate over 24 hours or subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.|Very low|PICO 16 and PICO 15|p. 206\u201310|\nMethotrexate monotherapy is conditionally recommended over dual or triple csDMARD therapy for DMARD-naive patients with moderate-to-high disease activity. The recommendation favors methotrexate monotherapy because the higher burden of combination therapy (e.g., multiple medications, higher cost)\nMethotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.  \n|Continuation of all DMARDs at their current dose|is conditionally recommended over a dose reduction of a DMARD.|\n|---|---|\nMethotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.",
    "ground_truth_context": "Continuation of DMARDs at the current dose is preferred over dose reduction, which is preferred over gradual discontinuation, which is preferred over abrupt discontinuation.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Continue methotrexate at the same dose when starting the bDMARD",
    "correct_answer_idx": 3,
    "model_reasoning": "According to the guidelines provided in the context, when a patient is on methotrexate monotherapy and is being started on a biologic DMARD (bDMARD), the recommendation is to **continue methotrexate at the same dose**. This approach is preferred because it allows for the potential synergistic effects of both medications, which can help manage moderate disease activity more effectively. Discontinuing methotrexate or reducing its dose is not recommended at this time, as it may compromise the overall treatment efficacy. The context explicitly states that the continuation of DMARDs at their current dose is preferred over dose reduction or discontinuation, reinforcing the choice to maintain the current methotrexate therapy while introducing the bDMARD.",
    "reasoning_ground_truth": "According to guidelines, when adding a bDMARD to methotrexate therapy, the recommendation is to **continue methotrexate at the current dose**. Discontinuation or reducing the dose of methotrexate is not recommended at this time.",
    "is_correct": false
  },
  {
    "question": "A 28-year-old male presents to the clinic with concern for possible gonorrhea. He reports a recent unprotected sexual encounter.  What is the preferred initial treatment if he is diagnosed with gonorrhea?",
    "context": "C. trachomatis, increasing the dosage of ceftriaxone to 250 mg for treatment of N. gonorrhoeae with continued monitoring of antimicrobial susceptibility, and consideration of whether azithromycin (2 g, single dose) should be recommended in early syphilis (16).\nIn people with gonococcal infections who have failed treatment, the WHO STI guideline suggests the following options.  \n- If reinfection is suspected, re-treat with a WHO-recommended regimen, reinforce sexual abstinence or condom use, and provide partner treatment.\nthe eventual development of untreatable gonococcal infections with serious sexual and reproductive health consequences (6). The previous WHO Guidelines for the management of sexually transmitted infections, published in 2003 (7), include ciprofloxacin as a first-line treatment for gonorrhoea, even\n- 4. Recommendations for treatment of gonococcal infections ............ 17\n- 4.1 Genital and anorectal gonococcal infections ............................ 17\n- Recommendation 1 ................................................................. 17\nSince laboratory diagnostic tests are not available in the majority of countries, diagnosis is often made clinically, based on the presence of symptoms such as vaginal and urethral discharge. Presumptive treatment is sometimes provided to those at high risk of gonococcal infection, if indicated",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Intramuscular ceftriaxone 500 mg and oral azithromycin 1 gram single dose",
    "correct_answer_idx": 3,
    "model_reasoning": "The preferred initial treatment for gonorrhea, as indicated in the context provided, is a combination of **intramuscular ceftriaxone 500 mg and oral azithromycin 1 gram as a single dose**. This dual therapy approach is recommended to effectively treat gonococcal infections and to address potential co-infections, such as chlamydia. \n\nThe other options are not recommended as first-line treatments for gonorrhea:\n- Option A (Oral azithromycin 1 gram single dose) is insufficient on its own for treating gonorrhea.\n- Option B (Oral doxycycline 100mg twice daily for 7 days) is not a recommended treatment for gonorrhea.\n- Option D (Oral ciprofloxacin 500 mg twice daily for 3 days) is outdated as ciprofloxacin is no longer recommended as a first-line treatment due to increasing resistance.\n\nThus, option C is the correct choice based on current guidelines for the treatment of gonorrhea.",
    "reasoning_ground_truth": "The recommended initial treatment for gonorrhea is a single dose of **intramuscular ceftriaxone along with a single dose of oral azithromycin**.",
    "is_correct": false
  },
  {
    "question": "A 70-year-old patient is admitted to the hospital for an acute medical illness. They have limited mobility during the admission. What is the preferred initial method of VTE prophylaxis?",
    "context": "Should VTE prophylaxis be used in medical outpatients with minor provoking factors for VTE (eg, immobility, minor injury, illness/infection)?\nhospitalization, and against extending pharmacological prophylaxis after hospital discharge. Conditional recommendations included not to use VTE prophylaxis routinely in long-term care patients or outpatients with minor VTE risk factors. The panel conditionally recommended use of graduated\nShould extended-duration pharmacological VTE prophylaxis after discharge (ie, up to 30 or 40 days) vs in-hospital\u2013only pharmacological VTE prophylaxis be used in acutely ill hospitalized medical patients?\nShould pharmacological VTE prophylaxis be used in chronically ill medical patients or nursing home patients?\nStudies on identification of high-risk subgroups of chronically ill medical patients who could benefit from VTE prophylaxis, with consideration given to those who are immobilized.\n- Studies on identification of high-risk subgroups of chronically ill medical patients who could benefit from VTE prophylaxis, with consideration given to those who are immobilized;\nadmission for surgery or acute medical illness. Hospital-acquired VTE is preventable, with interventions including anticoagulants and mechanical measures, including compression stockings and intermittent pneumatic compression.",
    "ground_truth_context": "LMWH vs UFH in acutely ill medical patients. Summary of the evidence. We found 8 systematic reviews51,52,54,58,59,63,65,67 that addressed this question and included 11 RCTs.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Pharmacological prophylaxis with LMWH or UFH",
    "correct_answer_idx": 3,
    "model_reasoning": "For acutely ill medical patients, the guidelines recommend pharmacological prophylaxis with low molecular weight heparin (LMWH) or unfractionated heparin (UFH) as the preferred initial method of VTE prophylaxis. This recommendation is based on evidence from systematic reviews and randomized controlled trials that support the effectiveness of pharmacological agents in preventing venous thromboembolism in hospitalized patients, especially those with limited mobility due to acute medical conditions. While mechanical prophylaxis methods, such as graduated compression stockings and intermittent pneumatic compression, can be beneficial in certain situations, they are not considered the primary approach for VTE prevention in this context. Therefore, option C is the correct choice.",
    "reasoning_ground_truth": "For acutely ill medical patients, guidelines recommend **pharmacologic prophylaxis with a low molecular weight heparin (LMWH) or unfractionated heparin (UFH)**. Mechanical prophylaxis can be used in certain situations, but is not the preferred initial method",
    "is_correct": false
  },
  {
    "question": "A 54 year-old male is admitted to the hospital with community-acquired pneumonia (CAP). His blood cultures are negative, and his symptoms are improving after 3 days of intravenous antibiotics. How long should he continue antibiotic therapy?",
    "context": "In Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of Antibiotic Treatment?\nAs recent data supporting antibiotic administration for ,5 days are scant, on a risk\u2013benefit basis we recommend treating for a minimum of 5 days, even if the patient has reached clinical stability before 5 days. As most patients will achieve clinical stability within the first 48 to 72 hours, a\nLonger courses of antibiotic therapy are recommended for 1) pneumonia e59\nat 48 hours in accord with microbiological results that do not yield MRSA or P. aeruginosa is safe and reduces duration of antibiotic treatment, length of hospitalization, and complications of broad-spectrum therapy. These results are reinforced by retrospective (162) and prospective and randomized\nand normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days.",
    "model_answer": "D",
    "model_answer_idx": 3,
    "correct_answer_text": "Continue antibiotics until clinical stability is achieved and for at least 5 days",
    "correct_answer_idx": 4,
    "model_reasoning": "According to the provided context, antibiotic therapy for community-acquired pneumonia (CAP) should be continued until the patient achieves clinical stability and for a minimum of 5 days. In the scenario presented, the patient has been on intravenous antibiotics for 3 days and is showing improvement, but the recommendation is to continue treatment until clinical stability is reached and for at least 5 days total. This aligns with the guidelines that emphasize the importance of not shortening the duration of antibiotic therapy below 5 days, even if the patient is improving. Therefore, option D is the most appropriate choice.",
    "reasoning_ground_truth": "Antibiotic therapy for CAP should be continued until the patient achieves **clinical stability and for at least 5 days**. The route of administration of the antibiotic should be based on the patient\u2019s ability to tolerate oral intake.",
    "is_correct": false
  },
  {
    "question": "A 60-year-old male presents with a 12-day history of purulent nasal discharge, facial pain, and nasal obstruction following a cold. He has no fever and is otherwise healthy. What is the most appropriate initial management strategy?",
    "context": "documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\n|Acute rhinosinusitis (ARS)|Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both: Purulent nasal discharge is cloudy or colored, in contrast to the clear secretions that typically accompany viral upper\nClinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS. Option based on randomized controlled trials with limitations and cohort studies with an unclear balance of benefit and harm that varies by patient.\nAnalgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\nOral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the\nsevere symptoms at the onset or has high fever (>39\u00b0C or 102\u00b0F) and purulent discharge or facial pain lasting at least 3 to 4 consecutive days at the beginning of illness.",
    "ground_truth_context": "A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of ARS worsen within 10 days after an initial improvement (double worsening). Offer watchful waiting* OR prescribe an antibiotic based on shared decision-making.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Offer watchful waiting or prescribe antibiotics based on shared decision-making",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient presents with a 12-day history of purulent nasal discharge, facial pain, and nasal obstruction, which are indicative of acute bacterial rhinosinusitis (ABRS). However, he does not have severe symptoms or fever, which suggests that he may not require immediate antibiotic treatment. \n\nThe most appropriate initial management strategy in this case is to recommend symptomatic relief measures such as analgesics, topical intranasal corticosteroids, and nasal saline irrigation. These treatments can help alleviate the patient's symptoms without the need for antibiotics, especially since the guidelines suggest offering watchful waiting or antibiotics based on shared decision-making for patients with uncomplicated ABRS.\n\nOptions A (prescribing a broad-spectrum antibiotic) and D (prescribing a short course of oral corticosteroids) are not the best initial strategies given the absence of severe symptoms. Option C (obtaining a CT scan) is unnecessary for uncomplicated ABRS. Therefore, option B is the most appropriate choice for managing the patient's condition.",
    "reasoning_ground_truth": "The patient's symptoms have persisted for more than 10 days without improvement after an upper respiratory infection, suggesting a possible acute bacterial rhinosinusitis (ABRS). However, without severe symptoms, a watchful waiting approach or antibiotics are an option.  Analgesics, topical corticosteroids, and saline irrigations are appropriate for symptomatic relief but do not address the potential bacterial infection. A CT scan is not indicated for uncomplicated ABRS. Oral corticosteroids are not a first-line treatment option for ABRS.",
    "is_correct": false
  },
  {
    "question": "A 45-year-old female with chronic rhinosinusitis (CRS) presents with persistent nasal congestion and facial pain despite using saline nasal irrigation and topical corticosteroids. She reports no history of allergies. What is the next most appropriate step in her management?",
    "context": "saline irrigation has been recommended by clinicians both as adjunctive therapy for chronic sinonasal symptoms and in the postoperative period to moisten and cleanse sinonasal clots and crust, as well as to promote mucosal healing.\nClinicians should assess the patient with chronic rhinosinusitis or recurrent acute rhinosinusitis for multiple chronic conditions that would modify management such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia. Recommendation based on one systematic review and multiple\nAdjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and\nClinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS. Option based on randomized controlled trials with limitations and cohort studies with an unclear balance of benefit and harm that varies by patient.\n|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nThe clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Clinicians should confirm the presence or absence of nasal polyps in a patient with CRS.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Perform nasal endoscopy to assess for polyps and obtain objective evidence of sinonasal inflammation.",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient in this scenario has chronic rhinosinusitis (CRS) with persistent symptoms despite the use of saline nasal irrigation and topical corticosteroids. Given that she has no history of allergies, the next appropriate step in her management is to perform nasal endoscopy. This procedure allows for direct visualization of the nasal passages and sinuses, enabling the clinician to assess for the presence of nasal polyps and obtain objective evidence of sinonasal inflammation. \n\nWhile prescribing oral antibiotics (Option A) may seem like a reasonable step, antibiotics are not typically the first-line treatment for CRS unless there is evidence of a bacterial infection, which is not indicated in this case. Allergy testing (Option B) is not necessary given the lack of allergy history, and while obtaining a CT scan (Option D) can provide valuable information about anatomical abnormalities, nasal endoscopy is a more immediate and direct method for assessing the patient's condition and guiding further management. \n\nThus, performing nasal endoscopy is the most appropriate next step in this patient's management.",
    "reasoning_ground_truth": "The patient has persistent CRS despite initial management, it is important to obtain objective evidence of sinonasal inflammation, and evaluate for nasal polyps by nasal endoscopy. Antibiotics are not a primary treatment for CRS. Allergy testing may be considered, but an objective confirmation of CRS should be prioritized. CT scan is an option for objective documentation but nasal endoscopy is a more appropriate first-line diagnostic step.",
    "is_correct": true
  },
  {
    "question": "A 52-year-old male, post-stent placement for stable ischemic heart disease (SIHD) 6 months ago, is scheduled for an elective cholecystectomy. He is currently on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. What is the most appropriate perioperative management of his antiplatelet therapy?",
    "context": "Guidelines from the cardiology community provide recommendations for the use of dual antiplatelet therapy for a period after acute coronary syndrome or percutaneous coronary intervention. These guidelines recommend to apply the same diagnostic and therapeutic strategies in people with CKD.663 CKD\n|I|C-EO|In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y12 platelet receptor inhibitor be restarted as soon as\nThe magnitude of incremental bleeding risk in patients treated with antiplatelet therapy who undergo surgery is uncertain (157,158). If P2Y12 inhibitor therapy needs to be held in patients being treated with DAPT after stent implantation, continuation of aspirin therapy if possible is recommended,\nopinion. If a P2Y12 inhibitor has been held before a surgical procedure, therapy is restarted as soon as possible, given the substantial thrombotic hazard associated with lack of platelet inhibition early after surgery in patients with recent stent implantation. Although several small studies have\nto \u201cafter 3 months.\u201d Figure 6 summarizes recommendations on timing of elective noncardiac surgery in patients with coronary stents.\n|IIa|C-EO|When noncardiac surgery is required in patients currently taking a P2Y12 inhibitor, a consensus decision among treating clinicians as to the relative risks of surgery and discontinuation or continuation of antiplatelet therapy can be useful.|\nPractice Point 3.15.2.1: Consider other antiplatelet therapy (e.g., P2Y12 inhibitors) when there is aspirin intolerance.",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Continue aspirin and discontinue clopidogrel 5 days prior to surgery.",
    "correct_answer_idx": 2,
    "model_reasoning": "In patients with stable ischemic heart disease (SIHD) who are scheduled for elective noncardiac surgery, the recommended approach is to continue aspirin therapy while discontinuing the P2Y12 inhibitor (in this case, clopidogrel) approximately 5 days prior to the surgical procedure. This strategy aims to minimize the risk of bleeding associated with the surgery while still providing some level of antiplatelet protection to reduce the risk of thrombotic events. \n\nContinuing both aspirin and clopidogrel (Option A) would increase the risk of bleeding during surgery, while discontinuing both medications (Option B) would elevate the risk of thrombotic complications. Discontinuing aspirin and continuing clopidogrel (Option D) is not advisable as aspirin provides essential antiplatelet effects that are crucial for patients with SIHD. Therefore, the most appropriate perioperative management in this scenario is to continue aspirin and discontinue clopidogrel 5 days prior to surgery (Option C).",
    "reasoning_ground_truth": "For patients with SIHD undergoing elective surgery, it is generally recommended to continue aspirin and discontinue the P2Y12 inhibitor (in this case, clopidogrel) 5 days prior to surgery to reduce the risk of bleeding. Stopping both medications increases the risk of thrombotic events. Continuing both medications increases bleeding risk",
    "is_correct": true
  },
  {
    "question": "A 68-year-old female presents with a 3-day history of fever, cough, and purulent nasal discharge. She has a history of well-controlled asthma. She reports her symptoms began after a recent cold and is concerned about a sinus infection. What is the most appropriate next step in her management?",
    "context": "documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nClinicians should assess the patient with chronic rhinosinusitis or recurrent acute rhinosinusitis for multiple chronic conditions that would modify management such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia. Recommendation based on one systematic review and multiple\nimprove diagnostic accuracy for adult rhinosinusitis, promote judicious use of systemic and topical therapy, and promote appropriate use of ancillary tests to confirm diagnosis and guide management, which include radiography, nasal endoscopy, computed tomography, and testing for allergy and immune\n- Exceptions: Include but are not limited to severe illness, complicated sinusitis, immune deficiency, prior sinus surgery, or coexisting bacterial illness; the clinician should also consider the patient\u2019s age, general health, cardiopulmonary status, and comorbid conditions in determining an\nRecommendation. We recommend that standard antibacterial treatment be initially prescribed for adults with clinical and radiographic evidence of CAP who test positive for influenza in the inpatient and outpatient settings (strong recommendation, low quality of evidence).\n|---|---|---|\n|Amoxicillin or doxycycline or macrolide (if local pneumococcal resistance is ,25%)\u2020|Combination therapy with amoxicillin/clavulanate or cephalosporin AND macrolide or doxycycline OR monotherapy with respiratory fluoroquinolonejj| |\n- A b-lactam plus a respiratory fluoroquinolone (strong recommendation, low quality of evidence).\nFor penicillin-allergic patients, either doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is recommended as an alternative agent for empiric antimicrobial therapy. Fluoroquinolones, however, are not recommended for first-line therapy of ABRS in patients without penicillin\nAnalgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the\nrhinitis and acute sinusitis, even though many patients likely had viral illness. The magnitude of effect, however, was small: 66% of patients improved with placebo at 14 to 21 days, rising to 73% with steroid therapy. Adverse events, however, were rare, so the choice of whether or not the modest",
    "ground_truth_context": "In contrast to the version of this statement in the original sinusitis guideline,1 we changed the diagnostic criteria to include not just the persistence of signs and symptoms beyond 10 days but failure to improve in 10 days, for greater specificity in distinguishing presumed bacterial infection for persistent, but resolving, viral illness. Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Recommend symptomatic relief and observe her symptoms for 7 days.",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient has presented with symptoms that have lasted for only 3 days, which is not sufficient time to diagnose acute bacterial rhinosinusitis (ABRS). Given her history of well-controlled asthma and the fact that her symptoms began after a recent cold, it is likely that she is experiencing viral rhinosinusitis (VRS). In such cases, the best management approach is to recommend symptomatic relief and observe her symptoms for a period of 7 days. \n\nStarting empiric antibiotics immediately (Option A) is not appropriate at this stage, as antibiotics are typically reserved for cases where bacterial infection is confirmed or highly suspected, which is not the case here. Obtaining a sinus CT (Option B) is unnecessary given the short duration of symptoms and the likelihood of a viral cause. Prescribing oral corticosteroids (Option D) is also not indicated at this time, as they are generally used for more severe inflammation or specific conditions, rather than for routine management of VRS.\n\nTherefore, the most appropriate next step in her management is to recommend symptomatic relief and observe her symptoms for 7 days (Option C).",
    "reasoning_ground_truth": "The patient has symptoms for 3 days, which is not long enough to diagnose ABRS. Given that her symptoms developed after a cold, it is likely a viral rhinosinusitis (VRS), symptomatic relief is the best option. Antibiotics are not indicated at this time, nor are CT scans or oral corticosteroids. It would be appropriate to reassess if symptoms worsen.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old male with a history of a myocardial infarction (MI) one year ago, treated with a drug-eluting stent, is currently on aspirin and clopidogrel. He has been free of any cardiac events since the procedure. Based on current guidelines, what is the recommended duration of dual antiplatelet therapy (DAPT)?",
    "context": "recommended duration of P2Y12 inhibitor therapy (in addition to aspirin therapy). Figure 1 summarizes recommendations for duration of DAPT according to clinical status.\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\nof patients 1 to 3 years after myocardial infarction (MI) assessing the efficacy of DAPT compared with aspirin monotherapy (28). These studies were published after the formulation of recommendations for duration of DAPT in prior guidelines. The specific mandate of the present writing group is to\nsupersede prior corresponding recommendations in the 6 relevant guidelines. These recommendations for duration of DAPT apply to newer-generation stents and, in general, only to those not treated with oral anticoagulant therapy.\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\nwith DAPT for 12 months, and were without ischemic or bleeding events during this period were randomized to an additional 18 months of DAPT or to aspirin monotherapy (16). Extended DAPT resulted in a 0.7% absolute reduction in very late stent thrombosis, a 2.0% absolute reduction in MI, a 1.6%\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable",
    "ground_truth_context": "For purposes of this focused update, patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Discontinue clopidogrel and continue aspirin.",
    "correct_answer_idx": 2,
    "model_reasoning": "According to the guidelines referenced in the context, patients with a history of myocardial infarction (MI) who have been treated with a drug-eluting stent and have remained free of any cardiac events for more than one year are considered to have transitioned to stable ischemic heart disease (SIHD). In such cases, the recommendation is to discontinue the P2Y12 inhibitor (in this case, clopidogrel) and continue with single antiplatelet therapy, typically aspirin. This approach is based on the understanding that the risks associated with prolonged dual antiplatelet therapy may outweigh the benefits for patients who are stable and have not experienced any further cardiac events. Therefore, the correct course of action for the patient described in the question is to discontinue clopidogrel and continue aspirin.",
    "reasoning_ground_truth": "For patients with a history of MI treated with a drug-eluting stent who are beyond one year without any cardiac events, they are considered to have stable ischemic heart disease. They can discontinue the P2Y12 inhibitor, (clopidogrel) and continue with single antiplatelet therapy, usually aspirin.",
    "is_correct": true
  },
  {
    "question": "A 28-year-old female presents with a 2-day history of nasal congestion, clear nasal discharge, and mild facial pressure. She denies fever or purulent discharge. What is the most appropriate initial management?",
    "context": "documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nDecongestants may help you breathe easier and can be taken as a nasal spray (for no more than 3 days in a row to avoid worsening congestion) or by mouth.|\nOral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the\nAnalgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\n|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\nThe clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over\nto symptomatic therapy, especially when nasal discharge is colored or purulent. Existing educational material from the Centers for Disease Control and Prevention (CDC) Get Smart Campaign can be used by clinicians to help clarify misconceptions about viral illness and nasal discharge.\naccompany viral upper respiratory infection, and may be reported by the patient or observed on physical examination. Nasal obstruction may be reported by the patient as nasal obstruction, congestion, blockage, or stuffiness, or may be diagnosed by physical examination. Facial pain-pressure-fullness",
    "ground_truth_context": "Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS.",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Recommend analgesics, decongestants and nasal saline irrigation for symptomatic relief.",
    "correct_answer_idx": 1,
    "model_reasoning": "The patient's symptoms\u2014nasal congestion, clear nasal discharge, and mild facial pressure\u2014are indicative of viral rhinosinusitis (VRS). In cases of VRS, antibiotics are not effective since they target bacterial infections, and the patient does not exhibit signs of a bacterial infection such as fever or purulent discharge. \n\nOrdering a sinus CT scan is unnecessary given the mild and non-severe nature of her symptoms, as imaging is typically reserved for more complicated cases or when there is a suspicion of a serious condition. \n\nPrescribing a short course of oral corticosteroids is also not appropriate for typical VRS management, as corticosteroids are generally used for more severe cases or specific conditions like allergic rhinitis or chronic rhinosinusitis.\n\nTherefore, the most appropriate initial management for this patient is to recommend analgesics, decongestants, and nasal saline irrigation for symptomatic relief, aligning with the guidelines for managing VRS.",
    "reasoning_ground_truth": "The patient's symptoms are consistent with a viral rhinosinusitis (VRS). Antibiotics are not indicated for viral infections. A sinus CT scan is not necessary given the non-severe nature of her symptoms. Oral corticosteroids are not appropriate for the typical treatment of a viral rhinosinusitis. Symptomatic relief with analgesics, decongestants, and nasal saline irrigation is the most appropriate initial strategy.",
    "is_correct": true
  },
  {
    "question": "A 65-year-old male with chronic rhinosinusitis (CRS) and nasal polyps has been using nasal saline irrigation and topical corticosteroids with minimal improvement. What is the most appropriate next step in management?",
    "context": "- Benefit: Prioritize referral for specialty evaluation, identify patients likely to benefit most from topical (intranasal) or systemic corticosteroid therapy, identify patients for additional diagnostic tests to assess for conditions other than CRS that are associated with nasal polyposis and may\n|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\ndyskinesia; (6) confirm the presence or absence of nasal polyps in a patient with CRS; and (7) recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.\n- Three new key action statements on managing CRS that focus on polyps as a modifying factor, a recommendation in favor of topical intranasal therapy (saline irrigations, corticosteroids), and a recommendation against using topical or systemic antifungal agents\nTopical nasal steroids have been used alone or in combination with oral antibiotics for symptomatic relief of ABRS. Nasal saline irrigation, alone or in conjunction with other adjunctive measures, may improve quality of life, decrease symptoms, and decrease medication use for ABRS, particularly in\nAdjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and\ndirectly with topical nasal steroids, the benefits of saline irrigation are less pronounced. 264 The safety and minimal side effects of saline irrigation, however, make it an attractive sole therapy for CRS. Common side effects of nasal irrigation include fluid dripping from the nose.\nA beneficial effect of nasal irrigation for symptomatic relief of CRS has been shown in a Cochrane review 264 and in other systematic reviews.258,265 Nasal saline irrigation is effective as sole treatment for CRS or as an adjunct to topical nasal steroids, but compared directly with topical nasal\nThe purpose of this statement is to highlight the importance of intranasal saline and intranasal corticosteroid therapy in providing symptomatic relief and improved quality of life for patients with CRS. Despite the benefits of these interventions seen in RCTs and systematic reviews, the GUG felt",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Clinicians should confirm the presence or absence of nasal polyps in a patient with CRS.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Confirm the presence of sinonasal inflammation and consider a referral to an otolaryngologist.",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient in this scenario has chronic rhinosinusitis (CRS) with nasal polyps and has not experienced significant improvement with nasal saline irrigation and topical corticosteroids. Given the persistence of symptoms, it is crucial to confirm the diagnosis of CRS and assess the extent of sinonasal inflammation. This can be achieved through methods such as nasal endoscopy or imaging studies like computed tomography. Additionally, considering a referral to an otolaryngologist is appropriate, as they can provide further evaluation and management options, including potential surgical interventions if necessary. \n\nPrescribing oral antibiotics (Option A) is not indicated for CRS, as antibiotics are generally ineffective unless there is a clear bacterial infection. Ordering an allergy skin test (Option B) may be useful in the long term but is not the immediate priority in this case. Continuing current therapy with close follow-up (Option D) would not address the lack of improvement and the need for further evaluation. Therefore, confirming the presence of sinonasal inflammation and considering a referral to an otolaryngologist (Option C) is the most appropriate next step in management.",
    "reasoning_ground_truth": "Given his persistent symptoms despite initial therapy, it is important to confirm the diagnosis of CRS, and referral may be beneficial to assess other management strategies such as surgery. Oral antibiotics are not effective for CRS. Allergy testing can be considered, but the next priority is to confirm the diagnosis and further evaluate other treatment strategies",
    "is_correct": true
  },
  {
    "question": "A 70-year-old male with stable ischemic heart disease (SIHD) underwent percutaneous coronary intervention (PCI) with a drug eluting stent (DES) 3 months ago. He is currently on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. He is now scheduled for a colonoscopy. What is the most appropriate perioperative management?",
    "context": "Guidelines from the cardiology community provide recommendations for the use of dual antiplatelet therapy for a period after acute coronary syndrome or percutaneous coronary intervention. These guidelines recommend to apply the same diagnostic and therapeutic strategies in people with CKD.663 CKD\n|I|C-EO|In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y12 platelet receptor inhibitor be restarted as soon as\nThe magnitude of incremental bleeding risk in patients treated with antiplatelet therapy who undergo surgery is uncertain (157,158). If P2Y12 inhibitor therapy needs to be held in patients being treated with DAPT after stent implantation, continuation of aspirin therapy if possible is recommended,\n|IIa|C-EO|When noncardiac surgery is required in patients currently taking a P2Y12 inhibitor, a consensus decision among treating clinicians as to the relative risks of surgery and discontinuation or continuation of antiplatelet therapy can be useful.|\nopinion. If a P2Y12 inhibitor has been held before a surgical procedure, therapy is restarted as soon as possible, given the substantial thrombotic hazard associated with lack of platelet inhibition early after surgery in patients with recent stent implantation. Although several small studies have\nThe timing of noncardiac surgery in patients treated with coronary stent implantation involves consideration of: (1) the risk of stent thrombosis (particularly if DAPT needs to be interrupted); (2) the consequences of delaying the desired surgical procedure; and (3) increased intra- and\n- Assess ischemic and bleeding risks using validated risk predictors (e.g., CHA2DS2-VASc, HAS-BLED)\n- Keep triple therapy duration as short as possible; dual therapy only (oral anticoagulant and clopidogrel) may be considered in select patients\nthrombosis, and the risk and consequences of bleeding. Given the complexity of these considerations, decisions are best determined by a consensus of the surgeon, anesthesiologist, cardiologist, and patient.",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Continue aspirin and stop clopidogrel 5 days before the colonoscopy.",
    "correct_answer_idx": 2,
    "model_reasoning": "For patients with stable ischemic heart disease (SIHD) who are undergoing elective noncardiac procedures, the guidelines recommend continuing aspirin while discontinuing the P2Y12 inhibitor (in this case, clopidogrel) about 5 days prior to the procedure. This approach helps to reduce the risk of bleeding during the procedure while still providing some level of protection against thrombotic events. \n\nContinuing both aspirin and clopidogrel (Option A) would increase the risk of bleeding during the colonoscopy, which is not advisable. Stopping both medications (Option B) could elevate the risk of thrombotic events, which is particularly concerning for a patient with a history of coronary artery disease. Lastly, stopping aspirin while continuing clopidogrel (Option D) is not recommended, as aspirin plays a crucial role in preventing thrombotic events in patients with SIHD.\n\nTherefore, the most appropriate perioperative management for this patient is to continue aspirin and stop clopidogrel 5 days before the colonoscopy (Option C).",
    "reasoning_ground_truth": "For patients with SIHD undergoing elective procedures, guidelines recommend continuing aspirin and discontinuing the P2Y12 inhibitor, (clopidogrel) 5 days before the procedure to reduce bleeding risk while maintaining some protection against thrombotic events. Stopping both medications can increase risk of thrombotic events. Continuing both medications increases bleeding risk during the procedure",
    "is_correct": true
  },
  {
    "question": "A 30-year-old patient presents with a 14-day history of persistent nasal congestion, facial pressure, and purulent nasal discharge. The patient has no fever, and their symptoms started after a cold. Based on these symptoms, what is the appropriate diagnosis?",
    "context": "Acute rhinosinusitis is diagnosed when a patient presents with up to 4 weeks of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both (Table 4). Nasal obstruction without purulent nasal drainage is not consistent with ARS and is beyond the scope\n|Acute rhinosinusitis (ARS)|Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both: Purulent nasal discharge is cloudy or colored, in contrast to the clear secretions that typically accompany viral upper\n|Chronic rhinosinusitis|Twelve weeks or longer of two or more of the following signs and symptoms: \u2022 mucopurulent drainage (anterior, posterior, or both), \u2022 nasal obstruction (congestion), \u2022 facial pain-pressure-fullness, or \u2022 decreased sense of smell. AND inflammation is documented by one or more\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without",
    "ground_truth_context": "A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of ARS worsen within 10 days after an initial improvement (double worsening).",
    "model_answer": "B",
    "model_answer_idx": 1,
    "correct_answer_text": "Acute bacterial rhinosinusitis (ABRS).",
    "correct_answer_idx": 1,
    "model_reasoning": "The patient's symptoms of persistent nasal congestion, facial pressure, and purulent nasal discharge lasting for 14 days after the onset of a cold are indicative of acute bacterial rhinosinusitis (ABRS). According to the context provided, ABRS is diagnosed when symptoms of acute rhinosinusitis, such as purulent nasal drainage accompanied by nasal obstruction and facial pain-pressure-fullness, persist without improvement for at least 10 days. In this case, the patient has exceeded that duration, which strongly suggests a bacterial infection rather than a viral one. Viral rhinosinusitis (VRS) typically resolves within 10 days, making it an unlikely diagnosis here. Allergic rhinitis and migraine headaches do not present with purulent nasal discharge, further supporting the diagnosis of ABRS.",
    "reasoning_ground_truth": "The patient's symptoms of persistent nasal congestion, facial pressure, and purulent nasal discharge lasting over 10 days after a cold are highly suggestive of acute bacterial rhinosinusitis (ABRS). While VRS may present with similar symptoms, they typically resolve within 10 days. Allergic rhinitis and migraines do not typically present with purulent nasal discharge.",
    "is_correct": true
  },
  {
    "question": "A 48-year-old male is diagnosed with chronic rhinosinusitis (CRS) based on his symptoms. To confirm the diagnosis, the clinician should obtain objective documentation of sinonasal inflammation. Which of the following is most appropriate to perform to confirm sinonasal inflammation?",
    "context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over\nObjective confirmation of sinonasal inflammation may be made by direct visualization or by CT scanning. Direct visualization is best accomplished with nasal endoscopy, but in some patients, anterior rhinoscopy using an otoscope or nasal speculum may suffice. An important part of direct\n|7B. Objective confirmation of a diagnosis of CRS|The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.|\nThe clinician may obtain testing for allergy and immune function in evaluating a patient with chronic rhinosinusitis or recurrent acute rhinosinusitis. Option based on observational studies with an unclear balance of benefit vs harm.\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Anterior rhinoscopy or nasal endoscopy.",
    "correct_answer_idx": 2,
    "model_reasoning": "To confirm a diagnosis of chronic rhinosinusitis (CRS), it is essential to obtain objective documentation of sinonasal inflammation. The context specifies that this can be achieved through anterior rhinoscopy or nasal endoscopy, which are both methods of direct visualization of the sinonasal passages. While computed tomography (CT) is also mentioned as a method for confirming sinonasal inflammation, it is typically not the first step in the diagnostic process. \n\nOptions A (Allergy skin test) and D (Blood test for infection) are not appropriate for confirming sinonasal inflammation, as they do not provide direct evidence of the condition. Option B (Sinus radiography) is less effective than the recommended methods of anterior rhinoscopy or nasal endoscopy for this specific purpose. Therefore, the most appropriate choice to confirm sinonasal inflammation in this case is option C: Anterior rhinoscopy or nasal endoscopy.",
    "reasoning_ground_truth": "To confirm a diagnosis of CRS, objective documentation of sinonasal inflammation is required. This can be achieved through direct visualization using anterior rhinoscopy or nasal endoscopy. While a CT scan is an option, it is usually not the first step. Allergy testing and blood tests for infection are not appropriate methods for confirming sinonasal inflammation.",
    "is_correct": true
  },
  {
    "question": "A 32-year-old male presents with a 5-day history of nasal congestion, facial pain, and clear nasal discharge following a cold. He denies fever or purulent discharge. What is the most appropriate initial treatment approach?",
    "context": "Adjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nagents, nasal saline, decongestants, antihistamines, mucolytics, cough suppressants, and topical or oral corticosteroids\u2014may be used alone or in varying combinations for symptom relief.\nClinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS. Option based on randomized controlled trials with limitations and cohort studies with an unclear balance of benefit and harm that varies by patient.\nOral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the\nAnalgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the\nimprove diagnostic accuracy for adult rhinosinusitis, promote judicious use of systemic and topical therapy, and promote appropriate use of ancillary tests to confirm diagnosis and guide management, which include radiography, nasal endoscopy, computed tomography, and testing for allergy and immune",
    "ground_truth_context": "Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Recommend analgesics, decongestants, and nasal saline irrigation.",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient's symptoms\u2014nasal congestion, facial pain, and clear nasal discharge following a cold\u2014are indicative of viral rhinosinusitis (VRS). In cases of VRS, antibiotics are not appropriate as they are ineffective against viral infections. Oral corticosteroids are not recommended as an initial treatment for VRS. Additionally, ordering a sinus CT scan is unnecessary in this scenario, as the patient's symptoms do not suggest a severe bacterial infection that would require imaging.\n\nThe most appropriate initial treatment approach for VRS is to provide symptomatic relief. This can be achieved through the use of analgesics for pain relief, decongestants to alleviate nasal congestion, and nasal saline irrigation to help clear nasal passages. This aligns with the recommendations in the provided context, which states that clinicians may recommend these adjunctive treatments for symptomatic relief of VRS. Therefore, option C is the correct choice.",
    "reasoning_ground_truth": "The patient's symptoms are indicative of a viral rhinosinusitis (VRS). Antibiotics are not indicated for a viral cause. Oral corticosteroids are not an initial therapy. A CT scan is not indicated. Symptomatic relief is the most appropriate first step",
    "is_correct": true
  },
  {
    "question": "A 55-year-old female with chronic rhinosinusitis (CRS) and nasal polyps has had minimal improvement with topical corticosteroids and saline irrigations. She has a history of mild asthma. What is the most appropriate next step in management?",
    "context": "Clinicians should assess the patient with chronic rhinosinusitis or recurrent acute rhinosinusitis for multiple chronic conditions that would modify management such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia. Recommendation based on one systematic review and multiple\n|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\nTopical nasal steroids have been used alone or in combination with oral antibiotics for symptomatic relief of ABRS. Nasal saline irrigation, alone or in conjunction with other adjunctive measures, may improve quality of life, decrease symptoms, and decrease medication use for ABRS, particularly in\nAdjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and\n- Benefit: Identify modifying factors that would alter management of CRS or recurrent acute rhinosinusitis; identify conditions that require therapy independent of rhinosinusitis.\n- Benefit: Prioritize referral for specialty evaluation, identify patients likely to benefit most from topical (intranasal) or systemic corticosteroid therapy, identify patients for additional diagnostic tests to assess for conditions other than CRS that are associated with nasal polyposis and may\nThe clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over\n- Three new key action statements on managing CRS that focus on polyps as a modifying factor, a recommendation in favor of topical intranasal therapy (saline irrigations, corticosteroids), and a recommendation against using topical or systemic antifungal agents",
    "ground_truth_context": "Clinicians should assess the patient with CRS or recurrent ARS for multiple chronic conditions that would modify management, such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia.",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Evaluate for other conditions such as asthma that might modify management and consider otolaryngology referral.",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient in the scenario has chronic rhinosinusitis (CRS) with nasal polyps and a history of mild asthma, and she has not experienced significant improvement with topical corticosteroids and saline irrigations. Given her persistent symptoms, it is crucial to evaluate for other chronic conditions that may influence the management of her CRS. The context emphasizes the importance of assessing patients with CRS for multiple chronic conditions, including asthma, which can modify treatment strategies. \n\nWhile allergy testing and obtaining a sinus CT scan could be relevant steps in the management process, the immediate next step should focus on evaluating her asthma and considering a referral to an otolaryngologist for further management. This approach aligns with the recommendation to assess for conditions that could complicate or modify the treatment of CRS. Prescribing antibiotics is not appropriate in this case, as they are not a standard treatment for CRS unless there is evidence of a bacterial infection. Therefore, option C is the most appropriate next step in management.",
    "reasoning_ground_truth": "Given her persistent symptoms and history of asthma, it is important to consider other comorbid conditions that can modify the management of her CRS. Allergy testing and a CT can be considered, but the primary step is to evaluate for other conditions, such as asthma. Antibiotics are not a standard treatment for CRS.",
    "is_correct": true
  },
  {
    "question": "A 70-year-old patient who underwent percutaneous coronary intervention (PCI) with a drug eluting stent (DES) 5 months ago for stable ischemic heart disease is currently on dual antiplatelet therapy (DAPT). He is scheduled for cataract surgery. What is the best way to manage his antiplatelet therapy?",
    "context": "|I|C-EO|In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y12 platelet receptor inhibitor be restarted as soon as\nThe magnitude of incremental bleeding risk in patients treated with antiplatelet therapy who undergo surgery is uncertain (157,158). If P2Y12 inhibitor therapy needs to be held in patients being treated with DAPT after stent implantation, continuation of aspirin therapy if possible is recommended,\nopinion. If a P2Y12 inhibitor has been held before a surgical procedure, therapy is restarted as soon as possible, given the substantial thrombotic hazard associated with lack of platelet inhibition early after surgery in patients with recent stent implantation. Although several small studies have\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\nGuidelines from the cardiology community provide recommendations for the use of dual antiplatelet therapy for a period after acute coronary syndrome or percutaneous coronary intervention. These guidelines recommend to apply the same diagnostic and therapeutic strategies in people with CKD.663 CKD\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\n|IIa|C-EO|When noncardiac surgery is required in patients currently taking a P2Y12 inhibitor, a consensus decision among treating clinicians as to the relative risks of surgery and discontinuation or continuation of antiplatelet therapy can be useful.|\n- Assess ischemic and bleeding risks using validated risk predictors (e.g., CHA2DS2-VASc, HAS-BLED)\n- Keep triple therapy duration as short as possible; dual therapy only (oral anticoagulant and clopidogrel) may be considered in select patients\nPrior recommendations with regard to duration of DAPT (9,104) and the timing of noncardiac surgery (15,156) in patients treated with DES were based on observations of those treated with first-generation DES. Compared with first-generation DES, currently used newer-generation DES are associated with\nlonger-duration DAPT may be reasonable for patients at higher ischemic risk with lower bleeding risk.Prior recommendations for duration of DAPT for patients treated with DES were based on data from \u201cfirst-generation\u201d DES, which are rarely if ever used in current clinical practice. Compared with\n|IIb|C-LD|In patients with ACS treated with DAPT after DES implantation who develop a high risk of bleeding (e.g., treatment with oral anticoagulant therapy), are at high risk of severe bleeding complication (e.g., major intracranial surgery), or develop significant overt bleeding, discontinuation\n|IIb|C-LD|In patients with ACS treated with DAPT after DES implantation who develop a high risk of bleeding (e.g., treatment with oral anticoagulant therapy), are at high risk of severe bleeding complication (e.g., major intracranial surgery), or develop significant overt bleeding, discontinuation",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery",
    "model_answer": "C",
    "model_answer_idx": 2,
    "correct_answer_text": "Continue aspirin and stop clopidogrel 5 days prior to surgery.",
    "correct_answer_idx": 2,
    "model_reasoning": "For patients with stable ischemic heart disease (SIHD) who are scheduled to undergo elective noncardiac surgery, the guidelines recommend continuing aspirin therapy while discontinuing the P2Y12 inhibitor (in this case, clopidogrel) 5 days prior to the surgery. This approach is taken to balance the risks of bleeding associated with antiplatelet therapy and the thrombotic risks that could arise from stopping antiplatelet therapy altogether. \n\nContinuing both aspirin and clopidogrel (Option A) would increase the risk of bleeding during the surgery, while stopping both medications (Option B) could lead to thrombotic events due to the lack of platelet inhibition. Stopping aspirin and continuing clopidogrel (Option D) is not advisable as aspirin provides essential antiplatelet effects that should be maintained. Therefore, the best management strategy for this patient is to continue aspirin and stop clopidogrel 5 days prior to surgery (Option C).",
    "reasoning_ground_truth": "For patients with stable ischemic heart disease who are undergoing elective noncardiac surgery, guidelines recommend to continue aspirin and to stop the P2Y12 inhibitor, (clopidogrel) 5 days before surgery to balance the risks of bleeding and thrombotic events. Stopping both medications could lead to thrombotic events. Continuing both medications increases the bleeding risk.",
    "is_correct": true
  },
  {
    "evaluation_metrics": {
      "accuracy": 0.6219512195121951,
      "total": 82,
      "correct": 51,
      "confusion_matrix": {
        "Pred A": {
          "True A": 14,
          "True B": 12,
          "True C": 0,
          "True D": 0
        },
        "Pred B": {
          "True A": 0,
          "True B": 28,
          "True C": 11,
          "True D": 0
        },
        "Pred C": {
          "True A": 0,
          "True B": 0,
          "True C": 1,
          "True D": 3
        },
        "Pred D": {
          "True A": 0,
          "True B": 0,
          "True C": 0,
          "True D": 0
        }
      }
    }
  }
]